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Abstract 
Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease predominantly causing 
synovial inflammation. Early and established RA exhibit both overlapping and distinct 
pathological processes. Early treatment improves clinical outcomes and delineating early 
disease pathology can inform novel therapeutic pathways. Type 1 interferons have diverse 
effects on immune function and relative exposure can be recorded using an interferon 
gene signature (IGS). The IGS is positive in 20-30% of established RA patients where it 
does not associate with disease activity but can predict response to some biological 
therapies. However, glucocorticoids and potentially other immunomodulatory therapies 
can modify the IGS. 
I therefore examined the IGS in early, drug naïve RA focusing on prevalence, association 
with clinical phenotype, and impact on disease progression. I additionally attempted to 
identify the source of type 1 interferons and triggers for their production.   
I demonstrated the IGS is increased in early RA, falls with treatment/time and appears to 
predict clinical response to initial therapies. In this latter capacity it out-performed 
baseline CRP, ESR and DAS-28. The IGS also positively associated with disease activity 
and IgM rheumatoid factor titres. The latter association was supported by an analysis of 
the B cell transcriptome of IGS+ early RA patients, where there was increased gene 
expression in pathways related to B cell activation; increased plasma cell differentiation; 
and propensity to produce IgM. Genes were also upregulated that are usually expressed 
in B cell malignancies, further emphasising a potentially pathologically activated state. 
Retroelements (SINE, LINE-1 and ERV), are putative triggers of type 1 interferons in 
autoimmunity. However early RA whole blood LINE-1 activity was comparable to 
healthy controls and was actually reduced in IGS+ patients. Furthermore pDCs showed 
uniformly reduced retroelement activity in early RA compared with healthy controls. 
Indeed there was differential retroelement expression across lymphocyte subsets in early 
RA; expression was highest in B and T cells and comparatively lower in DCs and 
monocytes. Finally despite being a major source of type 1 interferons, pDCs in IGS+ 
early RA patients had comparable interferon-α expression to other lymphocytes. 
In conclusion I demonstrate that type 1 interferons may play a pathogenic role in early 
RA and disease progression - although their source and triggers remain unclear. 
Nonetheless I hypothesise that therapies that target type 1 interferons could have clinical 
benefit in early RA. 
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1.1 Rheumatoid arthritis  
1.1.1 Rheumatoid arthritis overview 
Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology 
however it is thought to result from a breakdown in the immune regulation of autoreactive 
responses. RA has a prevalence of approximately 1% in the UK general population and 
commonly presents in those of working age. It is associated with significant morbidity 
and mortality; there is a 50% increased risk of death from cardiovascular causes and one 
third of patients will not be working 2 years after diagnosis (1). There is a predominance 
for women being affected, with a male: female ratio of 1:3, and smoking, as well as 
genetic background, increase the risk of developing RA (2).  
Autoantibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide 
antibody (ACPA or anti-CCP antibody), are often, but not always, detected in the 
circulation of RA patients. At diagnosis patients present classically with a symmetrical 
polyarthritis of the small joints of the hands and feet however they can also initially 
present with involvement of larger joints. Indeed there is marked heterogeneity in patient 
presentation, autoantibody status and clinical background. However in all affected joints 
there is an inflammatory infiltrate consisting of a wide range of immune cells, including 
B cells, T cells and dendritic cells (DCs). This results in excessive production of 
proinflammatory mediators, such as tumour necrosis factor α (TNF-α), interferon-γ, 
interleukin (IL)-1β, IL-6, and IL-17. In addition there is synovial hyper-proliferation 
culminating in damage to the cartilage and underlying bone (figure 1.1). This eventually 
causes joint deformity and ongoing pain. 
Therapies for RA generally involve either global immune suppression or 
immunomodulation by targeted means, e.g. TNF-α inhibition. These treatments 
unfortunately do not work in all patients. As such there is a need for the development of 
novel therapeutics (3). As understanding about disease pathogenesis and heterogeneity 
improves, the therapeutic potential for novel targeting of pathogenic cellular subsets and 
signalling pathways can be explored. 
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Figure 1.1. Schematic of a healthy joint and a rheumatoid arthritis joint  
(a) A healthy joint (b) A RA joint with marked inflammatory cell infiltrate, thickened and 
inflamed synovium and bony erosions.  
Image obtained from http://immunesystemrheumatoidarthritis.tumblr.com/ on 24/9/16. 
 
1.1.2 Early rheumatoid arthritis 
There is some suggestion that the pathological processes present in established RA may 
be distinct from those at disease onset (4-10). From a therapeutic perspective treating 
patients at this early stage has better long term outcomes in terms of patient morbidity, 
radiographic progression as well as disease control, the so called window of opportunity 
(10-20). In addition there is now an appreciation of the benefit of a “treat to target” 
approach in the management of early RA (21, 22). This involves rapid initiation, addition 
and escalation of disease-modifying anti-rheumatic drugs (DMARDs) in the early stages 
after diagnosis. The addition/modification of these therapies is based on disease activity 
as measured by conventional parameters, such as disease activity score-28 (DAS-28). 
This is a composite score which includes swollen and tender joint counts (SJC and TJC) 
as well as markers of inflammation, such as C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) as well as a patient reported measure, visual analogue scale 
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(VAS). The aim of the “treat to target” regimen is to achieve rapid and sustained low 
disease activity as soon as a patient has been diagnosed.  
From a research perspective there is therefore merit in identifying what are the prevalent 
pathological processes in early disease as these may provide therapeutic strategies with 
the potential for long term benefit. As expected DMARDs and glucocorticoids can 
modulate or mask the evidence of these processes (4, 23) and so examining a 
DMARD/glucocorticoid naïve population is likely to yield the most fruitful results.  
In an early arthritis cohort, prior to onset of arthritis there will have been a breach of 
tolerance to self. The exact timing of when this happens is unclear however over recent 
years it is appreciated that patients develop RA associated autoantibodies, such as ACPA, 
many years prior to the onset of arthritis which may suggest that elements involving 
breach of tolerance are a relatively early event (24). These ACPA+ individuals are felt to 
be in a “pre-RA state” and for some this is associated with arthralgia, but no actual 
associated inflammation. However approximately 50% of these ACPA+ arthralgia 
patients will develop RA within 2 years (25). As such this population is being increasingly 
targeted for research into the early pathogenic processes driving the initiation and 
progression of RA.  
1.2 Immune system overview 
The role of the immune system is to protect the host from insults related to microbes or 
chemicals. The immune response has been artificially divided into innate immunity and 
adaptive or specific immunity and these are outlined below. A key element underpinning 
these functions is the recognition of self and non-self. This tolerance to self is a crucial 
factor in preventing inappropriate and damaging immune system activation. When there 
is breach in this tolerance the immune system can target and attack self organs/structures 
resulting in autoimmunity.  
1.2.1 Innate immunity 
Innate immunity is an evolutionarily ancient part of the host defense mechanism (26). It 
consists of barriers, such as epithelial mucosal membranes lining the oral mucosa and gut, 
the complement system as well as a group of immune cells. These cells consist of 
monocytes/macrophages, mast cells, neutrophils, eosinophils and natural killer (NK) cells 
(27).  
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The innate response is not antigen specific and a universal feature of these cells is the 
expression of immune recognition receptors which are triggered upon detection of 
pathogen-associated molecular patterns (PAMPs). These are patterns shared between 
pathogens, for instance bacterial lipopolysaccharide (LPS), carbohydrates, and double-
stranded viral RNA. The best known of these receptors are the Toll like receptors (TLRs) 
which, when activated, promote rapid differentiation of short-lived effector cells whose 
main role is to eliminate any infection (28). 
The innate system therefore provides a background level of defence against invading 
pathogens. For more severe infections it provides protection pending the activation of the 
adaptive immune system but in some instances the innate immune system can also instruct 
the adaptive immune system about the nature of a certain pathogenic challenge.  
1.2.2 Adaptive immunity 
Adaptive immunity is a complex system by which the body learns to recognize a 
pathogen's unique antigens and builds an antigen-specific response to destroy it. These 
responses are performed, under the direction of dendritic cells (DCs), by two main classes 
of lymphocytes called T cells and B cells. These subsets facilitate cell-mediated immune 
responses and antibody responses, respectively (29). 
Dendritic cells 
DCs are professional antigen-presenting cells (APC) and are central in the orchestration 
of the various forms of immunity and tolerance. They are a heterogeneous population of 
cells and there are currently 3 main subtypes in humans which are defined by the 
differential expression of surface proteins. These include in decreasing order of frequency 
myeloid dendritic cells (mDCs), plasmacytoid dendritic cells (pDCs) and CD141+ 
dendritic cells. They each have relatively different specialised functions however all are 
able to provide a link between the innate and adaptive immune system and effectively 
translate the innate signals of damage to promote a targeted anti-pathogen response (30). 
They exist in an immature state at sites of interaction with the environment such as the 
skin and mucosa and continuously sample their environment by micropinocytosis. This 
allows uptake of both self and non-self proteins which are subsequently degraded into 
peptides. These peptides are loaded onto major histocompatibility complex (MHC) 
molecules in a post golgi compartment and trafficked to the cell membrane where they 
are displayed on the cell surface. This process is known as antigen presentation (31).  
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Innate immune system activation and release of cytokines is interpreted by DCs as a 
maturation signal. This causes a variety of effects which include migration of the DC to 
a draining lymph node and release of further proinflammatory cytokines. Maturation also 
increases stability of the peptide-MHC complex as well as triggering upregulation of co-
stimulatory molecules, such as CD40 and CD86. DCs however can also be directly 
activated by exposure to pathogens as they also express pathogen recognition receptors 
(PRRs), such as TLRs, and thus respond to PAMPs. This interaction triggers intracellular 
signalling which results in activation of mitogen-activated protein kinase (MAPK), 
nuclear factor kappa B (NF-κB) and interferon regulatory factor (IRF) pathways. This 
again leads to DC maturation, migration to lymphoid organs as well as upregulation of 
co-stimulatory molecules and release of proinflammatory cytokines (31, 32).  
The upregulation of these co-stimulatory molecules is very important in the 
differentiation of self and maintenance of tolerance as MHC-peptide presentation in the 
absence of co-stimulation will not induce T cell activation. Immature DCs typically 
express low levels of MHC II and costimulatory molecules and therefore are inclined to 
promote T cell anergy and regulatory T (Treg) cell generation, which is important for the 
maintenance of immune homeostasis (33-35). This is also a feature of a physiological 
subset of DCs cells found in vivo which are termed regulatory DCs or tolerogenic DCs. 
Although these DCs are still able to present antigen to antigen-specific T cells they are 
resistant to maturation-inducing signal and downregulate expression of co-stimulatory 
molecules and proinflammatory cytokines. Simultaneously however they also upregulate 
the expression of inhibitory molecules such as programmed death ligand 1 (PDL1) and 
anti-inflammatory cytokines release, such as TGF-β (36). This results in T cell anergy 
and generation of Tregs as well as T cell apoptosis (37). 
Therefore priming and activation of T cells following interaction with DCs requires both 
a MHC-peptide complex/T cell receptor (TCR) interaction as well as the engagement of 
co-stimulatory molecules, such as CD86 or CD40, with T cell expressed CD28 or CD40L, 
respectively. Notably MHC class I will activate naive CD8 cells whereas MHC class II 
leads to the activation of CD4 T cells (38). As well as cell-cell contact naive T cells are 
also exposed to inflammatory cytokines over this period which is an important element 
in activation and can skew downstream development (39) (see T cell section below). 
PDCs are a relatively newly identified DC subset. They were initially described by 
pathologists in the 1950s as plasmacytoid T cells or plasmacytoid B cells based on their 
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morphology and expression of surface markers which included, CD4, HLA-DR, CD36 
and CD68 (40). A few decades later in the 1980s a poorly defined cell subtype was 
identified that produced large amounts of type 1 interferon causing it to be categorised as 
a natural-type-1-interferon producing cell. From the work in the late 1990s of Nobel Prize 
winner Ralph Steinman and others these 2 cell subsets were shown to be the same and in 
fact were DCs, leading to the classification of pDCs that are known today (41). 
Identification in humans of the unique surface marker CD303 (BDCA-2), a novel type II 
transmembrane C-type lectin, has greatly aided in identification and subsequent 
investigation of pDCs and they are now generally defined (in humans) as being CD303+, 
HLA-DR+, CD123+, CD45RA+ and CD11c- (42).  Even within the DC population pDCs 
are a rare subtype and make up only 0.3-0.5% of circulating PBMCs. Despite their low 
number they function as the main producers of interferon-α in vivo and have been shown 
to produce 1000 times more interferon-α than any other cell type (43). PDCs do not exist 
in isolation and recently it has been shown that upon stimulation their interferon-α 
production can be further amplified through interactions with B cells, NK cells as well as 
T cells (44). They can also function as APCs by the upregulation of HLA-DR and 
production of other pro-inflammatory cytokines, such as TNF-α and IL-6 (45). 
Furthermore TGF-β exposed pDCs can participate in skewing towards a Th17 response 
(46). Thus pDCs, by their production of type 1 interferons as well as their APC capacity, 
can provide a link between the innate and adaptive immune system in the fight against 
foreign invaders or in the promotion of an autoimmune phenotype (41).  
Conversely pDCs have also been proposed to have tolerogenic potential (45). They 
express high levels of the immunomodulatory enzyme indoleamine-pyrrole 2,3-
dioxygenase (IDO) (45, 47, 48). This is a rate limiting intracellular enzyme in the break-
down of the essential amino acid tryptophan into kynurenine and this can have tolerising 
effects by a variety of ways (49). The localised depletion of tryptophan can activate the 
stress kinase general control nonderepressible 2 (GCN2) in developing CD4+ T cells 
which, along with the generation of soluble tryptophan catabolites, promotes Treg 
differentiation (49, 50). In addition kynurenines have been recently identified as ligands 
for the aryl hydrocarbon receptor (AHR) and ligation of this receptor promotes Tregs 
differentiation as well as inhibiting Th17 differentiation (51-53). These effects are seen 
in vivo and in vitro where pDCs skew naïve T cells towards a functional Treg phenotype 
via IDO (45, 47, 54, 55) as well as by increased expression of PDL1 and inducible T-cell 
co-stimulator ligand (ICOSL) (56-61). However what is the net effect of pDCs in human 
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disease with regards to these two, relatively conflicting, functional capacities is often 
unclear.  
 
T cells 
T cells are divided into two main classes, CD4+ and CD8+ but both start their development 
in the thymus from bone marrow derived progenitor cells. Here they undergo extensive 
positive and negative selection that ultimately results in naive CD4+ and CD8+ T cells 
displaying on their cell surface an extensive and comprehensive selection of unique TCRs 
(62). These TCRs recognise a wide range of foreign peptides displayed in conjunction 
with MHC molecules on the surface of APCs, the most efficient of which is the DC. 
CD4+ T cells can form a variety of diverse functional subsets depending on the signals 
they receive during their differentiation process. These include a growing diversity of T 
helper (Th) subclasses each with a distinct transcription factor resulting in distinctive 
cytokine production profiles and functions (38) (figure 1.2). Th1 cells produce, among 
others, pro-inflammatory cytokine interferon-γ and evoke cell-mediated immunity and 
phagocyte-dependent inflammation. An imbalance favouring Th1 response has 
conventionally been associated with the development of autoimmunity. Th2 cells, which 
produce IL-4, IL-10, and IL-13, evoke strong antibody responses (including those of the 
IgE class) and eosinophil accumulation, but inhibit several functions of phagocytic cells. 
When the balance favours Th2 response it classically promotes allergy (63). More 
recently Th17 cells were described which produce, amongst other cytokines, IL-17 which 
has been shown to facilitate anti-fungal responses, as well as having a major role 
inflammation and autoimmunity (64-66). Naive CD4+ T cells can also differentiate into 
follicular helper T (Tfh) cells, which assist B cell responses, or Tregs, which are involved 
in homeostasis and tolerance.   
Activation of naive CD8+ T cells results in a highly cytotoxic cell subset. They traffic 
rapidly out of the lymphoid tissue into the peripheries to the site of infection where they 
kill any infected cells and release cytokines such as interferon-γ. This has earned them 
their alternative name, cytotoxic T cells (67).  
Once primed and activated T cells undergo clonal expansion and acquire effector cell 
functions. This is followed by an eventual reduction in number and a formation of 
memory cell populations that are long lived and remain in the circulation and lymphoid 
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organs. Upon re-exposure to the same antigen the T cells are able to expand rapidly from 
the memory T cell pool demonstrating the existence of immune memory (68).  
 
Figure 1.2 Dendritic cell and Naive T cell interactions  
Dendritic cells (DCs) have the ability to skew T cell differentiation. Naïve CD4+ T cells 
can be polarized into different effector T cell subsets; T helper 1 (TH1), TH2, TH17 and 
regulatory T (Treg) cell. This process is controlled by distinct sets of transcription factors 
as well as the inflammatory cytokine milieu; IL-12 will promote TH1 differentiation 
characterised by expression of the transcription factor T-bet and STAT4; IL-4 will 
promote TH2 differentiation characterised by expression of the transcription factor 
GATA3 and STAT6; TGFβ will promote Treg differentiation characterised by expression 
of the transcription factor FOXP3; IL-6 and TGFβ will promote TH17 differentiation 
characterized by expression of the transcription factors RORγt and STAT3, additionally 
IL-1 and IL-23 can promote and/or stabilize TH17 cell differentiation and expansion.  
IL, interleukin; STAT, signal transducer and activator of transcription; GATA3, GATA-
binding protein 3; TGFβ, transforming growth factor-β; FOXP3, forkhead box P3; 
RORγt, retinoic acid receptor-related orphan receptor-γt; IFNγ, interferon-γ; TCR, T cell 
receptor Figure adapted from Zou et al, 2010 (65)   
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B cells 
The other arm of the adaptive immune system is the B cell. These cells differentiate in 
the bone marrow before migrating to lymphoid organs and circulating in the blood. They 
require external signals for survival which maintains a stable homeostasis of the B cell 
pool. The B cells express a B cell receptor (BCR) which can sense soluble antigen as well 
as membrane bound antigen, e.g. provided by APCs. The BCR consists of membrane 
bound immunoglobulin (IgM) non-covalently bonded to a heterodimer composed of 
CD79a (Igα)/ CD79b (Igβ). The antigen specificity is determined by the variable domain 
of the IgM.  Following the binding of the BCR to its cognate antigen tyrosine residues in 
the cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM) portion of 
CD79a and CD79b are phosphorylated and trigger downstream signaling pathways that 
trigger the first signal of B cell activation and cause migration to lymphoid tissue (69). 
The B cell can also present antigen in MHC class II complexes. This results in further 
costimulation by interactions with Tfh residing within the lymphoid tissue (70). In 
addition, B cells can respond to antigen independently of T cell help by activation of 
PRRs, such as TLR7, and after costimulation signals from other immune cells, such as 
DCs via B-cell activating factor (BAFF)–BAFF receptor interactions (71-73).  
After activation the naïve B cell can differentiate into a short-lived IgM (or IgG) secreting 
plasma cell which occurs outside germinal centres. Alternatively within germinal centres 
the B cell can undergo class switch and differentiate into memory B cells or long-lived 
plasma cells that produce IgG, IgA or IgE antibodies (Figure 1.3) (68). Memory B cells 
remain in the circulation and in the secondary lymphoid organs after the infective insult 
has passed but are intrinsically programmed for enhanced antigen responses, in part due 
to their increased receptivity to antigen and to co-stimulation. Thus if the same antigen is 
ever encountered again they rapidly proliferate and differentiate into a high affinity 
antibody (IgG, IgA, IgE isotypes) producing plasmablast and plasma cell (68).  Finally 
there is a further subset of B cells that has only been relatively recently identified termed 
regulatory B cells (Bregs). This subset has the ability to suppress or modulate T cell 
immune responses via a variety of mechanisms, including IL-10 and TGF-β production, 
as well as cell-cell contact (74).  
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Figure 1.3 Naïve B cell differentiation pathways  
Naïve B cells can be become activated by antigen and T cell help whereby they can 
differentiate into short lived plasma cells which reside in the lymphoid tissue. These are 
generated during the primary response and mainly generate IgM but can produce IgG as 
well. However upon activation naïve B cells can also seed into germinal centres. From 
there, often with the help of T follicular cells, they can either become 1) memory cells 
which are long lived and remain in the circulation, or 2) they can terminally differentiate 
into long lived plasma cells in the bone marrow which make mainly IgA, IgG and IgE. 
Finally there is some suggestion that upon encountering the same antigen again memory 
B cells can differentiate into terminally differentiated long lived plasma cells also. All 
arrows are driven by both antigen exposure and T cell help.  Figure adapted from Gray, 
2010 (68). 
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1.2.3 Evidence of immune dysfunction in RA 
Rheumatoid arthritis is an autoimmune condition where there is dysregulated immune 
function and this can affect nearly all immune cells (10, 75-83). Understanding the 
pathogenic processes involved can both direct understanding of the disease as well as 
help identify new therapeutic targets. 
Dendritic cells 
Due to their ability to link both the innate and adaptive immune systems DCs are of 
interest in RA. Synovial tissue and fluid of RA patients has a marked infiltration of both 
immature and mature DCs which closely associate with T cells and B cell follicles. These 
DCs are highly activated with upregulation of MHC and costimulatory molecules. They 
are likely to also play a key role in promoting synovial inflammation by the production 
of large amounts of T cell attracting chemokines, as well as the pro-inflammatory 
cytokines IL-12 and IL-23 which promote T cell differentiation into pathogenic Th1 or 
Th17 cells, respectively (84). 
A number of groups have shown that pDCs are not normally seen in the synovial 
compartment but migrate there in inflammatory settings, such as RA (85-88). Synovial 
fluid pDCs can activate T-cells ex vivo and have high CD303 expression suggesting 
interferon-α production (85-87, 89). Synovial fluid pDCs also have marked expression of 
myxovirus resistance protein A (MxA), a cytoplasmic protein induced by type 1 
interferons suggesting active exposure to these cytokines intra-articularly (85, 89). 
Furthermore pDCs appear to cluster with B-cells within the rheumatoid synovium and 
there is a positive association between the number of pDCs in the joint and RF antibodies 
and ACPA titres (88). However the role of pDCs is likely to be complex and remains 
controversial as RA patients with inactive disease had higher levels of pDCs within the 
circulation which were able to skew T cells into IL-10 producing Tregs (54). In addition 
pDC depletion in a mouse model of RA actually caused a deterioration in phenotype with 
increased autoantibody generation (90). Thus it is still unclear if the net function of pDCs 
in RA is inflammatory or tolerogenic.  
T cells  
Over recent years T cells have been acknowledged as one of the main pathological cell 
subsets in RA. Some of the earliest evidence has been the infiltration of inflamed RA 
synovial tissue with T cells (91). There has also been success with therapies modulating 
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T cell function which includes the use of abatacept, a cytotoxic T lymphocyte-associated 
antigen-4 (CTLA4) fusion protein (92). 
RA was historically considered a Th1 disease due to the clear association between 
interferon-γ and pathogenesis (93). Currently however there is evidence that an abnormal 
Th17 population is also present in RA. IL-17 is present at sites of inflammatory arthritis 
and in several animal models of arthritis inhibition of IL-17 limits inflammation and joint 
erosion. One proposed mechanism may be that IL-17 can amplify the inflammation 
induced by other cytokines, primarily TNF-α (94). However it is becoming apparent that 
Th2 cytokines are likely to be relevant also, particularly in early disease (80, 95). There 
is debate over the number of Tregs in RA with no clear consensus if there is a change in 
number, nonetheless there is some evidence that those that do exist also a have reduced 
functional capabilities making them less efficient at supressing inflammatory responses 
(75, 96-99). 
B cells 
As mentioned autoantibodies are frequently a hallmark of RA where there has been a 
breach of tolerance (100).  This finding suggests B cells may be an important player in 
RA disease initiation and progression. The most frequently reported autoantibodies are 
RF and ACPA or anti-CCP, however the autoantigen(s) for these antibodies has not been 
defined with certainty (100). Autoantibodies are often present many years before the onset 
of symptoms (24) and ACPA antibodies present an independent risk factor for the 
development of RA (25, 100). These antibodies may have effects on clinical features; 
ACPA antibodies have been associated with increased bone erosions (101) and in vitro 
promote the differentiation of mononuclear cells to osteoclasts and therefore directly 
promote bone loss (102). Recently other antibodies have also been associated with RA 
and pre-RA states, for example anti-carbamylated protein antibodies (anti-CarP) (103). 
As well as their ability to produce autoantibodies, B cells can further contribute to disease 
pathogenesis by cytokine production, antigen presentation and T cell activation and have 
also been shown to be increased in the inflamed synovial compartment in RA, sometimes 
arranged in ectopic lymphoid follicles which appear to produce autoantibodies (83, 104, 
105). There is also increasing evidence that Bregs are reduced in RA (106). The 
pathogenic role of B cells in RA has also be validated by the therapeutic success of B cell 
depleting therapies, such as rituximab which depletes CD20 expressing B cells (92).   
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1.3 Type 1 interferons 
There is clear evidence of dysregulated cytokine production in RA and the importance of 
certain pathways, such as TNF-α or IL-6 has again been confirmed by the success of 
therapies that target them or their receptors (92). These cytokines have been further 
proposed as a mechanism whereby interaction between the innate and adaptive immune 
systems may occur and dysfunctional pathways entrenched (66). The work presented in 
this thesis focuses on one of these classes of cytokines, type 1 interferons.  
Type 1 interferons are a family of cytokines first discovered over 50 years ago and were 
identified by their ability to inhibit or “interfere with” viral replication. Since their initial 
discovery it has emerged that, in humans, the type 1 interferon family is more extensive 
and complex than initially presumed. It consists of 13 functional interferon-α genes and 
single genes for interferon-β, interferon-κ, interferon-ε and interferon-ω (107). For the 
majority of this thesis I will focus on the effects of interferon-α. With the appropriate 
stimuli, usually during viral infections, all cell subsets can produce type 1 interferons.  
However DCs, and particularly pDCs, are the most prolific producers of type 1 interferons 
(43). 
1.3.1 Type 1 interferon signalling 
All members of the type 1 interferon family (interferon-α, -β, -κ, -ε and –ω) bind to a 
common heterodimer receptor consisting of 2 subunits, interferon-α receptor 1 and 2 
(IFNAR1 and IFNAR2). Ligation of this receptor results in the activation of two receptor 
associated protein tyrosine kinases, Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2). 
These phosphorylate signal transducer and activator of transcription (STAT) 1 and 
STAT2 which subsequently dimerise into a STAT1/STAT2 heterodimer. This binds to 
interferon regulatory factor 9 (IRF9) to form a trimer and it is this complex that binds to 
specific DNA target sequences within the nucleus celled interferon stimulated response 
elements (ISREs). Once bound these promote the transcription of interferon response 
genes (IRGs), such as MxA. There are over 2000 IRGs that can affect a wide range of 
signalling pathways generally associated with anti-viral response (108). Alternatively, the 
phosphorylated STAT proteins can form STAT1-STAT1 homodimers and these are able 
to bind to gamma-activated sequences (GASs) to induce pro-inflammatory genes. These 
are normally activated by type 2 interferons, such as interferon-γ, hence there can be an 
element of overlap between type 1 and type 2 interferon signalling (figure 1.4). 
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Figure 1.4 Interferon receptors and activation of classical JAK–STAT pathways by 
type I and type II interferons. 
Type I interferons (interferon-α, -β, -κ, -ε and –ω subtypes) bind a common type 1 
interferon receptor (IFNAR) made up of two subunits IFNAR1 and IFNAR. These 
subunits associate with TYK2 and JAK1 respectively. TYK2 and JAK1 activation results 
in phosphorylation of STAT2 and STAT1; this leads to the formation of STAT1-STAT2-
IRF9 complexes which translocate to the nucleus where they bind DNA interferon 
stimulated response elements (IRSEs) and initiate transcription of interferon response 
genes (IRGs). Type 2 interferon (interferon-γ only) binds the type II interferon receptor 
which is made up of IFNGR1 and IFNGR2. These subunits associate with JAK1 and 
JAK2 respectively. Both type I and II interferons can also induce STAT1-STAT1 
homodimer formation. These translocate to the nucleus and bind GAS elements which 
are also present in the promotor regions of certain IRGs. Thus there can be a cross over 
between type 1 and type 2 interferon signalling.  
STAT, signal transducer and activator of transcription; IRF, interferon regulatory factor; 
TYK2, tyrosine kinase 2; JAK, Janus kinase. Figure adapted from Platanias, 2005 (107) 
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1.3.2 Sensors that trigger type 1 interferon production 
The production of type 1 interferons occurs predominantly following the encounter of 
PAMPS which are associated with foreign bacteria/viruses, such as viral RNA or bacterial 
DNA. These are detected by PRRs and can help discriminate between self and non-self 
since PAMPs are widely expressed in pathogens but not in host/human cells. PPRs that 
detect nucleic acids can be broadly grouped into TLRs, which monitor the contents of 
endosomal compartments, and cytosolic receptors, such as the retinoic acid-inducible 
gene-I-like receptors (RLRs), which monitor nucleic acids within the cytoplasm.  
PDCs express the endosomally located TLR7 and TLR9 which detect single stranded 
RNA (ssRNA) and DNA hypomethylated CpG motifs, respectively. ssRNA is found in 
viruses and hypomethylated CpG is mainly found in bacterial DNA. TLR9 CpG ligands 
can be divided into CpG-A and CpG-B and, due to their intrinsic structure and the 
resultant speed of intracellular transport, CpG-A and CpG-B have different effects on 
pDCs. They both bind TLR9 which triggers signal transduction through the adaptor 
protein myeloid differentiation factor 88 (MyD88). However due to the 
phosphodiesterase backbone seen in CpG-A it is trapped for longer in the endosome. This 
predominantly induces the nuclear translocation of IRF7 and the subsequent rapid and 
potent transcription of interferon-α. CPG-B is more rapidly trafficked through the 
endosome and subsequently, via activation of MyD88-NFκB, predominantly causes the 
upregulation of co-stimulatory molecules and antigen presentation markers, such as 
CD86, HLA-DR, as well as the release of other inflammatory cytokines such as IL-6 and 
TNF-α (109). TLR7 signalling causes increase of type 1 interferons by MyD88 associated 
pathways but also causes pDC maturation (110). 
The effect of TLR signalling can be modulated by ligation of certain pDC surface 
markers. Immunoglobulin-like transcript 7 (ILT7) is selectively expressed on human 
pDCs and crosslinking of ILT7 induces an ITAM-mediated signalling cascade which 
negatively regulates TLR7/9-induced type I interferon and cytokine responses. In vivo the 
physiological ligand for ILT7 is bone marrow stromal cell antigen 2 (BST2) which is 
expressed on B cells and pDCs upon exposure to type 1 interferons, thereby potentially 
functioning as a negative feedback mechanism (111). CD303 ligation is another important 
negative feedback mechanism on the production of type 1 interferons. CD303 signalling 
causes intracellular calcium mobilisation and protein tyrosine kinase phosphorylation, 
such as spleen tyrosine kinase (SyK). This reduces IRF7 nuclear translocation and can 
also decrease NFkB signalling, thus reducing type 1 interferon production and other pro-
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inflammatory cytokine production (42, 112-114).  More recently death receptor 6 (DR6) 
has been identified as being able to modulate pDC production of type 1 interferons 
although what relevance this has in vivo is unclear (115). 
Other intracellular PRRs important in the induction of type 1 interferons are the 
cytoplasmic RLRs. This family consists of retinoic acid-inducible gene-I (RIG-
I/DDX58), melanoma differentiation associated gene-5 (MDA5/IFIH1) and ‘laboratory 
of genetics and physiology’ (LGP2/ DHX58). These receptors detect structural features 
of viral RNA that are distinct from host RNA and initiate a potent antiviral response. RIG-
1 is reported to detect short dsRNA and MDA-5 long dsRNA within the cytoplasm. Upon 
activation these RLRs bind to MAVS, a mitochondrial transmembrane protein that acts 
as an adaptor between the RLR sensors and TANK binding kinase 1 (TBK1) and the 
transcription factors IRF3 and IRF7. This ultimately promotes the production of type 1 
interferons (116-118).  Intracellular receptors for DNA include stimulator of interferon 
genes (STING), another transmembrane receptor, which also functions to link cytosolic 
DNA to a TBK1/IRF3/IRF7 antiviral response; thus stimulating type 1 interferons 
production (116, 119). STING expression is further amplified by exposure to type 1 
interferons (120).  In addition STING can also be activated by cyclic dinucleotides 
produced by bacteria as secondary messengers (121). Other DNA receptors include IFI16 
and it is hypothesised that many more are still to be discovered (122). 
Despite their overlapping function certain aspects are quite distinct between these PRRs. 
For example TLR are differentially expressed across cell types (i.e. pDCs only express 7 
and 9) and are predominantly found in leukocytes, whereas cytosolic PRRs are expressed 
much more broadly and are present in most cells (116, 117). They may also have distinct 
relative importance in some cell subsets, for example one study suggested that in mice 
pDCs preferentially use the TLR system for viral detection (123) and, unlike monocytes, 
express constitutively low levels of RIG-1 (124).  Other distinctions are that when 
pathogen-derived nucleotides interact with endosomally expressed TLRs following 
endocytosis this process does not require cellular infection.  Alternatively, cytosolic PRRs 
detect nucleic acids that reach the cytosol, which typically indicates that the cell has been 
infected. This means TLR-expressing cells respond to pathogens independently of 
cellular infection, whereas cytosolic PRRs act as general cell-autonomous sensors of 
infection. Nonetheless taken together these two groups of PRRs can facilitate the 
recognition of viral/bacterial nucleic acids in multiple scenarios of infection and initiate 
a rapid anti-viral/bacterial type 1 interferon response. 
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1.3.3 Effect of type 1 interferons on immune cells 
Type 1 interferons have the potential to enhance the survival, proliferation and effector 
functions of numerous immune cell types, many of which have implications for 
autoimmunity.  
Dendritic cells  
DCs exposed to type 1 interferons become activated with upregulated HLA-DR 
expression and increased expression of co-stimulatory molecules such as CD40, CD80 
and CD86. In predisposed individuals this can lead to the efficient presentation of self-
antigen to previously non proliferative and low-affinity autoreactive T cells, leading to 
induction of autoimmunity (125). Type 1 interferon signaling can also increase DC 
survival and this may also contribute to autoimmunity as, in SLE susceptible mice, 
apoptosis resistant DCs can induce a lupus like syndrome (126). Interferon-α, along with 
GM-CSF, can also cause the differentiation of monocytes into functional DCs which have 
an activated phenotype and can efficiently stimulate T cells (127-129). Finally, 
interferon-α upregulates pDC, mDC and monocyte expression of TLR7 and IRF leading 
to an increased responsiveness of these cells to any immunostimulatory TLR7 ligands, 
which would further augment interferon-α synthesis (130). 
T cells 
Type 1 interferons can also affect T cells. They can skew naïve CD4+ T cells towards a 
Th1 phenotype, which results in increased interferon-γ production, as well as promoting 
the generation of T-follicular helper cells that are efficient at activating B cells and 
promoting antibody production (131). Regulatory T cell immunosuppressive function is 
also impaired by high interferon-α levels (132). Type 1 interferons can promote T cell 
survival and promote the cytolytic activity of CD8+ cytotoxic T cells, as well as 
prolonging the proliferation and expansion of antigen specific CD8+ T cells (133-137). 
Furthermore type I interferons can inhibit B- and T-cell lymphopoiesis. This would 
effectively limit any dilution of expanded antigen-specific clones which would be 
potentially beneficial in the response to foreign antigens, but harmful in autoimmunity 
(138). 
B cells 
Type 1 interferons can directly affect B cells in a number of ways. They can lower the 
BCR signaling threshold, increase TLR7 expression as well as upregulate cell surface 
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molecules such as CD69, CD86 and HLA-DR that affect B-cell function and survival 
(139, 140). Type 1 interferons further promote longevity by upregulating BCL2 which 
makes the B cells relatively resistant to apoptosis (141). Finally type I interferon exposure 
also positively affects the B-cell response to IL-6, which is an important cytokine 
involved both in B-cell survival and differentiation (142). Autoantibody production may 
be further affected by interferon-α due to it enhancing BAFF release from other immune 
cells, particularly DCs or monocytes. This promotes the survival, differentiation and 
activation of (auto)reactive B cells as well as promoting differentiation into plasmablasts 
and immunoglobulin class-switched cells (143-146). B cells may also positively feedback 
into the production of type 1 interferons by autoantibody containing immune complexes 
binding to FcγRIIa (CD32) on pDCs and subsequent internalization of the immune 
complex. These can contain self-antigen in the form of nuclear material, particularly in 
SLE, which can trigger intracellular nucleic acid sensing pathways to promote further 
pDC interferon-α release (147-151) (figure 1.5). 
 
Figure 1.5 Schematic demonstrating the diverse effects of interferon-α on immune 
cells 
Plasmacytoid dendritic cells (pDCs or natural interferon producing cells, NIPCs) are 
activated to release interferon-α (IFN-α) on interaction with either viruses/bacteria or with 
autoantibody containing immune complexes formed with necrotic or apoptotic cell 
material. IFN-α can cause type 1 DC (or myeloid dendritic cell) maturation which 
promotes T cell activation. T cells can also be directly affected by IFN-α and the end 
product of both these effects is B cell help. B cells are also directly activated by IFN-α 
but the additional T cell help can promote the generation of antibodies, some of which 
can be autoantibodies. These can form further immune complexes which promote further 
IFN-α release from pDCs.  
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1.3.4 Type 1 interferons in autoimmunity  
As previously highlighted many of the effects induced on exposure of cells to type 1 
interferons have relevance to autoimmunity. These effects have been investigated in a 
number of autoimmune conditions such as primary Sjogrens syndrome (pSS), 
dermatomyositis but most research has been done in systemic lupus erythematous (SLE) 
(152, 153). I will therefore mainly present evidence relating to type 1 interferons and 
SLE. SLE is a chronic autoimmune condition affecting the skin, joints, and internal 
organs. In the 1970s it was first noticed that patients with SLE had increased levels of 
interferon-α in their sera (78, 154). There have been a number of gene expression studies 
showing activation of the type 1 interferon pathway in SLE and in cross-sectional studies 
this was associated with disease severity as well as propensity to develop renal 
involvement (155-159). Furthermore interferon-α inducible chemokines (e.g. CXCL10, 
CCL2 and CCL19) have a clear temporal association with disease and could predict future 
disease flares (160). Finally trials interferon-α signalling inhibition have had some 
success ameliorating disease and autoantibody titres (157, 161, 162).  
In vivo type 1 interferon activity is predominantly measured by expression of IRGs that 
are upregulated upon exposure to type 1 interferons. This is known as an interferon gene 
signature (IGS) and the majority of SLE patients have evidence of an IGS (108, 130, 155). 
There is increasing appreciation however that, in SLE at least, there is overlap between 
the effects of type 1, type 2 (interferon-γ) and indeed type 3 interferons (interferon-λ), in 
the generation of an IGS (163, 164). Nonetheless sufficient evidence as outlined above 
links type 1 interferons to disease pathology and SLE is acknowledged as a prototype 
disease where type 1 interferons play a clear pathogenic role (157). 
1.4 Type 1 interferons in RA 
In spite of the body of evidence that links interferon-α to autoimmunity, this cytokine has 
received relatively little attention in RA. However there is nonetheless an emerging 
appreciation that type 1 interferons may be implicated in the pathogenesis of RA. 
1.4.1 Type 1 interferon associated genes and RA susceptibility 
The most common polymorphism associated with increased RA risk is in the HLA-DRB1 
allele, termed the “shared epitope.” This is a five amino acid sequence motif in residues 
70–74 of the HLA-DRβ chain and is carried by the vast majority of RA patients (165). 
However increased availability of techniques that interrogate the genome has identified 
other gene polymorphisms that increase RA susceptibility. Among those identified a 
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considerable number are involved in the regulation or production of type 1 interferons 
(166). Three polymorphisms that increase susceptibility have been identified in IRF5 and 
these effects are most marked in those that have the shared epitope (167-170). There are 
also copy number variations of IRF1 which increase RA susceptibility (171), and in vivo 
RA mouse models lacking IRF1 had a reduced frequency and severity of disease (172). 
There have also been reports of associations with downstream signalling of type 1 
interferons with STAT4, STAT1 and STAT2 all being implicated (173, 174). Upstream 
signalling is also implicated with polymorphisms in IFI1H, a RNA cytoplasmic sensor 
for viral infection, as well as TLR genes (TLR2, TLR4, TLR8 and TLR9) increasing 
disease risk (175). In SLE these polymorphisms were associated with increased interferon 
activity suggesting there may also be a functional consequence of these polymorphisms 
in RA (176). 
1.4.2 Type 1 interferons in early and established RA 
There is evidence from both mouse work and clinical studies that type 1 interferons may 
be important early on in disease. In mice intra-articular type 1 interferon injections induce 
inflammatory arthritis (177) and inhibition of interferon-α signalling pathways by a 
variety of means prevented the development of inflammatory arthritis in susceptible 
animal models (172, 177-179). In humans interferon-α administered as an anti-viral 
therapy in some patients triggered a symmetrical polyarthritis consistent with RA and 
some even developed RA associated autoantibodies (180). Some have suggested that 
infections, known to produce a surge in circulating interferon-α, may promote disease 
flares in RA, although this is not been conclusively proven  (181). Finally in ACPA 
positive arthralgia patients, an at risk group for developing RA, an IGS predicted the 
development of RA (182, 183).  
There is an IGS reported in a subset of established RA patients, normally quoted to be 
present in between 20-30% (155, 184-186). This signature is also reported in synovial 
membrane which supports the involvement of type 1 interferons in target tissue (153). 
Nonetheless, contrary to what is seen in SLE, in established RA there is no published 
association between the IGS and disease activity, although notably for all these studies 
patients were on DMARDs (186, 187). One study did report an association between serum 
interferon-α and DAS-28 in established RA but this has not been replicated (188). There 
is currently conflicting evidence to support the hypothesis that the IGS in RA is the same 
“signature” as that seen in SLE. Some studies report the transcriptomics are the same (5, 
189), whereas others suggest they are distinct with RA displaying a lower type 1 
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interferon involvement with a further emphasis on JAK/STAT pathways, chemokines and 
chemokine receptors (153, 185, 190, 191).  This suggests the type 1 interferon associated 
pathology between these two conditions may be distinct. In addition the type 1 interferon 
family may be more complex than previously appreciated as the different type 1 
interferons do not have a universal effect on RA pathophysiology. Interferon-β, a type 1 
interferon encoded by a single gene, appears to be distinct from the interferon-α subtypes 
despite both cytokines binding to IFNAR (figure 1.4). Interferon-β has mainly anti-
inflammatory properties and, following its successful use in the treatment of multiple 
sclerosis (MS) (192), investigations into a potential therapeutic role in RA were 
commenced.  RA is frequently characterised by bony erosions and in vitro interferon-β 
plays an important role in bone homeostasis (193, 194). Interferon-β also downregulates 
the in vitro production of proinflammatory cytokines, such as IL-6 and TNF-α, from 
lymphocytes, macrophages and fibroblast like synoviocytes (FLS) as well as reducing the 
release of matrix metalloproteinases and GM-CSF from RA FLS (193, 195). These effects 
are also seen in vivo where interferon-β administration was able to ameliorate or prevent 
disease in animal models (196-198). Furthermore there was a modest response to 
interferon-β therapy in a phase 1 trial for the treatment of RA, however this was not 
reproduced in a double blinded phase 2 study (197, 199).  
Despite the above caveats the IGS does have clinical relevance in RA as it can affect the 
response to certain biological therapies. The most extensively investigated of these has 
been rituximab, an anti-CD20 monoclonal antibody which depletes B cells. There is 
convincing evidence that a high IGS predicts, and is associated with, a poorer response 
to rituximab (23, 186, 200-202). Conversely however a high IGS predicts a better 
response to tocilizumab, an IL-6 targeting antibody (203), and, although there has been 
some variability between studies, a similar effect has been reported with infliximab, an 
anti-TNF-α antibody (204-206). There has been no investigation whether the IGS affects 
response to non-biological therapies, such as methotrexate or other standard DMARDs. 
Nonetheless the IGS is currently emerging as an intriguing biomarker in the treatment of 
RA.  
What may be driving this production of type 1 interferons in RA is not clear. A study 
using a lymphotoxin-beta receptor-immunoglobulin fusion protein that blocks the 
lymphotoxin-αβ/LIGHT axis demonstrated a fall in the IGS in RA following its 
administration suggesting that this pathway may be involved, although to date it is not 
clear how (187). Another mechanism may be related to PRR signalling. TLR transcripts 
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are increased in early RA synovial tissue and in active disease (207, 208). Triggers of 
these pathways, such as microbial products or endogenous cellular breakdown products, 
are also found in the RA joint (209-212). Therefore, although PRR signalling has not been 
linked to the production of type 1 interferons in RA, it is conceivable that they may be 
implicated.  
1.5 Retrotransposons  
1.5.1 Retrotransposon biology 
DNA has been traditionally categorised into protein coding sections (genes) which make 
up approximately 2% of the human genome, and non-protein coding sections which have 
been termed “junk DNA”. However, it is increasingly appreciated that these non-protein 
encoding sections are not truly “junk” and in fact have transcriptional activity and 
potential regulatory relevance (213). A substantial portion of the human genome is 
derived from ancient transposable elements, such as retroviruses, that have been 
incorporated into the genome. These transposable elements were first described in the 
1950s and have been divided into two separate major classes: DNA transposons or RNA 
retrotransposons/retroelements which replicate via an RNA intermediate (214) These 
make up approximately 3% and 40% of the human genome, respectively. The majority 
of these transposable elements no longer retain the ability to replicate, however some of 
the RNA retrotransposons do and this subset is the focus of a part of my work (121). 
RNA retrotransposons replicate through what has been described as a “copy and paste” 
mechanism whereby they insert new copies of themselves into the genome. A strand of 
mRNA is generated and is developed into a double stranded DNA product which is then 
inserted into a unique region of the genome, often separate from the area of origin (121, 
215). Retrotransposons/retroelements can be divided broadly into two main classes 
(figure 1.6). The first of which are able to encode all proteins required for this replication 
and insertion process. These include endogenous retroviruses (ERVs), often detected as 
long terminal repeats (LTRs), and long interspersed nuclear element 1 (LINE-1). 
LTR/ERVs make up approximately 8% of the human genome and are more clearly 
identified as relics of ancient retroviruses that have been incorporated into the genome. 
Their replication cycle and organisation is similar to that seen in exogenous retroviruses, 
such as human immunodeficiency virus (HIV), and they contain the pol gene encoding 
reverse transcriptase. They also encode additional proteins, gag and env but generally, 
although transcriptionally active, do not expand through new integration (216, 217). 
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LINE-1 are smaller than ERVs, approximately 6kb in length, and encode 2 proteins, 
ORF1 and ORF2 that coordinate replication through target-primed reverse transcription. 
ORF2 can generate a “nick” in the genomic DNA allowing for retroelement insertion as 
well as facilitating ORF-2 dependent reverse transcription into c-DNA at the site of 
insertion (215, 218). The final class of retroelements are termed non-autonomous 
retroelements. These are short interspersed nuclear elements (SINEs), the most common 
of which are known as “Alu”. These are quite small at only 300bp but make up 
approximately 11% of the human genome (215). Due to their smaller size they do not 
encode the machinery necessary for their retrotransposition into the genome. However 
they are highly active and hijack the LINE-1 reverse transcription to facilitate their 
insertion/replication (218).  
 
Figure 1.6 Types of retroelements in a mammalian genome 
The types of retroelements in a mammalian genome are shown. Autonomous 
retroelements include endogenous retroviruses (ERV) - detected as long terminal repeats 
(LTRs) - as well as long interspersed nuclear element 1 (LINE-1). These both encode all 
proteins necessary for their replication and retrotransposition. Non-autonomous 
retroelements, such as short interspersed nuclear element 1 (SINE), the most common of 
which is Alu, are much smaller and hijack LINE-1 machinery to facilitate their mobility.  
Gag, group-specific antigen; Prt, protease; Pol polymerase; Env, envelope; UTR 
untranslated region.  Figure adapted from Volkman et al., 2014 (121).  
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1.5.2 Retrotransposon processing and degradation 
The retrotransposition of retroelements generates viral nucleic acid within the cell as both 
RNA and c-DNA but RNA-DNA hybrids can also form. This means that cytosolic RNA 
and DNA sensing pathways, such as the RLRs and STING (see section 1.3.2) can be 
triggered resulting in the release of type 1 interferons.  
Research performed in the infectious diseases field on HIV, an exogenous retrovirus, as 
well as on so called type 1 interferonopathies, such as Aicardi–Goutières syndrome (AGS)  
has greatly aided understanding about intrinsic cellular mechanisms that have evolved to 
modulate retroviral replication (121). These mechanisms include a series of enzymes that 
can modulate both LINE-1 and ERV replication. The best characterised of these is three 
prime repair exonuclease 1 (Trex1), a human 3’ repair exonuclease. This enzyme 
metabolises the DNA products of reverse transcription and therefore can block 
retrotransposition. This also prevents subsequent activation of cytosolic DNA sensing 
pathways, such as STING (219). Mutations in Trex1 which inhibit its function have been 
identified in AGS, as well as in some forms of familial chilblain SLE. These mutations 
cause a marked interferon-α response resulting in a severe autoimmune phenotype (220, 
221). Other key enzymes include SAM Domain and HD Domain 1 (SAMHD1), which 
degrades cellular dNTPs thus preventing reverse transcription, and ribonuclease H2 
(RNase H2), which degrades the RNA of any RNA-DNA hybrids and has also been 
proposed to degrade viral RNA in the context of reverse transcription. Again mutations 
in both these enzymes have been associated with the development of AGS (222, 223). 
These pathways are depicted in figure 1.7. 
Additional pathways relating to nucleic acid sensing are also important. The enzyme 
cyclic GMP-AMP synthase (cGAS) can bind to immunostimulatory DNA, such as that 
formed during the process of retrotransposition, and promotes the formation of cyclic 
GMP-AMP. This can bind directly to STING and trigger downstream inflammatory 
responses (224). It is increasingly appreciated that the interferon response to DNA 
viruses, HIV and other retroviruses is mediated by the cGAS-cyclic GMP-AMP-STING 
pathway. However other pathways are also able to detect cytosolic DNA, for example 
IFI16 recognised HIV infection in monocytes (225) and undeniably it is likely that many 
potential DNA sensors are still currently unknown (122).  
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Figure 1.7 Retroelement replication and enzymatic pathways modulating this 
process 
Various enzymes act to restrict the steps of LINE and retrovirus replication and 
retrotransposition by affecting products of reverse transcription: SAMHD1 inhibits 
reverse transcription through the degradation of cellular dNTPs; Trex1 metabolises the 
DNA products of reverse transcription; RNase H2 is hypothesised to degrade the RNA of 
RNA-DNA hybrids. These latter processes can block the retrotransposition of 
endogenous retroelements. U3, R and U5 denote regions of the ERV LTRs; TSD, target 
site duplication. Figure from Volkman et al., 2014 (121) 
 
1.5.2 Retrotransposons in autoimmunity  
The understanding of how retrotransposons interact with the genetic environment has 
been relatively recent. Through their ability to reinsert themselves at various points in the 
genome, thereby facilitating genetic innovation, their role in historical human genomic 
evolution is appreciated (215). However these same mechanisms, can also have relevance 
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in human disease. These have been most extensively examined in malignancy where 
retroelement activity has been shown to be increased (226). This activity could potentially 
generate insertion mutations which disrupt normal gene function thereby predisposing to 
malignant processes (226).  
More recently however retrotransposons have been implicated in the development of 
autoimmunity, for example a mouse model with a similar phenotype to SLE had 
amelioration of disease when treated with anti-retroviral therapy (227) and there are 
suggestions that HERV-K113 may be a genetic risk factor for some types of autoimmune 
diseases (228). Some have suggested that these ERVs could create so-called super 
antigens which could trigger autoimmune responses via molecular mimicry (229). 
However to date the link between retroelements and autoimmunity has mainly focused 
on viral nucleic acids present during the retrotransposition process triggering intracellular 
DNA/RNA sensing pathways and culminating in the production of type 1 interferons 
(121). Thus most research into this process has been done in diseases, such as SLE and 
pSS, where type 1 interferons play a defined pathological role (121, 230). For example 
an increase in LINE-1 transcripts was detected in the kidneys of patients with lupus 
nephritis and in the salivary glands of pSS patients. These LINE-1 RNA transcripts were 
subsequently implicated in the generation of type 1 interferons and activation of innate 
immune pathways and there was a suggestion that pDCs were associated with the 
increased interferon-α transcripts (231). The autoantibody Ro60, frequently found in pSS 
and SLE, can bind Alu elements and Alu transcripts were up-regulated in SLE whole 
blood samples relative to controls. Furthermore anti-Ro60-positive SLE immune 
complexes contained Alu RNAs and these could also trigger the production of type 1 
interferons from PBMCs (232). Activation of downstream RNA/DNA sensing pathways 
is likely to be important in these processes as gain of function mutations in the pathways 
related to the sensing of viral RNA/DNA can result in marked interferon signalling and 
an autoimmune phenotype similar to SLE (121, 233-235). Indeed increased pDC TLR 
and RLR expression, potentially due to increased intracellular ligation, has been noted in 
IGS+ PSS patients when compared with IGS- patients (236). 
Although retroelements have not been examined as extensively in RA they are 
nonetheless still likely to be relevant. There is evidence that LINE-1 transcripts and 
multiple ERV transcripts are increased in RA synovium when compared with OA or 
reactive arthritis (237-239). In keeping with this there is also down regulation of Trex1 
in RA synovial fibroblasts. This means there will be a decrease in DNA degradation and 
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thus reduced inhibition of retroelement replication/activity (240). There is also evidence 
of ERV activity in peripheral blood of RA patients, particularly HERV-K (HML-2). The 
viral load of HERV-K is increased in RA plasma and synovial fluid when compared with 
healthy controls and OA patients and positively correlated with RA disease activity. 
There is also evidence of HERV-K gag and env proteins in RA and intriguingly these 
shared the same peptide sequences with rheumatoid factor epitopes on IgG1Fc (241-243).  
Finally there is HERV-K LTR repeat in the “shared epitope” RA risk allele, HLA-DQB1. 
This increases both the relative risk and the positive predictive value that an individual 
will develop RA compared with the shared epitope alone (244). 
The current understanding of how these viruses have been integrated and sustained within 
the genome suggests that they may have been subject to some form of positive 
evolutionary selection pressure. Having increased retroelement activity may keep the 
immune system in a primed state which would allow a rapid and effective response 
against viral triggers. However the trade-off for this would be increased type 1 interferon 
signalling, which, in a susceptible individual, could trigger autoimmunity (121). Viral 
infection itself, with herpes viruses for example, has been shown to increase endogenous 
retroviral activity (242, 245). There is a current theory that infection may, in part, trigger 
the onset of autoimmune disease, such as RA (246). Thus how an individual responds to 
an infection and the subsequent degradation of retroelement products may play a role in 
the development of RA. These processes however have never been examined in early RA 
nor in the context of the RA IGS.   
Faye A. H. Cooles                                                                         Chapter 1: Introduction 
 
29 
  
1.6 Hypotheses  
The hypotheses underpinning my PhD relate to type 1 interferons in glucocorticoid and 
DMARD naive early RA.  
Given the putative increased role of type 1 interferons at the onset of autoimmune disease 
I hypothesised that a similar effect may be occurring in early RA.  
Furthermore, as pDCs are the main type 1 interferon producing cell, I hypothesised that 
pDCs produce the type 1 interferons in early RA that subsequently generate the IGS, and 
propose that pDCs are triggered by increased retroelement activity. 
To address these hypotheses my PhD was divided into the following areas of study: 
1) The IGS and early drug naïve RA 
 
2) Peripheral blood pDCs and early drug naïve RA 
 
3) Peripheral blood lymphocyte transcriptomics in IGS+/IGS- early drug naïve RA 
 
4) Retroelement activity and the IGS in early drug naïve RA
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2.1 Patient recruitment  
 
2.1.1 Ethics 
Ethical approval was provided by North East - Newcastle & North Tyneside 2 Research 
Ethics Committee for the project entitled Prognostic and therapeutic biomarkers in an 
observational inception cohort: the Northeast Early Arthritis Cohort; REC reference 
12/NE/0251. In addition ethics was provided by South West 3 REC for the project 
entitled Newcastle Autoimmune Inflammatory Rheumatic Disease Research Biobank; 
REC reference 10/H0106/30. 
 
2.1.2 Newcastle Early Arthritis Clinic 
The Freeman Hospital Musculoskeletal Unit Early Arthritis Clinic is a NHS service for 
patients that have arthralgia with concurrent inflammatory features, as determined by the 
referring clinician. At visit 1 (week 1) patients were reviewed by the nurse specialist and 
have their disease activity assessed, undergo ultrasound examination of their hands and 
feet as well as have routine inflammatory and rheumatology blood tests performed. 
Disease activity is measured by the DAS-28 which is a composite score including tender 
joint count (TJC), swollen joint count (SJC), patient report visual analogue scale (VAS) 
and inflammatory markers CRP or ESR. At visit 2 (week 2) the patient is reviewed by a 
consultant rheumatologist and a diagnosis made on the basis of clinical history, 
examination and the above investigations.   
Over the period of recruitment to this project (Dec 2013-July 2016) individuals which 
fulfilled the 2010 ACR/EULAR classification criteria for Rheumatoid arthritis (see 
Appendix A 1.0) were, where possible, recruited. All these patients were naïve to disease 
modifying anti-rheumatic drugs (DMARDs) and biological therapies. Any patient that 
had received any oral, intramuscular or intra-articular glucocorticoid steroids in the last 
3 months were excluded. We also recruited patients that were positive for anti-CCP 
antibody (ACPA) and had arthralgia but had no evidence of inflammatory disease on 
ultrasound. These patients were termed to be in a “pre-RA” state. 
Some of these early RA patients were followed up at 1, 3, 6 and 12 months and had 
peripheral blood and clinical parameters (including DAS-28) reassessed.  
For all early RA patients where possible the drug history, including glucocorticoid 
steroid use was obtained at 3 and 6 months post diagnosis. Furthermore clinical response 
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to initial therapy at 3 months and 6 months was quantified by EULAR response criteria 
as defined in table 2.1.  
 
 
Present DAS-28 score 
Improvement in DAS-28 score 
>1.2 >0.6 or  ≤1.2 ≤0.6 
≤3.2 Good response Moderate 
response 
No response 
>3.2 to ≤5.1 Moderate response Moderate 
response 
No response 
> 5.1 Moderate response No response No response 
Table 2.1 EULAR response criteria, using the DAS-28 
 
2.1.3 Established RA and SLE patients 
Patients who had a RA or SLE disease duration of >12 months and were established on 
anti-rheumatic treatments were also recruited. These were recruited from rheumatology 
clinics/ day unit services at the Musculoskeletal Unit, Freeman Hospital Newcastle upon 
Tyne. Where feasible patients who were not on oral glucocorticoid steroids were chosen, 
however this was not always possible. For all patients however an attempt was made to 
record the date of last glucocorticoid administration or dose of current treatment. 
 
2.1.4 Healthy controls 
Individuals with no personal history of autoimmunity or other medical conditions were 
used as healthy controls. They were recruited mainly from staff and students at 
Newcastle University.  
 
2.2 RNA Analysis Techniques 
 
2.2.1 RNA extraction  
Whole blood RNA 
Peripheral blood was collected in to Tempus blood RNA tubes (ThermoFisher Scientific) 
and stored at -80 °C.  The tubes were then thawed and RNA extracted using the Tempus 
Spin RNA Isolation Kit (ThermoFisher Scientific, MA, USA) according to 
manufacturer’s instructions. An additional step was included to exclude any 
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contaminating genomic DNA. This was carried out as per manufacturer’s suggestion, 
where 100µl of Absolute RNA wash solution containing an optimised buffer and DNase 
enzyme mix (Applied Biosystems, CA, USA) was applied to the column and left for 15 
minutes. This was then washed away (Wash buffer 2) and the remainder of the protocol 
was carried out as stipulated.  
To determine the concentration and quality of RNA the NanoDrop ND-1000 
spectrophotometer was used (NanoDrop Technologies, Wilmington, USA). The RNA 
was then frozen down at -80 °C. 
Cell subset RNA 
To isolate RNA from the flow cytometry sorted cell subsets (see flow cytometry sorting 
section 2.6.4) cells were first spun at 300g for 7 minutes to form a pellet. This was then 
re-suspended in 350µl of RLT Plus Lysis Buffer from Qiagen RNeasy Plus Micro kit, 
(Qiagen, Germany) to which β-mercaptoethanol (Sigma-Aldrich, MO, USA) had been 
added at ratio 1:100. This lysate was then added to a QIAshredder column (Qiagen, 
Germany) and spun at 1700g for 2 minutes. The eluate was then frozen at -80 °C pending 
the following steps.  
The Qiagen RNeasy Plus Micro Kit (Qiagen, Germany) was used to extract the RNA as 
per manufacturer’s instructions apart from one single modification. To optimise RNA 
yield the eluting solution was left on the column for 10 minutes and then spun as directed 
(1700g for 2 minutes). This eluate was then re-added to the column and the above step 
repeated. The concentration of RNA nucleic acids in this final eluate was again 
determined using the NanoDrop (as above) and the RNA was frozen at -80 °C.  
Of note in this kit the lysate was first passed through a genomic DNA (gDNA) Eliminator 
spin column to remove any contaminating gDNA. To ensure adequate performance of 
this gDNA Eliminator spin column, a test run was performed where cell subset lysates 
were either passed or not passed through this column prior to all other steps being 
identical. Downstream purity with regards to gDNA removal was then checked (see PCR 
and Gel Electrophoresis sections). 
2.2.2 Concentrating RNA samples 
To standardise the cellular subset RNA content added to the NanoString nCounter Human 
Immunology V2 Panel (see section 2.7), upon thawing of the RNA 2µl of RNaseOUT 
recombinant ribonuclease inhibitor (40U/µl, Invitrogen) was added to the prevent 
Faye A. H Cooles                                                         Chapter 2: Materials and methods  
 
34 
  
degradation and together this was centrifuged using the DNA 120 SpeedVac system 
(Thermo Scientific, Epson, UK) until completely dry. The pellets were then re-suspended 
in RNase Free water to final concentration of RNA of 10ng/µl. This was then re-frozen 
at -80°C prior to use.  
2.2.3 Reverse transcription 
Two separate reverse transcription techniques/protocols were used depending on the 
downstream application.  
Whole blood interferon gene signature (IGS) 
For analysis of the whole blood interferon gene signature (IGS) the following protocol 
was used. The total amount of RNA was normalised within each batch by adding an 
appropriate amount of RNA (depending on the concentration ng/µl) and RNase/DNase 
Free water (Sigma-Aldrich) to make a final volume of 10µl in a 0.2ml PCR strip. This 
was done in duplicate for each sample. For each reverse transcription negative controls 
were included; 10ul RNase/DNase Free water and for the sample where the RNA was 
relatively the most abundant 2 additional wells were created to which the DNA 
polymerase was later excluded. To all wells 1ul of random hexamers (1ug/ul, Integrated 
DNA Technologies, Inc, IA, USA) was added and the mixture was pulse spun to >800g 
and covered with a StarSeal adhesvive lid (StarLab, Germany). In a Takara PCR Thermal 
Cycler Dice the strip was heated to 70°C for 10 minutes and then chilled at 4°C for a 
further 10 minutes. A mastermix was generated of which 9ul added to each well. This 
mix included 0.01M DTT, 0.25mM dNTP, 1 unit SuperScript II and 4µl of 5X First 
Strand Buffer (all Invitrogen) with remaining volumes made up with RNase/DNase free 
water. An additional mix was made up where SuperScript II was excluded and the missing 
volume made up with RNase/DNase Free water.  This separate mix was added to the 
reverse transcriptase negative control wells. The strip was then heated for 1 hour at 42°C. 
The resultant cDNA was then diluted down to 1:2.5 and 1:100 with RNase/DNase Free 
water and stored at -20°C.  
Super-clean cDNA generation for retrotransposon analysis 
For analysis of the whole blood retrotransposon activity the following separate reverse 
transcription protocol was used to ensure complete elimination of any contaminating 
genomic DNA. For future reference this was termed the “super-clean” protocol. 4µl of 
RNA (independent of starting ng/µl concentration), 1U of TurboDNase and 0.5µl of turbo 
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Dnase buffer was added (both Ambion, TX, USA) to a 0.2ml PCR tube. Negative controls 
were included; 4µl UltraPure™ DEPC-treated Water (ThermoFisher Scientific, UK) and 
a duplicate of the most abundant RNA sample from which future reverse transcriptase 
enzyme steps would be excluded. This mix was incubated in a Takara PCR Thermal 
Cycler Dice for 30 minutes at 37°C before 0.9µl of 100mM EDTA was added to inactivate 
the DNase and the tubes were incubated at 75°C for a further 10 minutes. Next 2.5ul of a 
master mix containing 4mM dNTPs (Invitrogen) and gene specific primers at final 
concentration of 2uM for each. Remaining volume was made up with UltraPure™ DEPC-
treated water, which in this case was 0.5ul. These gene specific primers included those 
that specifically reverse transcribed LINE1 elements and the housekeeper gene TATA–
binding protein (TBP). For our final analysis we only used LINE-1 and TBP sequences. 
Their nucleic acid sequences are shown in the following table 2.2. 
Gene specific Primer Sequence 
LINE-1 elements ACATGTGCACATTGTGCAGGTTAG 
TATA –binding protein (TBP) GGTGCAGTTGTGAGAG 
Table 2.2 Sequences of gene specific primers used in reverse transcription  
 
This mix was then incubated at 65°C for 5 minutes and then placed on ice for a further 2 
minutes prior to a master mix being added to each tube which contained 4µl of 5X strand 
buffer (Invitrogen), 9mM MgCl (Life Technologies), 0.02M DTT and 40U RNase out 
(40U/µl) all from Invitrogen. This was then incubated at 25°C for 1 minute.  SuperScript 
enzyme was diluted 1:3 dilution of in UltraPure™ DEPC-treated water and 1µl of this 
dilution was added to each tube, apart from the negative control tube which excluded any 
reverse transcription enzyme steps. For this tube 1µl of in UltraPure™ DEPC-treated 
water was added instead. The following PCR programme was subsequently run: 25°C for 
10 minutes, 42°C for 50 minutes, 70°C for 10minutes. RNaseH (5000U/µl, New England 
Biolabs, MA, USA) was diluted 2:3 with UltraPure™ DEPC-treated water and 1µl of this 
dilution added to each tube before the final incubation at 37°C for 20 minutes. The 
resultant cDNA was diluted 1:2.5 with UltraPure™ DEPC-treated water and frozen at -
20°C.  
2.2.4 Polymerase Chain Reaction  
We used polymerase chain reaction (PCR) as part of the steps to verify that there was no 
gDNA contamination in either the RNA or cDNA that would be used to examine 
retrotransposon activity.  
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To verify the purity and lack of gDNA contamination in cDNA generated from the 
“super-clean” protocol we used HBP1 gene specific primers that cross an exon intron 
boundary and can concurrently amplify both gDNA and cDNA.  gDNA contaminated 
cDNA would therefore produce different fragment sizes (570bp and 152bp) whereas 
cDNA would only produce one band (152bp). Primer sequences can be found in the table 
2.3. In brief 0.5µl of c-DNA was added to a 13μl PCR master mix containing 0.5μM 
forward and reverse primers (10mM, Sigma Aldrich, UK), PCR buffer (50mM KCL, 
10mM Tris-HCL pH 8.3), 2mM MgCl2, 0.2mM dNTPs, 0.08 units of AmpliTaq Gold 
DNA polymerase (Applied Biosystems, ABi, Life Technologies, UK) and UltraPure™ 
DEPC-treated water. Positive controls of genomic DNA (Gift from Professor John 
Loughlin) and a negative control of UltraPure™ DEPC-treated water were also amplified 
as above. 
In an Applied Biosystems® Veriti® 96-Well PCR Thermal Cycler the following 
thermocycling conditions were used: a denaturation stage for 2 minutes at 94°C, followed 
by 32 cycles of 94°C for 30 seconds, annealing at 57°C for 30 seconds, and extension at 
72°C for 30 seconds and a final step of 72°C for 5 minutes.  
HBPI Primer sequence for c-DNA 
PCR 
Sequence 
Forward Primer TCGAAGAGTGAACCAGCCTT 
Reverse Primer GAAGGCCAGGAATTGCACCATCC 
Table 2.3 HBP1 primer sequence used for PCR of “superclean” cDNA to validate 
gDNA removal  
 
With RNA generated from the individual cell subsets (Qiagen RNeasy Plus protocol) the 
following method was applied to check for adequate gDNA removal. Again HPB1 
primers were used (see table 2.4) but this time they were in the last exon of the 3’UTR 
region and so expressed only in gDNA.  In brief 2ul of RNA was added to 8ul of a master 
mix containing 4ul 5X Phire reaction buffer, 0.4ul Phire Hot start DNA II polymerase 
(both Thermofisher scientific), 2mM dNTPs (Invitrogen) and 1.25mM forward and 
reverse HPBI primers. Positive controls of gDNA (Gift of Professor David Young, UK) 
at known concentrations (50ng, 5ng, 0.05ng and 0.005ng) as well as a negative control of 
water were also amplified as above.  
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HBPI Primer sequence for RNA PCR Sequence 
Forward Primer TGCATATACATTGACTCTTGATGG 
Reverse Primer GTTGCCCCTAAATTTTGCA 
Table 2.4 HBP1 primer sequence used on RNA to validate gDNA removal 
 
In an Applied Biosystems® Veriti® 96-Well PCR Thermal Cycler the following 
thermocycling conditions were used: a denaturation stage for 30 seconds at 98°C, 
followed by 35 cycles of 98°C for 30 seconds, annealing at 58°C for 5 seconds, and 
extension at 72°C for 45 seconds, 72°C for 45 seconds and a single final step of 72°C for 
1 minute.  
For both of these PCR products were further analysed immediately afterwards by using 
gel electrophoresis (see below in 2.2.5). 
2.2.5 Gel electrophoresis 
The PCR products were electrophoresed through a 1% weight/volume agarose gel 
containing ethidium bromide (10 mg/ml; Sigma) at a concentration of 1 μl/100 ml agarose 
and UV visualised using a G:BOX gel doc system (Syngene, Cambridge, UK). A 2-Log 
DNA ladder (New England Biolabs, MA, USA)  was used for the whole blood c-DNA 
super-clean protocol products where Contaminating DNA will produce 2 bands (570bp 
and 152bp), while uncontaminated cDNA will have just one product (152bp). A 
GeneRulerTM 100bp and 1Kb DNA ladders (Thermo Fisher Scientific) was used to assess 
the band sizes for the cell subset specific RNA PCR products, where a detectable band at 
1011bp indicated gDNA contamination.   
2.2.6 Quantitative Real-Time PCR 
For quantitative real time PCR (qRT-PCR) calculation of expression of interferon 
response genes (IRGs) 15µl of master mix containing 0.2 µl of 10uM universal 
ProbeLibrary probe (Roche), 0.4uµl of 10mM forward and reverse primers (SIGMA 
Aldrich), 4ul RNase/DNase Free water and 10 μL 2 X TaqMan® gene expression master 
mix (Life Technologies) was added to 5 μL of 1:2.5 diluted cDNA in a MicroAmp Fast 
Optical plate (Applied Biosystems). Probe and primer sequences for IRGs are shown in 
table 2.5 Regarding the housekeeper 18S expression 5ul of a separate master mix 
containing 0.1µl of 10uM 18S Probe, 0.1µl of 10mM forward and reverse primers, 
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(SIGMA Aldrich), and 4.7µl of  2 X TaqMan® gene expression master mix was added 
to 5µl of 1:100 diluted c-DNA. Probe and primer sequences for 18S shown in table 2.6. 
mRNA expression was determined using a TaqMan 7900HT fast-real time PCR system 
(Life Technologies) with the thermal cycler set to 50°C x 2 minutes, 95°C x 10 minutes, 
then (95°C x 15 seconds, 60°C x 1 minute) x 40.  
 
 
Gene 
Primer Roche 
Universal 
Probe Library 
Number 
Forward Reverse 
MxA GGAGAACATGGTGTGATAATC
CT 
CACCGTGACACTGGGATTC 83 
ISG15 GCGAACTCATCTTTGCCAGTA CCAGCATCTTCACCGTCAG 23 
OAS1 CATCCGCCTAGTCAAGCACT CAGGAGCTCCAGGGCATA
C 
87 
IFI6 CGGGCTGAAGATTGCTTCT AAAGCGATACCGCCTTCTG 25 
IFI44L TGACACTATGGGGCTAGATGG GAATGCTCAGGTGTAATTG
GTTT 
15 
Table 2.5 IRG forward and reverse primer sequences and corresponding probe 
number from Roche universal probe library  
 
 
 18s 
Forward primer CGAATGGCTCATTAAATCAGTTATGG 
Reverse primers TATTAGCTCTAGAATTACCACAGTTATCC 
Probe FAM-TCCTTTGGTCGCTCGCTCCTCTCCC-TAMRA 
Table 2.6 Housekeeper gene 18S primer and probe sequences used in IGS 
calculations 
 
For qRT-PCR quantification of whole blood L1-5’UTR and L1-ORF2 expression 4µl of 
1:2.5 diluted “super-clean” c-DNA was added to a master mix containing 5µl Fast SYBR 
Green Master Mix (Thermo Fisher Scientific), 0.4µl of 10mM forward and reverse 
primers (for L1-5’UTR, L1-ORF2 or housekeeper TBP) and 0.2µl RNase/DNase Free 
water in a MicroAmp Fast Optical plates (Applied Biosystems). Each sample was 
amplified in duplicate. Primer sequences for L1-5’UTR and L1-ORF2 and TBP are 
shown in table 2.7. 
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Gene or  
L1 
element 
Primer 
Forward Reverse 
L1-
5’UTR 
ACAGCTTTGAAGAGAGCAGTGGTT AGTCTGCCCGTTCTCAGATCT 
L1-
ORF2 
TGCGGAGAAATAGGAACACTTTT TGAGGAATCGCCACACTGACT 
TBP GAACATCATGGATCAGAACAACAG ATAGGGATTCCGGGAGTCATG 
Table 2.7 Primer sequences used for qRT-PCR quantification of LINE-1 (L1) 
elements including house keeper TATA-binding protein (TBP) 
 
However since SYBR green does not use a probe as well as primers, there is a risk that 
there may be amplification of additional products due to mis-annealed primers or primer 
dimers. Melt analysis curves were therefore run after each assay where a single peak 
implies a single amplified product. An example of melt curves is shown in figure 2.1 
where a single peak is show for L1-5’UTR, L1-ORF2 and TBP confirming a single 
amplified product and accuracy of the qRT-PCR amplification results. 
 
Figure 2.1 An example of melt/dissociation curves for each SYBR green amplified 
primer pair  
Melt curves were performed for all the SYBR green qRT-PCR assays to ensure there was 
only a single product being detected/amplified. Representative curves are shown for each 
of the products where there is only a single, uniform curve observed suggesting only a 
single product was generated.  
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As a positive control HEK293T cDNA (see section 2.3.2), which contains LINE1 
elements, was generated from a single “super-clean” reverse transcription, which had the 
same number of freeze-thaws cycles as sample cDNA and was run in duplicate on each 
MicroAmp Fast Optical plates (Applied Biosystems). 
mRNA expression was determined using a 7900HT fast-real time PCR system (Life 
Technologies) with the thermal cycler set to 50°C x 2 minutes, 95°C x 10 minutes, then 
(95°C x 15 seconds, 60°C x 1 minute) X 40.  
Of note when using the SYBR Green dye due its potential to bind to double stranded 
DNA dissociation/melt curves of RT-qPCR products were carried out to ensure there 
were no primer dimers or splice variants affecting the assay. In addition since SYBR 
green was used with non-library validated primer sequences we checked primer binding 
efficiency by performing the above SYBR green RT-qPCR on serial cDNA dilutions at 
1:25, 1:250, 1:2500 and 1:25000. The target for primer binding efficacy was 100% +/- 
5%. 
2.2.7 Analysis of Quantitative Real-Time PCR 
Results were analysed using SDS 2.4 software (Life Technologies). For IRG MXA, IFI44-
L, IFI6, OAS1 and IGS15 expression levels were normalised to the level of housekeeper 
18S using the calculation 2-Δ CT, where ΔCT represents CT (target gene) – CT(18S).  
For L1-5’UTR and L1-ORF2 there was sub-optimal primer efficiency and a mathematical 
model, called the Pfaffl correction, for relative quantification in real-time RT–PCR was 
used to take this variability into account (247). This is a mathematical model for data 
analysis to calculate the relative expression ratio on the basis of the amplification 
efficiency.  A titration of cDNA undergoing qRT-PCR is performed to determine 
amplification efficiency (E) for both target genes (L1-5’UTR and L1-ORF2) and 
housekeeper genes (TBP). The relative expression (ratio) of L1-5’UTR and L1-ORF2 in 
the samples of interest is then calculated using the formula below. 
 
To provide an additional internal control after Pfaffl correction L1-5’UTR and L1-ORF2 
expression was expressed as a relative ratio compared with HEK293T expression.  
 
 
Faye A. H Cooles                                                         Chapter 2: Materials and methods  
 
41 
  
2.3 Calculation of the IGS  
2.3.1 Interferon response genes (IRGs)  
There are over 2000 interferon response genes (108). There is a spectrum in the published 
literature of the number of IRGs chosen to calculate an IGS with 3 being the lowest 
number shown to generate meaningful results (186). I examined 5 IRGs and this number 
was chosen as it increased our chance to show meaningful results as well as for practical 
and technical reasons when performing qRT-PCR.  
I choose 5 IRGs; MxA, IFI6, IFI44L, OAS1 and ISG15. These had all been previously 
shown to be increased in RA and SLE whole blood expression studies (158, 184, 200, 
203, 206, 248-251). I attempted to choose those genes that had the highest differential 
expression. However some of the top expressed IRGs reported in the literature could also 
be induced by type 2 interferons. These genes were excluded when chosing IRGs for my 
score in an attempt to preferentially examine a type 1 interferon response. Once these 
genes had been identified I cross referenced them with those that had been used in 
published literature in the generation of an IGS in RA or ACPA+ arthralgia. The 5 final 
IRGs chosen as are listed in table along with their function and evidence of dysregulation 
and use. As I was going to be comparing SLE patients with the early RA patients I ensured 
that I chose IRGs that had demonstrated IGS related abnormalities in both RA and SLE 
(figure 2.8).  
2.3.2 Calculating the IGS and defining a positive/negative IGS 
The relative expression of the 5 IRGs was calculated by qRT-PCR as described in section 
2.2.6 and 2.2.7.  The mean expression of 2 -Δ CT values for all 5 IRGs was termed the 
interferon gene signature (IGS) or “IGS score.” Patients were defined as exhibiting a 
positive IGS if their IGS was ≥ 2 standard deviations above the mean healthy control IGS. 
It was termed negative if it fell below this cut-off. This is an acknowledged method and 
has been previously published (248, 252).  
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Interferon Response 
Gene (IRG) 
 
Function  
Evidence of 
derangement in 
RA, SLE or 
ACPA+ arthralgia 
 
Degree of dysregulation in 
RA or ACPA+ arthralgia 
MxA 
(MX Dynamin Like 
GTPase ) 
Encodes a guanosine 
triphosphate (GTP)-
metabolizing protein 
that participates in 
the cellular antiviral 
response 
RA (182-187, 200, 
203, 204, 248, 253) 
SLE (250) 
RA fibroblast: in top 5 IRG 
DEG (184).  
Whole blood: In top 15 DEG 
IRG in RA (185). In top 15 IRG 
in RA (187)  In top 59 DEG 
IRGs in RA (204). 3x  increased 
expression RA (183) 
Used to calculate IGS in 
RA/ACPA+ arthralgia (182, 
186, 200, 203, 248, 253) 
IFI6 
(Interferon Alpha 
Inducible Protein 6) 
Protein may play a 
critical role in the 
regulation of 
apoptosis 
RA (182, 183, 187, 
203), 
 SLE (250, 251) 
Whole blood: In top 15 IRG in 
RA (187) . 3x  increased 
expression RA (183). 
Used to calculate IGS in 
RA/ACPA+ arthralgia (182, 
203) 
OAS1 
(2'-5'-
Oligoadenylate 
Synthetase 1) 
Synthesizes 2',5'-
oligoadenylates (2-
5As). This activates 
latent RNase L, 
resulting in viral 
RNA degradation and 
the inhibition of viral 
replication 
RA (182, 185-187, 
204, 206, 249)  
SLE (158, 250, 251) 
Whole blood: Top 15 DEG IRG 
in RA (185). In top 59 DEG 
IRGs in RA (204) In top 15 
IRG in RA (187) . 3x  increased 
expression RA (183) 
Used to calculate IGS in 
RA/ACPA+ arthralgia (186, 
187, 206, 249)  
ISG15 
(ISG15 Ubiquitin-
Like Modifier) 
Multiple functions:  
chemotactic activity 
towards neutrophils, 
direction of ligated 
target proteins to 
intermediate 
filaments, cell-to-cell 
signalling and 
antiviral activity 
during viral 
infections 
RA (184-187, 200, 
204),  
 SLE (158) 
RA fibroblasts: in top 5 IRG 
DEG (184). 
 Whole blood: In top 15 DEG 
IRG in RA (185). In top 59 
DEG IRGs in RA (204) In top 
15 IRG in RA (187) . 3x  
increased expression RA (183) 
Used to calculate IGS in 
RA/ACPA+ arthralgia (186, 
187, 200) 
IFI44L 
(Interferon Induced 
Protein 44 Like) 
Protein exhibits a low 
antiviral activity 
against hepatitis C 
virus 
RA (182, 183, 185, 
187, 200, 204, 248, 
249, 253)  
SLE (251) 
Whole blood: In top 15 DEG 
IRG in RA (185). In top 59 
DEG IRGs in RA (204) In top 
15 IRG in RA (187) . 3x  
increased expression RA (183) 
Used to calculate IGS in 
RA/ACPA+ arthralgia (182, 
200, 248, 249, 253) 
Table 2.8 IRGs used to calculate the IGS  
The 5 interferon response genes (IRGs) that were used to calculate the IGS are shown 
here. All genes have been shown to be dysregulated in RA and SLE. DEG: differentially 
expressed gene.  
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2.4 Cellular analysis techniques 
2.4.1 Cell isolation  
Peripheral blood mononuclear cells (PBMCs) 
Blood was collected into a BD EDTA Vacutainer® tubes and then diluted 1:2 with Hanks 
Balanced Salt Solution (HBSS, ThermoFisher Scientific, UK) containing 2mM EDTA 
(Sigma Aldrich, UK). Density centrifugation was performed by layering 20ml of this 
diluted blood over 15ml of Lymphoprep (Axis-Shield Diagnostics Ltd, UK) which was 
centrifuged for 30mins at 895g (room temperature). The resulting interface contained the 
PBMC layer (see figure 1) and this was pooled (up to 2 tubes) and HBSS with 1% foetal 
calf serum (FCS, Sigma Aldrich, UK) was added until total volume of 50ml. This was 
centrifuged at 600g for 7 mins (4°C) and pellets from up to 2 tubes were again pooled 
topped up to 50ml with HBSS with 1% FCS and centrifuged at 250g for 7 mins (4°C) to 
remove any platelets. Any remaining tubes were pooled and cells re-suspended in 50ml 
HBSS 1% FCS and then cells in this PBMC suspension were counted.  
 
Figure 2.2 Pictorial representation of the interface containing the PBMC layer 
generated by density centrifugation 
  
Plasmacytoid Dendritic Cells 
Plasmacytoid dendritic cells (pDCs) were isolated from the PBMC population using the 
positive selection CD304 (BDCA-4/Neuropilin-1) MicroBead Kit (Miltenyi Biotech, 
Germany). The rationale for this method is shown in Figure 2.3. It was performed as per 
manufacturer’s instructions, however to improve purity the isolated pDC suspension 
underwent an additional purification by passing the eluate through a secondary LS 
magnetic column. The purity checks to identify pDC yield were performed by quantifying 
co-expression of CD123 (PerCP/Cy5.5, clone 6H6 eBioscience, UK) and CD303 (APC, 
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clone AC144, Miltenyi Biotech, Germany) by using flow cytometry (see section 2.6). 
Purity >90% was deemed acceptable for downstream applications. All magnetic cell 
separation used LS columns from (Miltenyi Biotec, UK) that were pre-cooled at 4°C for 
at least 20 minutes prior to use.   
 
Figure 2.3 Pictorial demonstration of the positive selection magnetic microbeads 
method used to isolate CD304+ cells (pDCs).  
 
 
Figure 2.4 pDC purity was optimised following use of 2 eluting columns 
CD304+ magnetic beads allowed positive selection of plasmacytoid dendritic cells to 
isolate from PBMCs. The use of these beads was optimised as shown above where the 
purity (as determined by CD123 (APC) and CD303 (PerCP/Cy5.5 co-expression) was 
best when the magnetic bead-cell mixture was passed twice through magnetic columns. 
A representative purity shown here is 97% purity.  
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CD4+ T-cells 
CD4+ T-cells were isolated from whole blood using a human CD4+ T-cell enrichment 
cocktail (RosetteSep; StemCell Technologies). In brief this cocktail was added to whole 
blood at a ratio of 20:1, mixed well and incubated for 20 min at room temperature. The 
sample was diluted 1:2 with PBS (Lonza) with 2% FCS and enriched cells were separated 
by density gradient centrifugation (895 g, 30 min, room temperature) on Lymphoprep 
(Axis-Shield Diagnostics). CD4+ T cells were recovered from the resulting interface and 
washed in PBS + 2% FCS (600g, 7 min, room temperature) and counted using a Burker 
counting chamber. The CD4+ T-cells were further enriched for CD45RA+/RO- naïve T-
cells using a CD45RA positive selection magnetic selection kit (Stem Cell Technologies, 
UK) as per manufacturer’s instructions. Purity was assessed by examining concurrent 
CD45RA and CD4 expression by flow cytometry (see section 2.6). Purity >95% was 
considered suitable for downstream applications. These were then frozen down (see 
section 2.3.6) and stored at -80ºC until required. 
 
2.3.2 Cell Lines  
The cell line HEK -293T (ATCC® CRL-3216™) was used (Gift from Professors David 
Young and Tim Cawston). The HEK-293T cell line, originally referred as 
293tsA1609neo, is a highly transfectable derivative of human embryonic kidney 293 
cells, and contains the SV40 T-antigen. It is semi adherent and due to its oncogenic 
potential and high expression of LINE-1 elements was used as a positive control for 
LINE-1 experiments. 
2.3.3 Cell Culture  
Peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMCs) were cultured in RPMI medium (Sigma-
Aldrich, St Louis, USA) containing 10% (v/v) serum replacement (Invitrogen) and 
supplemented with, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin 
(Sigma-Aldrich, St Louis, USA). PBMCs were cultured in flat bottomed 96 well plates at 
a final density of 5x106 cells/ml. This is a higher concentration than normally used for 
PBMC cultures. However during preliminary optimisation I found due to the low number 
of circulating pDCs at least 2 million PBMCs were needed to be cultured overnight to 
allow for enough pDCs to perform reliable phenotyping. Less than this resulted in erratic 
and unreliable results due to low cell number. Normal culture volumes (i.e. 1x106/ml) 
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would have meant using large volume of reagents, such as the TLR agonists (see below), 
and this was not possible within the scope of this project’s finances. Others have 
successfully used increased numbers of PBMCs in culture, for example between 2x106/ml 
(149) and 1x107/ml (254). I found that 5x106 cells/ml gave reliably sufficient data without 
high death (as determined by DAPI) and allowed conservative use of reagents. To these 
cultures TLR 9 agonists CPG-B (ODN 2006) (InvivoGen, CA, USA) was added at a final 
concentration of 5µg/ml and cultures left in an incubator at 37°C (5% CO2) for 18-22 
hours.  For some experiments the pDC depleted PBMCs (see 2.4.1) were also cultured in 
parallel with 5µg/ml TLR 9 CPG-B. Supernatants from these cultures were frozen at -
20°C prior to further analysis whereas cells were immediately analysed by flow cytometry 
(see 2.7).  
Plasmacytoid dendritic cells (pDCs) 
pDCs were cultured in RPMI (Sigma-Aldrich, St Louis, USA) containing 10% (v/v) 
serum replacement (Invitrogen, UK) and supplemented with 10mM HEPES, 2 mM 
glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (all Sigma-Aldrich, St Louis, 
USA) in a 96 well flat bottomed plate at a density of 200,000 cells/ml. TLR 9 agonists 
CPG-B (ODN 2006) (InvivoGen, CA, USA) was initially titrated (concentrations ranging 
between 0.05µg/ml to 10ug/ml) and cultured with the pDCs for 18-22 hours. For final 
experiments an optimal concentration of 5µg/µl for CPG-B was chosen.  Supernatants 
from these optimised cultures were frozen at -20°C prior to further analysis whereas cells 
were analysed immediately by flow cytometry (see section 2.7). 
Cell line cultures  
HEK-293T cells were cultured in Dulbecco’s Modified Eagle Medium with high glucose 
(Life Technologies, UK) supplemented with 2 mM glutamine, 100 U/ml penicillin, and 
100 μg/ml streptomycin and 10% FCS.  
Upon thawing of a cryovial of frozen HEK 293-T cells they were washed once with 
warmed (37°C) culture medium and centrifuged at 400g for 7 minutes. The resultant 
pellet was then re-suspended in 24ml warmed medium and split into 2 T75 culture flasks. 
These were then incubated at 37°C with 5% CO2 overnight and on day 2 the medium was 
entirely removed and replaced to ensure any residual DMSO was completely removed. 
Once the flasks were 80-90% confluent as they were semi-adherent trypsin (Sigma-
Aldrich, St Louis, USA) was used to detach the cells and then they were either split or 
used for their desired application. 
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2.3.4 Mixed Lymphocyte Reactions (MLRs) 
PDCs from both healthy donors and established RA patients were cultured overnight in 
either RF10 alone (as described above), or with RF10 and 5ug/ml CpG- B (ODN 2006, 
InvivoGen, CA, USA).  PDCs were harvested the next day and washed twice in HANKS 
+ 1% FCS to remove excess stimulus. Tryptan blue was used to determine viable cell 
number.  
Naïve CD4+ T-cells were thawed (as section 2.3.6) and washed twice in room temperature 
RF10. They were then labelled with 2.5µg/ml CFSE (Biolegend, USA) by adding 5µg/ml 
of CFSE in PBS (LONZA, Switzerland) to equal volume of T-cells in PBS and incubating 
this in the dark at room temperature for 15 minutes. The reaction was stopped by adding 
ice cold RF10 and the cells were washed twice in RF10 before being used in the MLR. 
Viable pDCs were co-cultured with CFSE labelled allogenic naive CD4+ T cells in round-
bottomed 96-well with a final ratio of 1:10 pDCs to T-cells and cultured for 6 days. At 
this point culture supernatant was collected and frozen at -20°C prior to further analysis 
and T-cell surface marker expression was phenotyped by flow cytometry (section 2.6).  
2.3.5 Cell freezing and thawing 
Cell freezing 
Cells were pelleted (400g, 7min 4°C) and re-suspended in 37 °C warmed FCS (Sigma-
Aldrich) with a maximum concentration of 20 x106 cells per 500ul. Warmed 37°C FCS 
with 20% dimethyl sulfoxide (DMSO, Sigma Aldrich) was added drop wise in equal 
volume, with the final concentration of DMSO at 10%. This suspension was added to 
cryovials (1ml per vial) and slowly frozen to -80°C in a freezing box that facilitated a fall 
of temperature of 1°C/minute. 
Cell thawing 
Frozen cryovials from heathy and patient donors were thawed as follows. Cryovials were 
warmed to 37 °C for 10 minutes in a standard waterbath. Contents of 2-3 cyrovials were 
each added to a universal container and warmed (37°C) thawing medium HBSS (Sigma-
Aldrich) with 10% FCS was added was added dropwise to a final volume of 25mls or 
until the cryovial suspension volume had been diluted by a factor of 10. Suspensions were 
spun at room temperature (400g for 7 mins) and the pellet was resuspended in warmed 
thawing medium and the above spin repeated. After this any duplicate universals were 
pooled, resuspended in thawing medium and the cells were counted ready to use for 
downstream applications.  
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For PBMCs used for flow sorting there was a slight modification in the thawing protocol. 
The thawing medium was RPMI-1640 with 10% FCS (both Sigma-Aldrich, St Louis, 
USA). For the first resuspension of cells 0.6mg/ml DNAse I (grade II from bovine 
pancreas, Sigma-Aldrich, St Louis, USA) was added and the cells left for 5 mins at room 
temperature. After this the above protocol was applied.  
2.3.7 Cytospins 
Cells of interest were pelleted and re-suspended in 50ul FCS (Sigma-Aldrich, St Louis, 
USA) which resulted in a 1:1 mix of cell medium and FCS. Slides were labelled with a 
pencil and placed in to the cytospin cartridges along with the filter facing the centre of 
the cytospin. Cells were aliquoted in to each cytospin well and spun at 500rpm for 10 
minutes. The slides were dried overnight. The next day they were placed in pre-prepared 
vials containing the following; ice cold ethanol (20 seconds, to fix the slide); May-
Grunwald (red dye, 10 seconds); Giemsa (blue dye, 45 seconds). Slides were left for at 
least one hour to dry before being imaged.  
2.4 Serum isolation 
Peripheral blood was collected into a BD Vacutainer® Tube (BD Biosciences, CA, USA) 
containing clot activator and gel for serum separation (red top). This was then centrifuged 
at room temperature at 1800g for 12 minutes. The serum was divided into 500ul aliquots 
and frozen at -80°C until further use.  
2.5 Cytokine measurement 
2.5.1 ELISAs 
Interferon-α was measured from cell culture supernatants using Human interferon-α 
Platinum ELISA (eBioscience, CA, USA) as per manufacturer’s instructions. Circulating 
BAFF in the serum of patients and healthy controls was measured using the Human 
BAFF/BLyS/TNFSF13B Quantikine ELISA kit (RnD Systems, Bio-Techne Ltd, UK) 
again according to manufacturer’s instructions.  
Performance testing Human BAFF/BLyS/TNFSF13B Quantikine ELISA was carried out 
to ensure that there was no interference from heterophillic autoantibodies in the patient 
samples which could compromise accuracy of these assays. To do this samples with and 
without known heterophillic antibodies were used as well as spiked concentrations of 
known respective cytokine. To some of these samples Heteroblock at 32µg/ml (Omega 
Biologicals Inc, MT USA) was added and the concentration of detected cytokine levels 
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and spike recovery recorded. There did not appear to be any interference from 
heterophillic antibodies, with normal spike recovery in all cases. Therefore Heteroblock 
was not used in further patient serum assays.   
2.5.2 MSD multiplexing technology 
Interferon-α was also measured in the serum and in some culture supernatants by MSD 
technology using the Human interferon-α2α Ultra-Sensitive Kit technology (Meso Scale 
Discovery, Maryland, USA). Other inflammatory cytokines including IFN-γ, IL-10, IL-
12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, TNF-α were also measured by MSD 
technology using the V-PLEX Proinflammatory Panel 1 (human) Kit.  
The same performance testing as explained above (2.5.1) was performed on the Human 
interferon-α2α Ultra-Sensitive Kit technology (Meso Scale Discovery, Maryland, USA) 
with no evidence of interference from heterophillic antibodies. Previous testing in the 
laboratory had confirmed no evidence of heterophillic antibody interference in the V-
PLEX MSD kits.  
2.6 Flow cytometry 
2.6.1 Cell surface protein expression 
PBMCs (either fresh of following overnight culture) or isolated cell subsets were washed 
once in FACS buffer (phosphate-buffered saline (PBS) containing 3% FBS, 0.1% sodium 
azide and 2 mM EDTA) by centrifuging at 400g for 3-5 minutes. Cell pellets were 
resuspended in either FACS buffer (MLR phenotyping/purity checks) or BD Horizon 
Brilliant Stain Buffer (BD Biosciences, CA, USA) (DC subset phenotyping) containing 
selected fluorophore labelled surface marker antibodies (see Tables 2.9 – 2.13 for 
fluorophore labelled antibodies used for each experiment set) and 4µg/ml IgG (Gift from 
Prof Sophie Hambleton, UK) at a final volume of 50ul. This was incubated at 4ºC in the 
dark for 30 mins and if being used, CyStain® was added for the last final 10 minutes of 
incubation. Cells were then washed twice in FACS buffer (400g for 3 minutes) and 
resuspended in a final volume of 200μl FACS buffer and data were acquired. PDC 
phenotyping panels were acquired on a BD LSR Fortessa™ whereas MLR associated 
pDC and T cell phenotyping was acquired on a FACSCanto II (both Becton Dickinson, 
NJ, USA).  
The T cell staining panel underwent intracellular protein expression steps (see below 
2.6.2) which involved a fixation step but other samples were fixed with 1% 
paraformaldehyde and kept for up to 7 days if immediate acquisition was not possible. 
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Surface marker Fluorophore Clone Dilution 
Factor 
Source 
Lineage: CD3 FITC HIT3a 1:25 Biolegend CA USA 
Lineage: CD19 FITC HIB19 1:10 Biolegend CA USA 
Lineage: CD20 FITC 2H7 1:10 Biolegend CA USA 
Lineage: CD203c FITC NP4D6 1:10 Biolegend CA USA 
CD11c   PerCP-Cy5.5 Bu15 1:10 Biolegend CA USA 
ILT7  PE 17G10.2 1:25 Biolegend CA USA 
CD14 BV510 M5E2 1:25 Biolegend CA USA 
CD123 BV650 6H6 1:25 Biolegend CA USA 
CD141 BV711 1A4 1:25 Biolegend CA USA 
HLA-DR AF700 L243 1:10 Biolegend CA USA 
CD1c APC-Cy7 L161 1:10 Biolegend CA USA 
CCR7 APC 150503 1:25 RnD Systems, Abigndon, 
UK 
Alive/Dead CyStain® (DAPI) n/a 1:5 Partec, Japan 
Table 2.9A Fluorophore labelled antibodies used for DC subset phenotyping – 
Tube 1 
 
Surface marker Fluorophore Clone Dilution 
factor 
Source 
Lineage: CD3 FITC HIT3a 1:25 Biolegend CA USA 
Lineage: CD19 FITC HIB19 1:10 Biolegend CA USA 
Lineage: CD20 FITC 2H7 1:10 Biolegend CA USA 
Lineage: CD203c FITC NP4D6 1:10 Biolegend CA USA 
CD11c   PerCP-Cy5.5 Bu15 1:10 Biolegend CA USA 
CD40 PE C40-1457  1:25 BD Biosciences, CA, 
USA 
CD14 BV510 M5E2 1:25 Biolegend CA USA 
CD123 BV650 6H6 1:25 Biolegend CA USA 
CD141 BV711 1A4 1:25 Biolegend CA USA 
HLA-DR AF700 L243 1:10 Biolegend CA USA 
CD1c APC-Cy7 L161 1:10 Biolegend CA USA 
CD86 APC FUN-1 1:25 BD Biosciences, CA, 
USA 
Alive/Dead CyStain® (DAPI) n/a 1:5 Partec, Japan 
Table 2.9B Fluorophore labelled antibodies used for DC subset phenotyping – 
Tube 2 
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Table 2.10 Fluorophore labelled antibodies used for MLR pDC purity check 
 
Table 2.11 Fluorophore labelled antibodies used for MLR Naïve CD4 T cell purity 
check 
 
Table 2.12 Fluorophore labelled antibodies used for pDC phenotyping from 
overnight PBMC cultures 
 
Table 2.13 Fluorophore labelled antibodies used for MLRs CD4+ T cell 
phenotyping  
  
Antibody Fluorophore Clone Dilution  Factor Source 
CD303 APC 201A 1:25 Miltenyi Biotech, 
Germany 
CD123 Percp-Cy5.5 6H6 1:25 eBioscience, CA USA 
Antibody Fluorophore Clone Dilution Factor Source 
CD4 APC UCHT1 1.50 Biolegend CA USA 
CD45RA FITC H1100 1.25 BD Biosciences, CA, 
USA 
Antibody Fluorophore Clone Dilution Factor Source 
CD123 Percp-Cy5.5 6H6 1:25 eBioscience, CA USA 
HLA-DR APC-H7 L243 1:50 BD Biosciences, CA, 
USA 
PDL1 BV421 29E.2A3 1.10 Biolegend CA USA 
ICOSL APC MIH12 1.10 Miltenyi Biotech, 
Germany 
ILT7 PE 17G10.2 1:25 Biolegend CA USA 
Lineage: CD3 FITC HIT3a 1:25 Biolegend CA USA 
Lineage: CD19 FITC HIB19 1:10 Biolegend CA USA 
Lineage: CD20 FITC 2H7 1:10 Biolegend CA USA 
Lineage: 
CD203c 
FITC NP4D6 1:10 Biolegend CA USA 
Antibody Fluorophore Clone Dilution Factor Source 
CD3 BV510 UCHT1 1.50 Biolegend CA USA 
CD4 APC-Cy7 RPA-T4 1.50 Biolegend CA USA 
CD25 PE-Cy7 BC96 1.25 Biolegend CA USA 
FoxP3 Alexaflour 647 206D 1.10 Biolegend CA USA 
CFSE On FITC channel - - Biolegend, CA USA 
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2.6.2 Intracellular protein expression 
To assess intracellular expression of FoxP3 T cells were first harvested and surface 
stained with respective antibody mix (as outlined in 2.6.1 above). They were then fixed 
and permeabilised using staining buffer set (eBioscience, CA USA) as per manufacturer’s 
instructions. To reduce background staining, the cells were blocked with 2% mouse serum 
(Sigma-Aldrich) for 15 minutes before addition of anti-human FoxP3 AlexaFlour 647 
antibody. Cells were incubated at 4°C for 30 mins, washed and re-suspended in FACS 
buffer and were then ready to acquire.  
2.6.3 Flow cytometry analysis  
Dead cell exclusion 
All data was analysed using FlowJo Version 8.7.1 (Treestar inc). Where possible dead 
cells were excluded by CyStain® (Partec, Japan) where positive uptake indicated cell 
death. Cellular debris and were excluded by their position on the forward and side scatter 
area and doublets were excluded on the basis of their side scatter height vs side scatter 
area.  
DC subsets 
The measurement of peripheral blood pDCs was identified according to their surface 
marker expression (panel used in table 2.9). The combination of markers used to identify 
the pDCs is shown in table 2.14 and the gating strategy is shown in figure 2.5. 
CD203c was used within the lineage cocktail to exclude any basophils. These are also 
CD123+ and fall within the lymphocyte gate. CD203c is expressed by all basophils and 
is increased upon activation (255).  
Of note CD303 was avoided as this can modulate the intracellular production of type 1 
interferons via (113). As this involves the modification of intracellular signalling 
pathways I wished to avoid any potential confounding effect of other phenotypes that 
could result from this and so avoided the use of CD303 when performing phenotyping 
(or flow cytometry cell sorting – section 2.6.4) of pDCs. 
Cell subset sorted Markers used to identify pDCs 
Plasmacytoid dendritic 
cells (pDCs) 
Lin – (CD19, CD20, CD3, CD203c), HLA-DR+, CD14-, 
CD1c-, CD141negative or dim , CD11c-,  CD123+ 
Table 2.14 Surface marker expression used to identify pDCs  
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Figure 2.5 Gating strategy  
This is the gating strategy used to identify the pDC subsets from isolated PBMCs. PDCs 
were defined as: Lin- HLA-DR+ CD14- CD141-/dim, CD1c-, CD11c - CD123+. Lin 
included lineage markers to exclude CD3 (T-cells), CD19, CD20 (all B-cells) and 
CD203c (Basophils).  
T cell proliferation 
Naïve CD4 T cell proliferation was measured using CFSE dilution. Percentage having 
undergone CFSE dilution was used as a marker of percentage undergone proliferation. 
This is demonstrated in figure 2.6 
 
Figure 2.6 CFSE dilution and resultant percentage proliferated T cells in the MLR 
This figure shows the percentage of naive CD4 T cells having undergone a dilution of 
CFSE signal following a 6 day pDC and CD4 T cell MLR. This percentage is then used 
as marker or percentage of cells having undergone proliferation over this period. 
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2.6.4 Flow cytometry cell sorting 
PBMCs were pelleted at 400g for 7 minutes (4 °C) and re-suspended in cold FACS buffer 
at a final concentration of 20 x 106 cells/ml. To each FACS tube 500µl of this cell 
suspension was added and topped up with an additional 500µl of FACS buffer. This was 
spun at 400g for 5 minutes at 4°C and the pellet re-suspended in the fluorophore labelled 
antibody mixture (antibodies used listed in table 2.15). 2µl of human IgG (4µg/mg) was 
again added and the final volume of the staining mixture was made up to 50µl by adding 
BD Horizon Brilliant Stain Buffer (BD Biosciences, CA USA).  
The cells and staining mixture were incubated for 30 minutes in the dark at 4 °C as above. 
After washes all tubes were pooled to a final volume of 1ml per 50 x 106 of stained 
PBMCs.  CyStain® (DAPI) (ratio of 1µl to 50µl of cell suspension) was added 15 minutes 
before acquiring. For some samples the suspension was strained through a 70um cell 
strainer (EASYstrainer, Greiner Bio-One, GmbH, Germany) and washed with another 
500ul of FACS buffer. This was performed immediately prior to sorting due to small cell 
clumps.  
The BD FACSARIA II (Becton Dickinson, NJ, USA) was used to sort the 6 immune cell 
subsets. The gating strategy is shown in figure 2.7 and the phenotype used to identify 
each subset shown in table 2.16. 
Surface marker Fluorophore Clone Dilution Factor Company 
CD56 FITC HCD56 1:25 Biolegend CA USA 
CD11c   PerCP-Cy5.5 Bu15 1:10 Biolegend CA USA 
CD8 PE HIT8a 1:25 BD Biosciences, CA, 
USA 
CD4  PE-CY7 RPA-T4 1:25 Biolegend CA USA 
CD14 BV510 M5E2 1:25 Biolegend CA USA 
CD123 BV650 6H6 1:10 Biolegend CA USA 
CD3 BV786 UCHT1 1:25 BD Biosciences, CA, 
USA 
HLA-DR AF700 L243 1:10 Biolegend CA USA 
CD1c APC-Cy7 L161 1:10 Biolegend CA USA 
CD19 APC HIB19 1:10 BD Biosciences, CA, 
USA 
CD20 APC 2H7 1:10 Biolegend CA USA 
Alive/Dead CyStain® (DAPI) n/a 1:50 Partec, Japan 
Table 2.15 Fluorophore labelled antibodies used for immune cell flow cytometry cell 
sorting  
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Figure 2.7 Gating strategy used to cell sort 6 different immune cell subsets  
Flow cytometry was used to sort 6 distinct cell subsets. The gating strategy is shown. 
Subsets sorted included plasmacytoid dendritic cells (pDCs), myeloid dendritic cells 
(mDCs+), B cells, CD8+ T cells, CD4+ T cells and CD14+ monocytes. 
 
Cell subset sorted Markers used to identify immune cell populations 
Plasmacytoid dendritic 
cells (pDC) 
CD19-, CD20-, CD3-, CD14-, HLA-DR+, CD1c-, CD11c-, 
CD123+ 
Myeloid dendritic cells 
(mDC) 
CD19-, CD20-, CD3-, CD14-, HLA-DR+, CD1c+, CD11c+ 
B cells CD19+, CD20+, CD14-, CD3- 
CD8+ T cells CD19-, CD20-, CD14-, CD3+, CD4-, CD8+, CD56- 
CD4+ T-cells CD19-, CD20-, CD14-, CD3+, CD4+, CD8-, CD56- 
CD14+ monocytes CD3-, CD14+ 
Table 2.16 Cell subsets sorted by follow cytometry and surface marker protein 
expression used to identify those populations.  
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2.7 NanoString Technologies 
2.7.1 Methodology and genes examined 
The NanoString nCounter Human immunology V2 Panel (NanoString Technologies Inc, 
WA, USA) was used to examine immune cell specific transcriptome. For a full list of 
genes included please see Appendix A 2.0. An additional panel of 20 genes was custom 
generated to specifically identify retrotransposon activity and DNA/RNA intracellular 
sensing pathways (shown in table 2.17, sequences included in Appendix A 3.0).   
Standard probes Customised probes 
ISG15 AluYa5 
DDX58 (RIG-1) AluYb5 
IDO2 LTR 5’ end 
STING LTR 3’ end 
IRF9 L1-5’UTR 
cGAS L1-ORF2 
MAVS  
CCR9  
IFI6  
IFI44L  
OAS1  
TREX1  
RNaseH2  
SAMHD1  
Table 2.17 Additional probes/genes included in the customised panel plus 
NanoString nCounter chip 
 
A total volume of 50ng RNA was used for each of the cell subsets and loaded onto the 
chip and the protocol was followed according to standard nCounter instructions. In brief 
each target gene of interest is detected using a pair of reporter and capture probes carrying 
35- to 50-base target-specific sequences. At the 5’ end each probe also carries a unique 
colour code allowing the molecular barcoding of the genes of interest (Figure 2.8 A).  The 
target mRNAs and reporter-capture probes are hybridized in a solution phase, excess 
probes are removed, and the probe/target complexes aligned and immobilised in the 
nCounter cartridge (Figure 2.8.B) This is then placed in a digital analyser for image 
acquisition and data processing (Figure 2.8.C). Each CodeSet includes a number of 
housekeeping genes to correct for RNA input amount and/or quality differences. 
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Figure 2.8 NanoString nCounter technology 
A: Capture probe and reporter probe hybridize to a complementary target mRNA in 
solution via the gene-specific sequences notably the 5’ end of each probe carries a unique 
colour code allowing the molecular barcoding of the genes of interest. B: Schematic 
representation of binding, electrophoresis, and immobilization. C False-color image of 
immobilized reporter probes. Figure from Geiss et al., Nature Technology 2008 (256) 
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2.7.2 Computational modelling 
The analysis of this data was greatly assisted by the help of Andrew Skelton from 
Newcastle University Bioinformatics Support Unit (BSU), who performed the following 
steps to allow interpretation of the findings. R Core team (2016) (257) was used in 
association with the Bioconductor repository (258) for this analysis 
Pre-processing 
Pre-processing steps were used to transform the data into a shape where it can be easily 
manipulated for the experimental questions. These steps included initial quality control 
(QC) inspection, and normalisation. 
NanoString data is provided in raw and normalised counts. Working with the raw counts 
adheres to the underlying assumptions of DESeq2 (Negative Binomial Distribution) 
(259). Normalisation is typical in high-throughput experiments to make samples 
comparable to one another. When working with DESeq2, the recommended protocol is a 
library size scaling factor normalisation which was performed in this case. 
Using the whole dataset of observations for each of the 6 immune cell subsets principle 
components analysis (PCA) was performed. PCA was used as a data dimensionality 
reduction technique to get an overall view of the dataset, and identify samples that showed 
similar variation.  
Generalised Linear models 
Generalised Linear models (GLM) implemented using the DESeq2 package allow for a 
flexible framework in interrogating integer count data. Due to the different experimental 
questions in this project, there were 3 different model fits. The different model fits 
grouped together known experimental conditions, to simplify coefficient estimation. 
These included:   
Term1 – ‘CellType_DiseaseType’; where for each cell type, healthy samples were 
compared against RA.  
Term2 – ‘CellType_DiseaseType_IGSClass’; where for each cell type, positive IGS early 
RA patients were compared against negative IGS in early RA patients.  
Term3 – ‘CellType_IGSClass’; where each cell type, positive IGS Patients (RA Only), 
are compared against negative IGS healthy controls.  
Differential gene expression was calculated using the Wald test. Differences between 
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these cohorts were considered to be statistically significant when the adjusted (taking into 
account false discovery rates [FDR]) p value was < 0.05 and Fold changes were > 1.5.  
 Ingenuity Pathway Analysis (IPA) 
The differentially expressed HGNC gene symbols from each list that was generated by 
the above GLMs were uploaded to the Ingenuity® Pathway Analysis (IPA®) software. 
IPA® uses a knowledgebase derived from the scientific literature to relate genes or 
proteins based on their interactions and functions. Based on the uploaded dataset, the 
program algorithmically generates biological networks, defines canonical pathways and 
functions as well as any potential unifying upstream modulators. 
A p value is generated during this process where significance is <0.05. An activation Z 
score (or Z score) is also generated by applying the differential genes expressed and the 
strength of their known associations with biological networks. The Z score infers 
activation state, for example if a pathway is upregulated there is a positive score and this 
related to an increase in associated biological functions whereas for a negative score the 
converse is true. Values > ±2 denote a strong signal.  However for some biological 
networks there is evidence that a gene set is implicated in that network but not enough 
published literature to clearly predict whether this causes a net increase or decrease of 
that biological function. In these cases a Z score is not generated, although a p value is.  
2.8 Statistical methods  
Statistical analysis included ordinal and nominal logistic regression, univariate multiple 
regression analysis, 1-way ANOVAs, Wilcoxon signed rank, Kruskal-Wallis, Mann-
Whitney U and Chi2 tests. These tests were performed using GraphPad Prism (ver. 5.0, 
San Diego USA) IBM SPSS statistics (ver. 22.0 Armonk, NY: IBM Corp) and JMP 
Statistical Visualization Software (ver. 11, SAS Inc, NC).  Significance was defined when 
p<0.05 however for some analyses where multiple parameters were simultaneously 
assessed, Bonferroni corrections were applied.  As mentioned above, R Core team 
(2016) was used in association with the Bioconductor repository (258) for the NanoString 
transcriptomics analysis.
Faye A. H Cooles 
60 
 
 
 
Chapter 3: The interferon gene signature in early rheumatoid 
arthritis 
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3.1 Introduction 
Type 1 interferons, such as the interferon-α family, are cytokines conventionally 
produced upon the immune system’s interaction with viruses and bacteria. Many 
interferon response genes (IRGs) control pathogen infection by targeting various 
pathways and functions required for pathogen proliferation. However type 1 interferons 
can also affect host cells, particularly immune cells, thereby amplifying the production of 
defensive cytokines and antibodies (260). For example type 1 interferons promote the 
differentiation of monocytes into an inflammatory phenotype dendritic cell (127, 129, 
261) and can promote the class switch of B cells into antibody and sometimes 
autoantibody producers (145).  
While these effects are effective and appropriate when the body is facing infection, type 
1 interferons, and the subsequent upregulation of IRGs termed an interferon gene 
signature (IGS), have also been implicated in autoimmunity (262).  This has mostly been 
looked at with regards to systemic lupus erythematous (SLE) where type 1 interferons 
and the IGS have been shown to predict disease flares and associate with certain 
aggressive presentations, such as lupus nephritis (156, 157). Furthermore some early 
phase 2 trials targeting the type 1 interferon pathway have been met with encouraging 
results (161, 263).  
In established rheumatoid arthritis (RA) a positive IGS is present in about 20% of patients 
however it does not associate with disease activity and there is very little clearly known 
regarding its role in RA pathogenesis (185, 264). It has been shown to correlate with a 
poor response to certain treatments, particularly rituximab (186, 200, 202) but conversely 
predicts a better outcome to others, such as tocilizumab and TNF-α inhibitors (203, 206). 
At the same time, in established RA certain ongoing therapies, namely glucocorticoids, 
can modulate the IGS (23) which could mask associations between type 1 interferons and 
disease activity or pathogenesis.  
I have therefore examined the IGS in DMARD-naive early RA patients and looked at 
both its prevalence and effect on disease outcome, as well as associations with disease 
parameters and clinical phenotype. I also looked at its expression in a longitudinal cohort 
of early RA patients at repeated points over a year to examine how its expression may 
change with both time and the initiation of conventional DMARD therapy. 
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3.2 Chapter Aims 
In this chapter I wished to answer the following questions: 
 
1. What is the prevalence of a positive IGS in drug naïve early RA? 
2. Does the IGS change with time and therapy in early RA? 
3. What association does the IGS have with inflammatory cytokines in early RA? 
4. Does the IGS associate with ANA and RA associated autoantibodies? 
5. Do serum derived factors trigger type 1 interferon production? 
6. Is there any association between the IGS, disease activity in early RA or on 
clinical outcomes? 
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3.3 Results 
3.3.1 IGS calculation and cohort demographical data  
Using qRT-PCR 5 interferon response genes (IRGs) were quantified in the whole blood. 
These IRGs included MxA, IFI44L, OAS1, ISG15 and IFI6. The rationale for each IRG 
chosen is explained in Chapter 2 methods (table 2.8). In brief IRGs previously shown to 
be highly differentially expressed in RA and SLE cohorts when compared to healthy 
controls were chosen (158, 184, 200, 203, 206, 248-251). Care was taken to choose IRGs 
that were preferentially activated by type 1 interferons to minimise any potentially 
confounding contribution from type 2 interferons.  
In keeping with previously published methods (248, 252) the IGS was calculated by 
averaging of the normalised expression of the 5 IRGs. This generated a score which was 
termed the IGS, sometimes termed the IGS score. A “positive” or “negative” IGS in the 
patient cohorts was determined using a healthy control population; any patient sample 
IGS that was greater than 2 standard deviations above the healthy control mean was 
termed positive and values that fell below this cut off was termed negative, or normal. 
This was again a published method to stratify patient cohorts (248, 252). 
The whole blood IGS was calculated in four separate cohorts; early drug naive RA, 
established RA and established SLE, as well as healthy controls. Principal component 
analysis (PCA) was used to assess whether a particular IRG appeared to be more highly 
differentially expressed. Ultimately all 5 IRGs were upregulated in a similar manner (data 
not shown). 
There were 50 patients in the early RA cohort and their demographic and clinical data are 
shown in table 3.1. All patients met the 2010 ACR/EULAR RA classification criteria.  
There were 23 individuals in each of the three other cohorts; established RA, SLE and 
healthy controls (table 3.2).  Some early RA data are also included in this table 3.2 for 
statistical comparison.   
As expected, the disease groups contained significantly more women than men and they 
were also significantly older. However between the established RA and early RA groups 
there was no significant difference between percentage seropositive or disease activity. 
The criteria for established disease was disease duration >12 months and for both SLE 
and established RA the median disease duration was 10 years.  
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A subgroup of the early RA cohort was followed up at intervals over a year (1, 3, 6 and 
12 months). The specific demographics of this cohort as well their initial DMARD and 
glucocorticoid drug history is shown in table 3.3. 
In view of the significant differences between the groups with regards to age and sex, 
correlations between the IGS score and these parameters were performed. There was no 
significant association between age and the IGS nor was there any association between 
sex and the IGS for either the entire cohort, early RA cohort or when examining pooled 
disease or healthy control populations separately (data not shown).  
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Early Rheumatoid Arthritis patients Number = 50 
Age (years, median and range) 57.5 (30-91) 
Male : Female ratio 2:3 
DAS-28 (median and range) 4.36  (1.33 – 7.63) 
CRP (mg/L, median and range) 7.5 (0-114) 
ESR (mm/hr, median and range) 22.5 (2-68) 
Tender joint count (median and range) 4 (0-25) 
Swollen joint count (median and range) 2 (1-24) 
Patient VAS (median and range) 57 (8-100) 
Duration of symptoms (weeks, median and 
range) 
12 (3-52) 
Early morning stiffness (minutes, median and 
range) 
52.5 (0-380) 
Anti-CCP positive 
(n and percentage) 
34  
(68%) 
Rheumatoid factor positive  
(n and percentage) 
32 
(64%) 
Seropositive  - either anti- CCP+ or RF+  
(n and percentage) 
n=36  
(72%) 
Patients starting MTX (n and percentage) 41 (82%) 
Patients starting HCQ (n and percentage) 18 (36%) 
Patients starting SSZ (n and percentage) 12 (24%) 
Patients starting LFU (n and percentage) 2 (4%) 
Patients given depot glucocorticoid at diagnosis  
(n and percentage) 
41  
(82%) 
 
Table 3.1 Early RA cohort demographics 
The demographical and disease activity data for the early glucocorticoid and DMARD 
naive early RA cohort that had their whole interferon gene signature (IGS) quantified is 
shown. All met the 2010 ACR/EULAR criteria for a new diagnosis of RA. There were 
50 patients in total all of who were started on a form of DMARD therapy at diagnosis. 
MTX, methotrexate, HCQ, hydroxychloroquine; SSZ sulfasalazine; LFU, leflunomide. 
RF rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide antibody.  
Faye A. H Cooles                                                                 Chapter 3: IGS in early RA  
 
66 
  
 Early 
RA 
patients 
Est RA 
patients 
Est SLE 
Patients 
Healthy 
Controls 
Difference 
between 
groups     
(p value) 
Number 50 25 23 23 - 
Age (years, median 
and range) 
57.5  
(30-91) 
68  
(28-81) 
55           
(33-69) 
36.5              
(25-62) 
<0.0001* 
Male : Female ratio 2:3 2:3 1:8 1:1 <0.0001* 
Disease duration, 
(years median and 
range) 
0# 10 
 (1 – 22) 
10 
 (1 – 35) 
- - 
 
DAS-28 
4.36        
(1.33 – 
7.63) 
5.45 
(3.11 - 
8.43) 
- - 0.059+ 
Seropositive RA 
(either RF or anti 
CCP+) (n and 
percentage) 
 
36  
(72%) 
 
20     
(87%) 
 
- 
 
- 
 
0.235+ 
Patients on oral 
immunomodulator
y therapy at time of 
recruitment (n and 
percentage) 
 
0 
 
21          
(91%) 
 
20       
(87%) 
 
0 
 
- 
Patients receiving 
glucocorticoids at 
time of recruitment 
or in the preceding 
1 month                   
(n and percentage) 
 
0 
 
3            
(13%) 
 
6          
(26%) 
 
0 
 
- 
 
Table 3.2 All cohorts demographics 
The demographical and disease activity data for the disease cohorts (early RA, n=50, 
established RA [est RA] n=25, SLE [Est SLE] n=23) and healthy controls (n=23) 
examined are shown here.  * one way ANOVA +Mann-Whitney U tests. # Disease 
duration is “0” as recruited at diagnosis.  
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Longitudinal early RA IGS cohort  Total n=15 
Age (years, median and range) 64 [35-84] 
Male : Female ratio 3:2 
DAS-28-ESR (median and range) 4.28 [2.61-5.73] 
CRP (mg/L, median and range) 7 [4-84] 
ESR (mm/hr, median and range) 18 [2-48] 
Tender joint count (median and range) 4 [0-16] 
Swollen joint count (median and range) 2 [1-12] 
Patient VAS (median and range) 49 [8-79] 
Duration of symptoms (weeks, median and range) 8 [3-52] 
Early morning stiffness (minutes, median and 
range) 
32.5 [0-380] 
Anti-CCP positive 
(n and percentage) 
11 (73%) 
Rheumatoid factor positive  
(n and percentage) 
12 (80%) 
Seropositive  - either anti- CCP+ or RF+  
(n and percentage) 
12 (80%) 
Patients starting MTX (n and percentage) 11 (73%) 
Patients starting HCQ (n and percentage) 4 (27%) 
Patients starting SSZ (n and percentage) 0 
Patients starting LFU (n and percentage) 0 
Patients given depot glucocorticoid at diagnosis  
(n and percentage) 
13 (87%) 
 
Table 3.3 Longitudinal IGS cohort demographics and drug history  
A subgroup of early RA patients (n=15) were followed up at 1, 3, 6 and 12 months after 
their baseline IGS sample. At these time points clinical parameters and IGS were re-
examined. The demographic data are shown here as well as their initial DMARD and 
glucocorticoid therapies.  
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3.3.2 IGS prevalence in disease cohorts 
The positive/negative status of the early RA, established RA and SLE cohorts was 
examined. Twice as many patients were IGS+ in early RA compared with established RA 
(42% vs 20%) (figure 3.1). This compared with SLE where 56% were IGS+. However 
when comparing early and established RA this difference was not significant. 
I then examined the IGS score itself between the groups (figure 3.2) and found that the 
IGS score was significantly higher in early RA compared to established RA.  It was also 
significantly higher in early RA compared with healthy controls but this difference was 
not observed when comparing established RA and healthy controls. Furthermore there 
was no significant difference between early RA and SLE patients although there was a 
slight trend towards increased IGS scores in SLE patients. There was however a 
significant difference between established RA patients and SLE patients. 
These data all suggest an increase in the expression of IRGs and the IGS in early drug 
naive RA compared with established RA.  
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Figure 3.1 Increased prevalence of a positive IGS in early RA compared with 
established RA 
Early RA patients (n=50), established RA (n=25) and SLE patients (n=23) had their whole 
IGS status (+/-) calculated. The percentage of patients who were IGS+ was: 42% early 
RA patients, 20% established RA and 56% SLE patients. These differences did not meet 
significance Chi2 test.  
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Figure 3.2 Significantly increased IGS score in early RA compared with established 
RA 
The whole blood IGS (IGS score) was calculated across disease cohorts: early RA (n=50), 
established RA (Est RA, n=25), established SLE patients (SLE, n=23) and healthy 
controls (HC, n=23). Horizontal bars depict median values. Mann-Whitney U tests. 
*p<0.05, ** p<0.01, *** p<0.001. 
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3.3.3 Longitudinal expression of the IGS 
Given the IGS increase in early RA, I wished to examine if it fell with time/treatment, 
which would explain the lower IGS score in established RA. Following diagnosis and 
initiation of therapy the IGS was repeatedly measured in 15 early RA patients over 12 
months (baseline, 1, 3, 6, 12 months). Compared with baseline I found a significant fall 
in the IGS at 1 month, 3 months, 6 months and 12 months (figure 3.3.A) 
I next looked at the individual IRGs to see which ones were most affected (figure 3.3.B). 
For MxA there was a non-significant fall at 1 month. However at 3, 6 and 12 months there 
was a significant fall in relative MxA expression. With IFI6 and IFI44L there was a 
significant reduction at all time points. For ISG15 the largest fall in expression was at 1 
and 3 months but this was not sustained at 6 and 12 months. OAS1 showed no significant 
change in expression over the 12 months, although at 1 month there was a trend towards 
reduced expression. 
It is known that glucocorticoids affect the expression of IRGs (23) and I therefore 
excluded 4 patients that had received glucocorticoids beyond baseline. The IGS score was 
re-examined and again showed a significant and sustained fall over 12 months that could 
not therefore be explained by glucocorticoid use (figure 3.4.A). I similarly looked at 
individual IRGs excluding patients that had received additional glucocorticoids, and 
found a similar pattern as previously described (figure 3.4.B).  
Treatment for this cohort included a single baseline intramuscular glucocorticoid depot 
(n=10) and methotrexate monotherapy (n=8), hydroxychloroquine monotherapy (n=1) or 
methotrexate with hydroxychloroquine (n=2).  
Given the change in IGS with time, I examined the IGS and individual IRG expression 
with relation to early RA patient reported symptom duration. There were no associations 
seen (data not shown).  However when examining symptom duration there was a recorded 
upper limit of 52 weeks due to information collection methods which may have been 
skewing the data via a ‘ceiling’ effect. I therefore excluded 8 patients with a disease 
duration of 52 weeks but there was still no significant association between symptom 
duration and the IGS or any individual IRGs (data not shown).   
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Figure 3.3 Significant and persistent fall in the IGS after initiation of treatment  
Early RA patients (n=15) had their whole blood IGS repeated at 1, 3, 6 and 12 months 
after diagnosis (0 months). Each line represents a different patient. A: Whole blood IGS 
expression over 12 months. B: Individual interferon response gene (IRG) expression over 
12 months. IRGs included MxA, IFI6, IFI44L ISG15 and OAS1. Wilcoxon Signed Rank 
Tests. *p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3.4 Significant and persistent fall in the IGS after initiation of treatment - 
excluding patients that had received additional glucocorticoids 
Early RA patients that had not received additional glucocorticoids beyond baseline (0 
months) (n=11) had their whole blood IGS repeated at 1, 3, 6 and 12 months. Each line 
represents a different patient. A: Whole blood IGS expression over 12 months. B: 
Individual interferon response gene (IRG) expression over 12 months. IRGs included 
MxA, IFI6, IFI44L ISG15 and OAS1. Wilcoxon Signed Rank Tests. *p<0.05, ** p<0.01, 
*** p<0.001. 
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3.3.4 The IGS and serum cytokines 
To correlate serum interferon-α with the IGS an ultra-sensitive interferon-α 
chemoluminescent assay was performed using early RA and SLE patients’ serum 
samples. However, in all cases interferon-α was below the detection threshold 
(0.58pg/ml) (data not shown). 
To see if the IGS was associated with a general inflammatory response in early RA 
circulating cytokines were examined for any association with the IGS. These were 
analysed using an MSD mutli-plex immunoassay and included interferon-γ (IFN-γ), IL-
6, IL-12 p70, TNF-α, IL8, IL-1β, IL-2, IL-13, IL-4, IL-10 and BAFF was also examined 
by standard ELISA. There was no significant association between the IGS and any of the 
cytokines measured (data not shown). Despite this I was interested to investigate if these 
circulating cytokine levels followed the same pattern as the IGS following initiation of 
therapy. I therefore examined their expression at 1, 3, 6 and 12 months post diagnosis. 
There was no change in TNF-α, IL-1β, IL-4, IL-13 or IL-12 at any time point. IFN-γ 
expression significantly increased at 12 months only. IL2, IL6 and IL-10 levels fell at 1 
month. IL-2 increased again subsequently to levels similar to baseline. IL-6 remained 
supressed at 3 months but also returned to baseline levels by 6 months, whereas IL-10 
remained reduced at 3 and 6 months. IL-8 was the only cytokine to remain reduced over 
the entire 12 months (Figure 3.5).  
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Figure 3.5 Circulating cytokines during the first 12 months of RA 
Early RA patients (n=15) had baseline circulating serum cytokines measured using MSD 
mutli-plex immunoassay. Cytokines included IL-12 p70, TNF-α, IL-1β, IL-13, IL2, IL6, 
IL-10, interferon-γ (IFN-γ), IL-8 and IL-4. Measurements were repeated at 1, 3, 6 and 12 
months after initiation of immunomodulatory therapies. Data are presented as box and 
whisker plots, in which the horizontal line represent the median value, the box represents 
upper and lower quartiles and the error bars represent range. Wilcoxon Signed Rank 
Tests. *p<0.05, ** p<0.01, *** p<0.001. 
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3.3.5 The IGS and autoantibodies  
Type 1 interferons have been shown to affect B cell function (145), thus the IGS was 
examined in the early drug naive RA cohort with respect to autoantibody status, in 
particular rheumatoid factor (RF), anti-cyclic citrullinated peptide titres (anti-CCP) and 
anti-nuclear antibody (ANA). 
Early RA patients were first separated by serostatus as defined by their anti-CCP titres or 
RF titres which were either “positive” or “negative” according to clinical laboratory 
standards.  Patients were further split into double negatives (i.e. anti-CCP-, RF-), double 
positives (i.e. anti-CCP+, RF+), single positives (i.e. anti-CCP+ or RF+) or single 
negatives (i.e. either anti-CCP- or RF-). There was no significant difference in median 
IGS score between the groups, (figure 3.6). Furthermore most early RA patients were 
ANA negative (43/50, 86%), and there was no significant difference in the IGS+ and IGS- 
cohorts in terms of ANA status (data not shown). 
The laboratory report for titres had an upper limit of detection and was reported as >340 
U for anti-CCP titres and >131 IU/ml for RF titres. This may have had a skewing (ceiling) 
effect on any potential correlations and so serum samples were re-analysed by the clinical 
laboratories to provide accurate titres on samples whose values were previously above 
the detection threshold. Re-examination of the data using these more accurate titres now 
demonstrated a different relationship between the IGS and RF versus anti-CCP (figure 
3.7). Median RF titre was significantly higher for IGS+ than IGS- patients and there was 
a significant positive association between the IGS (as a continuous variable) and the RF 
titre (figure 3.7.A). This was in contrast to anti-CCP+ titres in whom these significant 
associations were not seen (figure 3.7.B).  
Given the different relationships noted between the IGS and RF and anti-CCP titres, I 
examined whether any other immune parameters associated differentially with 
autoantibodies, particularly those cytokines known to influence B cell function. There 
was a significant positive association between RF titres and BAFF levels, a positive trend 
with IL-6 and a significant inverse association with IL-13 (figure 3.8.A). In contrast there 
was no association or trend between anti-CCP titres and BAFF or IL-13 levels. There was 
a significant positive association with IL-6 levels but this was driven by a single outlier 
with very high anti-CCP titres and IL-6 levels (figure 3.8.B). When this individual was 
removed, significance was lost (figure 3.8.C). 
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Figure 3.6 The IGS in relation to RF and anti-CCP status 
Early RA patients (n=50) had their whole blood IGS calculated and patients grouped by 
their serostatus for (positive or negative) RF and anti-CCP autoantibodies as defined by 
conventional laboratory parameters. Cohorts included double negatives (i.e. anti-CCP-, 
RF-, n=13), double positives (i.e. anti-CCP+, RF+, n=29), single positives (i.e. anti-CCP+ 
n=34 or RF+ n=32) or single negatives (i.e. anti-CCP- n=16 or RF- n=18). Horizontal 
bars depict median values. Kruskal-Wallis test 
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Figure 3.7 Autoantibody titres and the IGS score 
Early RA patients had their RF, anti-CCP titres and whole blood IGS quantified. 
Associations were sought between the IGS and autoantibody titres. A: RF+ early RA 
patients (n=41) were split into IGS+ (n=15) and IGS- (n=26); horizontal lines depict 
median RF titres B: Plot shows linear regression between RF titres in RF+ early RA 
patients and the IGS (as a continuous variable) C: Anti-CCP+ early RA patients (n=42) 
were split into IGS+ (n=13) and IGS- (n=29); median anti-CCP titre depicted D: Plot 
shows linear regression between anti-CCP titres in anti-CCP+ early RA patients and the 
IGS (as a continuous variable). Mann-Whitney U tests and linear regression. * p<0.05 
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Figure 3.8 Associations between RF and anti-CCP titres and circulating cytokines  
Early RA patients had circulating IL-13, IL-6 and BAFF quantified by MSD mutli-plex 
immunoassay and ELISA. Associations were sought with autoantibody titres A: Plots 
show linear regression between RF titres in RF+ early RA patients (n=22) and serum 
BAFF, IL-6 and IL-13. B: Plots show linear regression between anti-CCP+ titres in anti-
CCP+ early RA patients (n=25) and serum BAFF, IL-6 and IL-13. C: Linear regression 
between anti-CCP+ titres and serum IL-6 with single outlier removed. Linear regression 
for all. 
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3.3.6 Do factors in serum stimulate interferon-α production?  
I designed experiments to determine if serum-derived factors were driving the production 
of interferon-α. PBMCs from a healthy donor were cultured overnight with autologous 
serum as well as serum from early RA patients and healthy controls. Cultures were also 
repeated with pDC-depleted PBMCs as well as with pDCs alone. Interferon-α was 
measured in the culture supernatants.  
All results were close to the assay detection threshold (0.58pg/ml) which is shown as a 
dotted red line on all graphs. Values below this threshold are therefore technically 
unreliable but are included for comparison only. Despite these caveats there appeared to 
be increased interferon-α production from PBMCs cultured in RA serum when compared 
with healthy control serum (Figure 3.9.A). There was no detectable interferon-α in the 
serum samples themselves (data not shown). When the early RA cohort was divided into 
IGS+ and IGS- patients there was no clear difference between the interferon-α production 
induced from the serum of either cohort (figure 3.9.B). As pDCs are the main interferon-
α cell subset healthy control PBMCs with the pDCs-depleted (>60% depleted) were 
cultured under the same conditions in parallel. There was a significant reduction in 
interferon-α production in the pDC-depleted PBMCs thus highlighting that pDCs were 
primarily responsible or the interferon-α detected (figure 3.9.C). This was significant with 
IGS- RA patient serum (figure 3.9.D) but not IGS+ serum.  When isolated healthy pDCs 
were cultured with patient serum, only IGS+ patient serum stimulated interferon-α 
production (figure 3.9.E). 
Since I had shown associations between RF and the IGS I sought potential associations 
between autoantibody titres in serum and interferon-α production in PBMC cultures. 
However there was no significant association with either RF or anti-CCP+ titres (data not 
shown). Although notably, some measurements were again below the assay detection 
threshold.  
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Figure 3.9 Interferon-α production following culture of healthy donor PBMCs (+/- 
pDCs) with early RA and healthy control serum  
PBMCs from a healthy donor were cultured overnight with serum from either healthy 
controls (including autologous serum) or early RA patients. Interferon-α was measured 
in the supernatant by ELISA. A: PBMC Interferon-α production following culture with 
serum from early RA patients (n=19) and healthy controls (n=8). B: Healthy control 
PBMC Interferon-α production following culture with serum from IGS+ (n=10), IGS- 
(n=9) early RA patients and healthy controls (n=8)  C: Interferon-α production from 
healthy control PBMCs with or without pDC depletion when cultured with early RA 
serum (n=10) D: Interferon-α production from PBMCs with or without pDC depletion 
when cultured with IGS+ (n=5) and IGS- (n=5) early RA serum. E: Interferon-α 
production from purified healthy control pDCs cultured with serum from IGS+, IGS- 
early RA patients  and healthy controls (n=2 each) The red line on each graph 
demonstrates the lower detection threshold of the assay (0.58pg/ml). Mean and SEM 
depicted. Mann-Whitney U tests * p<0.05  
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3.3.7 The IGS and disease activity in early RA 
Early RA patients had their DAS-28 calculated alongside their IGS. Using multiple 
regression, and incorporating age and sex into the model, baseline DAS-28 positively 
associated with baseline IGS score (figure 3.10.A). A positive trend was seen between 
the baseline IGS and the DAS-28 at 3 months (figure 3.10.B) and a significant association 
between the baseline IGS and the 6 month DAS-28 (figure 3.10.C).   
Given the DAS-28 was a composite score of TJC, SJC, ESR and VAS I questioned if any 
of these parameters were more highly associated with the IGS. Using multiple regression 
analysis I found that TJC and SJC associated most strongly with the IGS. These findings 
were robust to the inclusion of age and sex (figure 3.11). 
A principal components analysis (PCA) was performed to identify if certain IRGs within 
the IGS were driving this association more than others. Ultimately all 5 IRGs in 
combination were important for the above observations with equally weighted 
contributions (data not shown). 
For comparison I performed a similar analysis in the established RA cohort. There was 
no significant association between DAS-28 (or any of its components) and the IGS score 
in established RA (data not shown). 
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Figure 3.10 The baseline IGS associates with contemporaneous disease activity as 
well as with 6 month disease activity 
Early RA patients had their whole blood IGS quantified at the time of diagnosis 
(baseline). They also had disease activity measured (DAS-28) at baseline (n=50), 3 
months (n=37) and 6 months (n=32) after diagnosis. Plots demonstrate age and sex 
matched multiple regression for: A: Baseline IGS and baseline DAS-28 B: Baseline IGS 
and 3 month DAS-28 C: Baseline IGS and 6 month DAS-28.  
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Figure 3.11 Associations with DAS-28 is predominantly driven by the combination 
of SJC and TJC 
Early RA patients (n=50) underwent a multiple regression analysis to determine which 
DAS-28 components underpinned the associations between baseline DAS-28 and whole 
blood IGS (shown in figure 3.10). DAS-28 components included swollen joint count 
(SJC); tender joint count (TJC); patient VAS; ESR and age and gender was also included. 
Swollen joint count (SJC) (p=0.017) and tender joint count (TJC) (p=0.043) were the key 
drivers of the association. This is demonstrated in the above schematic where an increase 
in SJC or TJC corresponds with an increase in IGS as depicted by changing colour (blue, 
low IGS; red high IGS).  
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3.3.8 The IGS predicts a poorer response to initial therapies 
In light of the relationship between baseline IGS and 6 month DAS-28, I questioned 
whether the baseline IGS could be a predictive factor for parameters of clinical response 
and disease activity. 
Patients who require additional glucocorticoids administrations in the first 6 months will 
have a worse disease activity/disease course than those who don’t. I examined the number 
of glucocorticoid depots required to control disease activity at up to 6 months following 
diagnosis (excluding glucocorticoids administered at baseline). This was again compared 
with the predictive function of baseline DAS-28, ESR and CRP. Using ordinal logistic 
regression (with Bootstrap probabilities included to guard against the relatively small 
sample size and any abnormal skewing of data) I found that the baseline IGS score 
predicted glucocorticoid requirements in the initial 3 and 6 months post diagnosis (figure 
3.12). The IGS was superior at predicting these outcomes as baseline DAS-28, CRP and 
ESR had no ability to predict the number of glucocorticoid administered.   
Multiple linear regression was performed to assess the ability of the IGS to predict 6 
month DAS-28. This was compared with the ability of baseline DAS-28, ESR and CRP 
to make the same prediction. It demonstrated the baseline IGS was highly significant at 
in predicting DAS-28 at 6 months, wheras all other baseline variables (CRP, ESR, DAS-
28) were non-significant (data not shown). 
In addition the EULAR response to initial therapy (good, moderate or poor) was 
calculated for patients at both 3 months and 6 months from baseline. There was a 
significant inverse association between baseline IGS score and the probability of a good 
EULAR response at both 3 and 6 months (figure 3.13). There was however no such 
association seen for baseline ESR, CRP or DAS-28. All of these above findings were 
robust to corrections for age and sex.   
I used a multivariate general linear model to examine for a potential influence of specific 
DMARD therapies initiated during the first 6 months of treatment on these findings. 
There was a slight suggestion that hydroxychloroquine mitigated the effects of a raised 
IGS when used in conjunction with methotrexate. However, this was non-significant and 
was shown to be unstable when using likelihood ratio tests which questioned the validity 
of any finding (data not shown). This effect was presumably due to the relatively small 
number in the follow up cohort. 
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Figure 3.12 The baseline IGS predicts glucocorticoid requirements at 3 and 6 
months 
In early RA patients the baseline IGS was calculated and the number of additional 
glucocorticoid requirements (beyond any baseline administration) required in the first 3 
and 6 months was recorded A: The baseline IGS significantly predicted the number of 
glucocorticoids required in the first 3 months after diagnosis (p=0.023, n=37) B: The 
baseline IGS significantly predicted the number of glucocorticoids required in the first 6 
months after diagnosis (p<0.0008, n=32). Ordinal logistic regression, age and sex 
corrected with bootstrap probabilities included. Numbers 0-3 denote number of 
glucocorticoid administrations beyond baseline; thus a low IGS has a high probability of 
having 0 extra glucocorticoids, whereas a high IGS has a low probability of having 0 extra 
glucocorticoids.  
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Figure 3.13 Inverse association between baseline IGS score and probability of 
achieving a good EULAR response at 3 and 6 months  
In early RA patients the baseline IGS was calculated and a relationship sought between 
the probability of achieving a good EULAR response at A: 3 months (n=37) and B: 6 
months (n=32). Nominal logistic regression age and sex corrected. 
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3.4 Discussion  
In this chapter I sought a potential role for the IGS in early RA. I found the IGS was 
increased in early RA compared with established RA and fell during the 12 months after 
diagnosis. This fall was independent of any confounding glucocorticoid administration.  
In early RA the IGS demonstrated clinical relevance as it associated with RF titres as well 
as baseline and 6 month disease activity (DAS-28) scores. In addition the baseline IGS 
was able to predict at 6 months the DAS-28, the number of additional glucocorticoids 
required as well as predict the clinical response to initial therapies. In all cases a higher 
IGS resulted in a worse clinical outcome. Importantly the baseline IGS outperformed 
conventional parameters of disease activity such as baseline DAS-28, CRP and ESR when 
making these predictions. 
The significance of the IGS in RA pathogenesis has been examined before however most 
previous studies have been performed in established RA cohorts, where findings may 
have been confounded by concurrent immunomodulatory therapies (23). In contrast I 
focussed on early, DMARD-naive RA patients. There are numerous IRGs that are 
upregulated in response to type 1 interferons (108). I examined 5 IRGs, which were either 
most differentially expressed or shown to be relevant in previous RA and SLE studies 
(158, 184, 200, 203, 206, 248-251). I demonstrated an increased prevalence of IGS-
positive patients in early RA, which subsequently fell with treatment (figure 3.1-3.4).  
Reassuringly my data in established RA and SLE cohorts were consistent with previous 
reports (186, 262). This increased prevalence of type 1 interferons in early RA mirrors 
other human autoimmune conditions, including type 1 diabetes, primary Sjogrens 
syndrome (pSS) and systemic sclerosis, where early exposure to these cytokines 
reinforces aberrant signalling pathways leading to breach of tolerance (148, 265, 266).  
Indeed historically interferon-α therapy used for the treatment of viral hepatitis was 
shown to induce a symmetrical inflammatory arthritis which, in some cases, was 
seropositive and consistent with a de novo diagnosis of RA (267-269). More recent 
developments have shown that certain genetic variants that increase RA susceptibility, 
particularly in patients harbouring the shared epitope, are associated with the type 1 
interferon pathway, such as IRF5 and STAT 4 (169, 173). In addition, upregulation of 
genes related to the type 1 signalling pathway predicted progression to RA in a 
seropositive arthralgia patient cohort (182, 183), and in established RA a higher IGS is 
seen in patients with a shorter disease history (191). In a mouse model, transfer of type 1 
interferon producing dendritic cells was sufficient to propagate an inflammatory arthritis 
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which persisted even beyond the period where type 1 interferons were being produced 
(270). In other murine models intra-articular type 1 interferon injections induced an 
arthritis phenotype (177) and inhibition of interferon-α signalling pathways by a variety 
of means prevented the development of inflammatory arthritis in susceptible animal 
models (172, 177-179, 271). Finally in mouse models of arthritis secondary to infection, 
blocking type 1 but not type 2 interferons was sufficient to supress arthritis (272). 
Cumulatively this evidence, along with my data, suggest that type 1 interferons may be 
an important pathophysiological mechanism early in RA. 
Consistent with an increased prevalence of a positive IGS in early RA I found a significant 
fall in the IGS at 3, 6 and 12 months after diagnosis and initiation of treatment (figure 
3.3-3.4). At diagnosis (baseline) most patients received a depot intramuscular 
glucocorticoid injection and to reduce confounding (23) those who received additional 
glucocorticoids were excluded from longitudinal analysis. Glucocorticoid exposure is 
likely to have influenced the IGS at 1 month but, by 3, 6 and 12 months other factors must 
have contributed to the reduced IGS, such as reduced disease activity and direct DMARD 
effects. This supports the observation that patients with a longer duration of RA had a 
lower IGS (191) although longitudinal analysis of established SLE has showed no change 
in the IGS even during dynamic disease activity (273, 274). Apart from steroids and a 
single report following a lymphotoxin-beta receptor-immunoglobulin fusion protein 
therapy (23, 187), no other therapies have been shown to modulate the IGS in RA. It is 
therefore intriguing that I saw this in early RA following conventional DMARD therapy. 
Notably however there was no change in OAS1 expression over 3 months (figure 3.3-3.4) 
but the PCA of the IGS showed all of the IRGs were similarly upregulated. It may be that 
OAS1 is relatively resistant to treatment-induced changes although this is currently only 
speculative. In light of these findings I also examined the IGS in the context of pre-
diagnosis symptom duration but no association was seen. This was slightly unexpected, 
however symptom duration is a self-reported retrospective measure and therefore subject 
to recall bias. Perhaps more importantly, time itself may not be crucial to the fall of the 
IGS, but rather initiation of DMARDs and reduction in disease activity are the primary 
factors.     
Multiple studies have shown no association between the IGS and disease activity in 
established RA (186, 187). This is despite established associations between the IGS and 
SLE disease activity (155) as well a single study reporting associations between serum 
interferon-α, extra-articular complications and disease activity (188). Nonetheless I 
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demonstrate for the first time an association between IGS and disease activity in early RA 
at both baseline and at 6 months (figure 3.10). When examining the composite parameters 
of the DAS-28 (ESR, TJC, SJC and patient VAS) I found that the association with IGS 
was mainly driven by TJC and SJC. Interestingly a recent Phase IIB trial of IFNAR1 
blockade in SLE, demonstrated a reduction in symptoms of joint inflammation, such as 
TJC and SJC (162). This may support a role for type 1 interferons in driving direct 
synovial pathology.  
My data also showed that in early RA the IGS had a predictive capacity; the baseline IGS 
predicted the DAS-28 at 6 months, EULAR response to initial therapies as well as 
glucocorticoid requirement over the 3-6 months after diagnosis and initiation of 
DMARDs (figure 3.12-3.13). Conventional models of inflammation, such as CRP, ESR 
and baseline DAS-28 were not able to make the same predictions, highlighting a distinct 
role for type 1 interferons in disease pathogenesis and treatment response. In SLE, 
simultaneous TLR7 and TLR9 signalling in pDCs causes relative glucocorticoid 
resistance, resistance to apoptosis as well as stimulating interferon-α release (275, 276). 
A similar mechanism may be occurring in RA also. A positive IGS predicts an inferior 
response to certain biological therapies in established RA (186, 200, 202), whereas this 
data show that the IGS also affects response to oral DMARDs and glucocorticoids in early 
disease. Some patients developing widespread polyarthritis following interferon-α 
therapy had substantial improvement following hydroxychloroquine (HCQ) therapy (269, 
277). HCQ can bind nucleic acids directly, masking their TLR-binding epitope and 
consequent TLR signalling capacity (278). HCQ can also affect endosomal acidification 
thus modulating pDC TLR7 signalling and subsequent interferon-α production (155). 
This has been shown in vitro and also ex vivo when examining pDCs from HCQ treated 
SLE patients (279, 280). Finally patients with primary antiphospholipid syndrome have 
a reduced IGS if taking HCQ (281). In light of this an attempt was made to see whether 
the inclusion of HCQ in initial DMARD therapy modulated the effect of the IGS. 
Although there was a suggestion that HCQ abrogated the effect of IGS on disease 
outcome, my study had insufficient power to substantiate this observation. Therefore 
whether simultaneous TLR7/9 signalling in pDC relates to the poorer outcome seen in 
IGS positive RA patients, and whether HCQ may be particularly beneficial in IGS+ 
patients, remain to be elucidated. Overall however my data suggest a prognostic rather 
than therapy-specific influence of the IGS. 
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I did not detect circulating interferon-α in serum, which is consistent with published work 
in both established RA and SLE where, despite high IGS expression in cellular RNA, 
there is often no detectable cytokine in the serum (186, 187, 282). One potential 
explanation is that lymphocytes are being exposed to interferon-α at other sites, such as 
within lymph nodes. Supporting this suggestion is the observation that, upon activation, 
most interferon- producing pDCs migrate to lymph nodes from the peripheral blood 
(283, 284).  I also examined for associations with other inflammatory cytokines but none 
significantly associated with the IGS at baseline. It is interesting that the IGS did not 
associate with interferon-γ as in SLE there is a suggestion that type 2 interferons, such as 
interferon-γ, may be important in upregulating IRGs associated with a positive IGS (163). 
However, in my cohort not only was there no association between IGS and interferon-γ 
at baseline but 12 months later interferon-γ levels had significantly risen, whereas the IGS 
had fallen (figures 3.3-3.5). When I chose the 5 IRGs to generate my IGS I specifically 
excluded any IRGs that could also be cross stimulated by type 2 interferons. Some of 
these genes were very highly expressed in the RA microarrays used to identify my IRGs, 
and potentially could have been upregulated due to interferon-γ exposure secondary to 
the known RA Th1 response (66). Due to my chosen IRGs however this potential 
confounding association would have been minimised and thus any potential association 
with type 2 interferons lost. Others suggest the IGS detected in RA synovial fluid is driven 
by TNF-α (285), but again, I did not identify a relationship between TNF-α levels and the 
IGS. These data are reassuring in allowing us to draw conclusions that the IGS reported 
here is predominantly generated by exposure to type 1 interferons. However caveats 
regarding different cytokines level at localised sites, such as lymph nodes would still 
remain.  
Treatment with interferon-α can induce de novo autoantibodies or increase titres of pre-
existing autoantibodies. This is most marked for ANA where, depending on the patient 
group, between 18% and 72% exhibited increased titres following treatment with 
interferon-α (267, 268, 286-289). This pattern is similar to that seen in SLE, where the 
IGS associates with ANA and anti-RNA binding protein antibodies (282). Conversely, I 
did not see an association between IGS and ANA titres in early RA. I did, however, see 
an association between IGS and RF factor but not anti-CCP titre (figure 3.7). This is 
intriguing and, in patients who developed a polyarthritis following interferon-α therapy, 
34% also developed RF autoantibodies but far fewer developed anti-CCP antibodies 
(180). Furthermore, in vitro, interferon-α can promote RA B-cells to produce RF (290). 
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The difference between the effect of the IGS and anti-CCP may in part be due to 
differences in mechanisms related to their generation. RF is a predominately a non-
switched IgM against self-IgG and some have supposed that, contrary to anti-CCP 
generation, RF is generated following TLR signaling in a T cell independent manner 
(291). B cells express TLR 7 and 9 (292) so it is conceivable that triggers for pDC 
interferon-α production could also trigger RF generation. Conversely in SLE a novel 
mechanism has been proposed where the IGS is generated by opsonisation of dead cells 
by complement and IgM (293). Potentially IgM RF in RA may be contributing to this 
observation via a similar mechanism. Nonetheless my finding is contrary to what has been 
reported in established RA where IGS did not associate with RF, anti-CCP, or ds-DNA 
titres (294). However, in this published study the median disease duration was 98 months. 
Given the fall in IGS following initiation of DMARDs in early RA (figure 3.3-3.4) it may 
well be that any associations become blurred over time. An alternative explanation is that 
type 1 interferons are more important for inducing RF generation in early disease. Indeed 
the proportion of IgM anti-CCP antibodies was higher in early RA than in established RA 
(4) and this potentially may be due increased exposure to type 1 interferons observed in 
early RA. 
There are a variety of ways that type 1 interferons can affect B cells and promote auto-
reactivity and autoantibody production. BAFF/BLyS is under the control of IRF 
transcription factors (295) and interferon-α induces its expression in other cell subsets 
(145, 146). Autoreactive B cells require higher levels of BAFF/BLyS for survival and 
increased BAFF/BLyS following can rescue autoreactive cells that would otherwise have 
been deleted at the transitional phase (296, 297).  It is interesting therefore that RF titres 
significantly associated with the IGS as well as with BAFF/BLyS (figure 3.8) although 
conversely there was no association between BAFF/BLyS and the IGS itself. However I 
only measured circulating levels of BAFF/BLyS; a membrane bound form also exists, 
which some propose to be a more potent stimulus for B-cells than soluble BAFF/BLyS 
(298). Indeed, RA fibroblast-like synoviocytes express membrane-bound BAFF/BLyS 
and are critical for the local activation of B-cells (299). Thus increased BAFF/BLyS 
signaling may be a mechanism whereby the IGS promotes RF generation. Type 1 
interferons can also affect B-cells independently of BAFF/BLyS. They lower the BCR 
signaling threshold (139), increase TLR7 expression (140), promote B cell longevity by 
upregulating BCl2 (141) and also upregulate cell surface molecules such as CD69, CD86 
and HLA-DR that affect B-cell survival and function (139). Finally type I interferon 
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exposure also affects the B-cell response to IL-6, which is involved both in B-cell survival 
and differentiation (142). There was a positive association between IL-6 and RF titres but 
not anti-CCP titres (figure 3.8). The association with the IGS in the RF+ cohort could 
therefore also be driven by the promotion of increased sensitivity to IL6 signaling.  
However with both these associations, although there is clear differential activation of 
anti-CCP and RF producing B cells, it is not clear why this occurs.  
Although type 1 interferons affect B cells, these cells can in turn affect the production of 
type 1 interferons by pDCs. In SLE an evolving body of literature implicates serum 
derived factors in the production of type 1 interferons, namely autoantibody containing 
immune complexes. Autoantibody-containing IgG from SLE patients can directly bind to 
FcγRIIa (CD32) expressed on pDCs. These complexes are then internalised and 
subsequently trigger intracellular signalling pathways and initiate the production of 
interferon-α (147-151). To determine whether serum derived factors, such as immune 
complexes, acting on pDCs may have contributed to the IGS I cultured PBMCs (with or 
without pDC depletion) overnight with serum from IGS positive and IGS negative early 
arthritis patients as well as from healthy controls. Given the observation between RF titres 
and IGS I hypothesised that RF containing immune complexes may have been implicated 
in interferon-α production. There were clear caveats to my findings, the main being that 
most of the values were below or close to the assay detection threshold. Nonetheless there 
was a suggestion that early RA serum induced greater production of interferon-α from 
PBMCs and pDCs appeared to play a significant role (figure 3.9). However this effect 
was not related to serum RF or anti-CCP titres. Potentially this could be explained by 
other RA autoantibodies, such as anti-CarP antibodies (103), participating in pathological 
immune complexes. However purified immune complexes isolated from established RA 
serum did not induce type 1 interferon production from pDCs when a similar experiment 
was performed (150). There could be a difference between early versus established RA, 
but additional serum derived factors (not immune complexes) could have underpinned 
these observations. For example neutrophils can extrude mitochondrial DNA or the 
alarmin human neutrophil peptide 1 (HNP1) both of which can trigger type 1 interferon 
production (300, 301). Furthermore neutrophil cell death termed NETosis causes 
extrusion of intracellular contents, including nuclear material, in a lattice structure termed 
a NET. NETs are increased in RA serum and have pathological relevance in SLE where 
they directly activate pDCs and, via TLR9 ligation, cause type 1 interferon release (77, 
302-304).  
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Finally I averaged the IRGs to calculate an IGS but some methods calculate an IGS value 
by comparing each individual gene to a healthy control population. A disadvantage of 
this method is that it does not generate a “positive/negative” cut off value but rather a 
continuous variable and thus limits the researcher being able to identify the prevalence of 
a “positive IGS” as I wished to do in this study. However an advantage of this method is 
that it does minimise skewing of the IGS by certain IRGs that may be more abundantly 
expressed. This would need to be taken into account when interpreting the findings, 
however the PCA of the IRGs in my IGS demonstrated no undue effect of one IRG over 
the other suggesting that this concern may be minimal.  
However, as indicated, I used IRGs that had previously been shown to be upregulated in 
established RA and in ACPA+ arthralgia. A recently published abstract demonstrates IRG 
expression in incomplete early SLE and established complete SLE is different and suggest 
that IRG expression may be a dynamic process with an intrinsic variability in expression 
over time (305). It would have been preferable therefore to only use genes that had been 
shown to be abnormal in early RA. However the paucity in the literature examining the 
IGS in early RA is likely to have hampered my evidence based choice of genes. 
Nonetheless there is a single study looking at drug naïve early RA IRG expression in 
which IFI44L, MxA and RSAD2 are used to generate the IGS (248). Two of these genes 
(MxA and IFI44L) do overlap with the genes chosen to calculate my IGS whereas RSAD2 
is also commonly activated by type 2 interferons and so was excluded from my choice. 
Theoretically as more is known about type 1 interferons in early RA, the gene list I used 
may need to be reviewed.  
A further option to identify suitable IRGs would be to culture PBMCs from early RA 
patients with type 1 interferons and measure the upregulated IRGs and subsequently 
chose the most highly differentially expressed genes. One caveat to this method however 
choice of interferon-α for culture. There are 13 subtypes of interferon-α and while it is 
appreciated that interferon-β can have separate effects downstream of the IFNAR due to 
altered phosphorylation associated protein (306) or by binding uniquely to IFNAR1 
independent of IFNAR2 and initiating downstream signalling pathways independent of 
JAK-STAT phosphorylation (307), the permeations of what each of the different 
interferon-α subtypes on cellular response or IRG upregulation is unknown. Furthermore 
it is unclear what interferon-α subtype is predominant in RA. Indeed different stimuli can 
promote the different release of interferon-α subtypes (308). Although the above 
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experiment would have provided a “positive control”, given these caveats, I felt using 
IRGs known to be dysregulated in vivo in RA was preferable.  
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3.5 Conclusions  
 
RA is highly heterogeneous disease and I hypothesize that, in a subgroup of patients with 
a susceptible genetic background, type 1 interferons contribute to initiation or 
reinforcement of early pathogenic pathways. These may involve the activation of B cells 
and the production of autoantibodies, such as RF.  
A positive IGS in early RA has relevance to clinical progress as it predicts lack of 
response to initial treatment, which I have shown for the first time. RA therapeutic 
strategies are increasingly focused on early treatment and there may be merit in targeting 
pathways triggered by type 1 interferons in a subset of patients with a high IGS at disease 
onset. For example, anti-interferon-α monoclonal antibodies and IFNAR1 blockers are 
both currently being trialled in SLE (161, 263) and JAK1/3 inhibitors, recently licenced 
for the treatment of RA in some parts of the world, also inhibit type 1 interferon signalling 
(309).  
In summary, I have demonstrated a high prevalence of the IGS in patients with early RA. 
This predicts increased disease activity as well as refractoriness to initial treatment. I 
suggest that a subset of early RA patients may therefore benefit from therapeutic 
strategies that target type 1 interferons and their downstream pathways.  
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3.6 Future work 
One of the key steps in the discovery of any prediction model is the validation of the 
findings. It would also be useful to increase the number of patients examined 
independently of validation. A benefit of this would be the ability to examine the role of 
different DMARDs, particularly HCQ, in modulating the effect of the IGS. Furthermore 
since the IGS associated most strongly with the TJC and SJC correlating the IGS with 
musculoskeletal ultrasound findings is likely to be additionally informative. 
I would also like to follow a larger cohort of early RA patients over 12 months to assess, 
more robustly, if there was any relationship between the fall in DAS-28 following 
treatment and if this was reciprocal to the changes in IGS at 1, 3, 6, and 12 months after 
diagnosis. It would be interesting to see if those with increased disease activity at 6 
months also had a persistently higher IGS also. I was not able to assess this aspect of the 
dynamic interaction between the IGS and the DAS-28 at 6 months due to limitations in 
patient recruitment and the finite timing of the PhD. Nonetheless with increased patient 
number and matched DAS-28/IGS over the first 6 months certain modelling techniques 
could be used to identify if a relationship persisted between these agents once treatment 
was initiated.  
I saw an interesting association with the IGS and RF but not anti-CCP. I only looked at 
the autoantibodies themselves and it would be ideal to examine immunoglobulin (IgA, 
IgM and IgG) levels within the serum to see if the IGS was associated with a global B 
cell activation or if it was primarily limited to RF or only IgM. In keeping with this it 
would also be interesting to follow up RF and anti-CCP titres and see if they changed 
with time parallel to the fall in the IGS.  
I could also culture B cells from either IGS+ or IGS- early RA patients (as well as healthy 
controls) and stimulate them with interferon-α. This would examine the proliferative 
capacity of the B cells as well as the production of immunoglobulins, particularly IgM. 
Cell culture supernatant could be analysed specifically for RF and anti-CCP antibodies.  
The results of experiments attempting to identify if serum derived factors were 
responsible for induction of type 1 interferons were very close to the assays’ lower 
detection threshold. I would repeat these but over a longer time frame and also with a 
higher percentage of patient serum. In SLE immune complexes bind to FcγRIIa (CD32) 
on pDCs to initiate interferon-α release. To see if this mechanism was also involved in 
early RA I would also perform these cultures with a FcγRIIa blocking antibody. As both 
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NETs as well as immune complexes may be responsible for these observations, future 
work would include measuring NETs in the circulation of IGS+/IGS- early RA patients, 
as well as using purified immune complexes from RA serum in culture.  
Finally I did not detect any interferon-α in the serum using MSD technology. Some have 
used a reporter assay (bioassay) to detect interferon-α in the serum and found that this is 
more sensitive than other conventional assays. This could be considered in the future to 
identify if there is increased interferon-α in the circulation. This would contribute to the 
understating of the location of the interferon-α producing cells, i.e. lymph node/joint or 
periphery. 
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4.1 Introduction 
T cells and B cells are generally considered to be the pathological cell subtypes that are 
deranged in rheumatoid arthritis (RA), a theory supported by the therapeutic success of T 
and B cell targeted treatments (92). However, the role of other cell subsets in RA 
pathophysiology is becoming increasingly appreciated. Dendritic cells (DCs) are of 
growing interest, not least because they can modulate both the innate and adaptive 
immune system and therefore have direct effects on both T cells and B cells (32).   
It is not only their ability to deviate T and B cell phenotype that makes DC of interest. 
DC also have tolerogenic capacities as shown by work in both cancer and autoimmunity 
(310, 311). Thus, DCs can induce cell death or anergy and can skew T cells towards a 
regulatory phenotype. This highlights the complexity of DC function and has further 
consolidated the important role of DCs in immune modulation and the need to understand 
their role in RA. Plasmacytoid dendritic cells (pDCs) are a relatively newly identified DC 
subset. The majority of work investigating their role in autoimmunity has been in SLE 
and focused on their prolific interferon-α production and the subsequent generation of an 
interferon gene signature (IGS) (157). They have not been studied in early RA and what 
role they play in RA pathogenesis remains unclear and to date contradictory (85, 90). In 
other environments pDCs have been reported to play a potentially tolerogenic role in part 
due to the expression of programmed death ligand 1 (PDL1) and inducible T-cell co-
stimulator ligand (ICOSL) which promotes the generation of regulatory T cells, or Tregs 
(56-61). Some report reduced Tregs in RA, but this is not a universal finding (75, 96-99). 
Nonetheless the potential effect of modified pDC function on Treg generation in RA has 
not been examined. 
Current evidence for the role of DCs in general in RA points towards a role in disease 
maintenance and progression, however most of this work has been performed in 
established RA and it remains unclear whether DCs initiate autoimmunity or facilitate 
breach of tolerance (81). Other cell types, such as CD4+ T cells have been examined in 
more detail in early RA, with evidence that the function and phenotype of these cells in 
early disease may be distinct from what is seen in established RA (9, 248, 291, 312). Thus 
examining pDCs at the start of disease prior to initiation of disease modifying therapies 
is likely to provide additional useful information into their role in RA. I therefore studied 
pDCs in early RA with focus on the IGS, maturation/activation phenotype, as well as their 
ability to generate Tregs.  
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4.2 Aims 
In this chapter I wished to address the following questions: 
1. Is the percentage of circulating pDCs or their activation status deranged in early 
RA?  
2. Does the IGS associate with pDC frequency or phenotype?   
3. Is there an association between pDC subset frequency/phenotype and clinical 
parameters or pro-inflammatory cytokines? 
4. What happens to pDC subsets with disease duration and treatment?  
5. Do pDCs from RA patients differ from healthy controls functionally? In 
particularly relating to their ability to induce Tregs? 
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4.3 Results  
4.3.1 Patient cohorts 
Cohorts for this analysis included early DMARD and steroid naïve early RA, ACPA+ 
arthralgia patients (also DMARD and steroid naïve), and healthy controls who had no 
personal history of rheumatological disease nor any other significant past medical history. 
Finally established RA and SLE patients cohorts were included, and for these latter 
cohorts inclusion criteria included disease duration of greater than 12 months. 
Patient and healthy control demographic data demonstrated a significant difference in age 
and sex of the different cohorts (table 4.1). 
The frequency of pDCs in peripheral blood was identified by flow cytometry where the 
proportion of the pDC in the lymphocyte gate recorded. The population was first divided 
into healthy controls and disease patients which included all the disease groups. There 
was no association between age and the circulating frequency of pDC for either cohort 
nor was there any association with gender (figure 4.1). 
Although age and sex did not affect pDC frequency, due to the highly significant 
differences in demographics between my cohorts, I corrected for age and sex when 
studying DC populations across the cohorts. However when looking at an individual 
cohort in isolation (e.g. early RA only) I did not correct for age and sex.  
The specific demographic data for the longitudinal early RA cohort examined in this 
chapter (which is a subset of the larger early RA cohort), are shown in Chapter 3, table 
3.4. 
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Patient 
Cohort 
Early 
RA 
Est            
RA 
 
SLE 
ACPA+ 
arthralgia 
HC Difference 
between 
cohorts 
Number 44 11 23 11 30 - 
Age (years) 
median [range] 
57 
[33-84] 
62 
[33-78] 
53 
[33-67] 
43 
[20-75] 
37 
[23-62] 
 
p<0.0001 
Male : Female 
ratio 
3:4 1:10 1:11 1:2 3:2 p=0.0008 
 
Table 4.1 Demographical data for cohorts used 
Patient cohorts included those with early RA (n=44), established RA (Est RA, n=11), 
SLE (n=33), ACPA+ arthralgia (n=11) and healthy controls (HC, n=30). Their 
demographic data are displayed including median age (and range) and male:female ratio. 
Cohorts were compared by one-way ANOVA. 
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Figure 4.1 pDC frequency in the peripheral blood by age and gender  
Subjects were divided into healthy controls (p=30) and disease categories (n=89). The 
latter included RA (n=44), established RA (n=11), SLE (n=33), ACPA+ arthralgia 
(n=11). PDCs were identified in the peripheral blood and the percentage of cells falling 
within the lymphocyte gate was recorded using flow cytometry. A: Plots show linear 
regression between age and pDC frequency for both healthy control and disease cohorts. 
B: pDC frequency by gender for healthy controls and disease cohorts. Horizontal lines 
depict median values. p>0.05 Mann-Whitney U tests.  
 
  
Faye A. H Cooles                                                                 Chapter 4: pDCs in early RA  
 
105 
  
4.3.2 pDC frequency by disease category and associations with the IGS 
There was a significant reduction in the frequency of pDCs in early RA and SLE 
compared with healthy controls. Similar trends were seen with the other disease cohorts 
(ACPA+ arthralgia and established RA) but these did not reach significance (figure 4.2). 
Given the role of pDCs in the production of type 1 interferons (43) associations were 
sought between pDC frequency and the interferon gene signature (IGS) in the early RA 
cohort. PDC frequency was comparable between IGS+ and IGS- early RA patients nor 
was there any association with the IGS (as a continuous variable) (figure 4.3).  
Given that pDCs produce type 1 interferons upon activation, I also examined the pDC 
phenotype with respect to the IGS. However there was no significant association between 
any of the activation markers studied (CD40, CD86, CCR7, HLA-DR and ILT7) and the 
background IGS (data not shown).  
 
 
 
 
 
 
Faye A. H Cooles                                                                 Chapter 4: pDCs in early RA  
 
106 
  
 
Figure 4.2 Proportion of pDC amongst peripheral blood lymphocytes in disease 
states compared with healthy controls 
Peripheral blood pDCs, were identified by flow cytometry and recorded as a percentage 
of the circulating lymphocyte population. This value was compared across disease 
cohorts; early RA (n=44); established RA (est RA, n=11); anti-CCP+ (ACPA+) arthralgia 
(n=11); SLE (n=23) and healthy controls (n=30). Univariate generalised linear model 
(age and sex corrected). Horizontal lines depict median values. * p<0.05 
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Figure 4.3 IGS and pDC frequency in early RA patients 
Early RA patients (n=39) were examined for associations between pDC frequency within 
peripheral blood lymphocytes and the IGS A: IGS+ (n=13) and IGS- (n=26) early RA 
patients and pDC frequency. Horizontal lines depict median values. Mann-Whitney U 
test. B: Plot shows linear regression between pDC frequency and the IGS (continuous 
variable).  
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4.3.3 pDCs and early RA clinical phenotype 
DCs can affect B cell function as well as T cell function (313). Given that B cell 
dysfunction in RA, commonly manifests in the production of autoantibodies, I questioned 
if serostatus had any effect on the percentage of circulating pDCs (figure 4.4).  
There was a significant reduction in pDC frequency in seropositive early RA patients 
compared with healthy controls and a non-significant trend for seropositive patients to 
have a lower pDC frequency than seronegative patients (figure 4.5). In light of this RF 
and anti-CCP titres were compared with pDC frequency. However, there were no 
significant associations (data not shown). 
As DC activation/maturation status can also affect interactions with other immune cells I 
examined pDC phenotype and serostatus. There was a trend towards increased CCR7 
expression in early RA seropositive patients compared with healthy controls. Conversely 
seronegative patients had significantly less CCR7 when compared with healthy controls. 
Furthermore when directly comparing pDCs from early RA seropositive and seronegative 
patients there was significantly higher CCR7 expression in seropositive patients. No 
differences were seen in CD86, CD40, HLA-DR and ILT7 expression between the 
cohorts, nor was there any significant difference when examining ACPA+ arthralgia 
patients for all surface markers (figure 4.5).  
An association was subsequently sought between CCR7 expression and pDC frequency 
where an inverse trend was seen (figure 4.6.A). This was significant when including only 
RF positive patients (figure 4.6.B) and there was a similar trend for anti-CCP positive 
patients, although not significant (figure 4.6.C).  There was however a significant positive 
association between anti-CCP titres and pDC CCR7 expression; this was not reproduced 
with RF titres (figure 4.7). These associations were not detected with any other pDC 
activation markers (data not shown).  
Finally in view of their potentially pathogenic role relationships between disease activity 
(DAS-28, VAS, TJC, SJC, ESR, CRP) and circulating pDC frequency and phenotype 
were sought; but no significant associations were seen (data not shown). There were also 
no significant relationships between serum cytokines (interferon-γ, IL-6, IL-12 p70, TNF-
α, IL-1β, IL-2, IL-13, IL-4, IL-10 and BAFF) and pDC frequency or phenotype (data not 
shown). 
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Figure 4.4 pDC frequency in relation to serostatus 
Early RA patients (n=45) were divided into seropositive (n=35, either RF+ or anti-CCP+) 
and seronegative (n=10, both RF- and anti-CCP-) and pDC frequency (as determined by 
flow cytometry) compared with healthy controls (n=23). Horizontal lines depict median 
values. Univariate generalised linear model (age and sex corrected) between early RA 
and healthy controls and Mann-Whitney U test for comparisons within early RA. * 
p<0.05. 
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Figure 4.5 pDC surface phenotype in RA and pre-RA  
PDC cell surface marker expression of CD86, CD40, ILT7 and HLA-DR was quantified 
by flow cytometry (median fluorescence intensity, MFI) in healthy controls (HC, n=13), 
anti-CCP+ arthralgia (ACPA+ arthralgia, n=7 for ILT7 and CCR7 expression, n=11 for 
remaining parameters) and early RA patients (n=30-32; further split into seronegative, 
n=5-7 and seropositive early RA, n=25).  Horizontal lines depict median values. 
Univariate generalised linear model (age and sex corrected) between healthy controls and 
early RA and Mann-Whitney U test for comparisons within early RA with ACPA+ 
arthralgia *p<0.05, ** p<0.01. 
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Figure 4.6 Relationship between percentage of circulating pDC and CCR7 
expression in early RA  
PDC CCR7 expression was quantified using flow cytometry derived median fluorescence 
intensity (MFI) and associations sought with pDC frequency. A: Plot depicts linear 
regression in all early seropositive RA patients (n=25) between pDC CCR7 expression 
and pDC frequency. B: Plot depicts linear regression in all RF+ early RA patients (n=25) 
between pDC CCR7 expression and pDC frequency. C: Plot depicts linear regression in 
anti-CCP+ early RA patients (n=21) between pDC CCR7 expression and pDC frequency.  
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Figure 4.7 Relationship between RF and anti-CCP titre and pDC CCR7 expression 
PDC CCR7 expression was quantified using flow cytometry derived median fluorescence 
intensity (MFI) in early RA patients and associations sought with autoantibody titres. A: 
Plot depicts linear regression between pDC CCR7 expression and RF titres. B: Plot 
depicts linear regression between pDC CCR7 expression and anti-CCP titres.  
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4.3.4 Longitudinal pDC frequency and phenotype 
A cohort of 15 early RA patients were followed up at time points 1, 3, 6 and 12 months 
after diagnosis. Their demographic data are shown in chapter 3, table 3.4. At each time 
point (including baseline) pDC frequency and phenotype were studied.  
There was no significant change in pDC frequency over the observation period (figure 
4.8). However there was a significant fall in pDC CD86, HLADR and CD40 expression 
at 3 months 6 months and 12 months. There was also a difference in CD40 expression 
between 3 and 6 months, and 3 and 12 months; and between 1 and 6 months for HLADR 
expression (figure 4.9).  
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Figure 4.8 Longitudinal measurements of circulating pDC frequency in early RA 
The percentage of pDC falling within the flow cytometry lymphocyte gate were 
enumerated longitudinally in an early RA cohort (n=15) at baseline and then 1, 3, 6 and 
12 months after diagnosis. Each line represents an individual patient. Wilcoxon signed 
rank tests. 
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Figure 4.9 Longitudinal measurements of pDC activation markers in early RA 
PDC cell surface marker expression (as determined by flow cytometry median 
florescence intensity, MFI) was quantified in an early RA cohort (n=15) at baseline and 
at 1, 3, 6 and 12 months after diagnosis. Each line represents an individual patient. 
Wilcoxon signed rank tests.*p<0.05, ** p<0.01, *** p<0.001. 
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4.3.5 pDC mixed lymphocyte reactions (MLRs) 
Demographics of the established RA patients and healthy controls whose pDCs were used 
in the mixed lymphocyte reactions (MLRs) are shown (table 4.2). Notably the healthy 
controls were significantly younger than the patient population, although male:female 
distribution was comparable. Ideally early RA patients would have been used for this 
work but patient sample material was limited hence the use of established RA patients.  
To quantify pDC response to maturation stimuli, PBMCs were stimulated with TLR-9 
ligand CPG-B (5ug/ml) for 18-24 hours and compared with unstimulated controls. The 
fold change in pDC expression of HLA-DR, ICOS-L and PDL1 was then examined. 
Healthy controls and early RA patients upregulated pDC surface expression of ICOSL to 
a greater extent than established RA patients, although not to a significant degree (figure 
4.10.A). This was inverse to what was seen with pDC PDL1 expression where healthy 
controls upregulated PDL1 significantly less than both early and established RA patients. 
Furthermore established RA patients upregulated PDL1 significantly more than early RA 
patients (figure 4.10.B). HLA-DR expression was comparable across groups and had a 
smaller range of fold-change induction than that seen for ICOSL and PDL1 (figure 
4.10.C).  
Mixed leukocyte reactions (MLRs) were performed between allogenic healthy control 
naive CD4+ T cells and pDCs from either established RA patients or healthy controls. 
Optimal conditions for the MLRs were previously determined by the work of a Masters’ 
student (Oliver Eltherington) within the laboratory and are not re-examined. These 
subsequent experiments were performed with his assistance.  
MLR CD4+ T cells were CFSE labelled and subsequent CFSE dilution (as determined by 
flow cytometry) was used to quantify the percentage of cells that proliferated. There was 
increased proliferation in MLRs from pDCs primed with CPG-B compared with control 
pDCs which was significant for RA but not healthy controls. However there was no 
difference between healthy controls and RA patient primed pDCs in the final level of 
proliferation achieved (figure 4.11.A). The co-expression of FOXP3 and high levels of 
CD25 has been described as one method of identifying Tregs (75). There was no 
difference in the proportion CD3+CD4+ FOXP3+CD25+cells following culture with pDCs 
from either healthy controls or RA patients (Figure 4.11.B).  
Cytokine levels (interferon-γ, IL-13 and IL-10) were quantified in the supernatant of the 
pDC and naive T cell MLRs. Both the RA and healthy control cohorts demonstrated a 
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trend towards increased IL-13 from the matured CPG-B primed pDCs, however this was 
not significant and there was no difference between the cohorts (figure 4.12.A). Other 
cytokine (IL-10 and interferon-γ) levels were comparable across both groups for all 
conditions (figure 4.12.A) with no significance noted.  I examined fold-changes in 
cytokine production between the unstimulated and CPG-B stimulated pDCs for both 
cohorts (figure 4.12.B). In the RA patients there was a slight trend for reduced fold-
change production with the primed pDC MLRs, but again this was not significant.  
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Patient cohort Rheumatoid 
Arthritis 
Healthy Controls Difference 
between groups 
(p value) 
Number 5 6 - 
Age, years 
median [range] 
55 
[53-68] 
32 
[29-32] 
0.030 
Male : Female 
ratio 
2:3 1:5 0.480 
Table 4.2 Demographics data for pDC origin used in mixed leukocyte reaction  
Mixed leukocyte reactions (MLRs) were performed using pDCs from healthy donors 
(n=6) and patients with established RA (n=5).  The demographic data for each groups is 
shown. Mann-Whitney U tests.   
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Figure 4.10 Surface marker expression in pDCs following stimulation via TLR9 
PBMCS were cultured overnight with TLR9 ligand CPG-B (ODN 2006) at 5ug/ml. Using 
flow cytometry pDCs were identified as being CD20-, CD19-, CD20-, CD203-, HLA-
DR+, CD123+ and their subsequent expression of ICOSL, PDL1 and HLA-DR quantified 
(median florescence intensity, MFI). A: Fold change in pDC ICOSL expression 
(unstimulated vs CPG-B stimulated) for healthy controls, early RA and established RA 
patients. B: Fold change in pDC PDL1 expression (unstimulated vs CPG-B stimulated) 
for healthy controls, early RA and established RA patients. C: Fold change in pDC HLA-
DR expression (unstimulated vs CPG-B stimulated) for healthy controls, early RA and 
established RA patients. Mean and SEM depicted. Kruskal-Wallis tests used. *p<0.05, 
** p<0.01  
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Figure 4.11 Proliferation and induction of CD4+FOXP3+CD25+ T-cells following 
MLR with pDCs from RA patients and healthy controls 
MLRs were performed using and pDCs from healthy controls (n=4) or established RA 
patients (n=4) and CFSE labelled naive allogenic CD4+ T cells. PDCs were either matured 
(overnight stimulation with TLR9 CPG-B) or immature (overnight in culture media only). 
A: CD4+ T cell proliferation (%) between the cohorts was calculated by CFSE dilution. 
B: Percentage of CD3+CD4+ T cells that were FOXP3+CD25+ compared between the 
cohorts. Mann-Whitney U test and paired t-tests used. Mean values with SEM are shown. 
*p<0.05 
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Figure 4.12 Cytokine secretion into supernatant of pDC: T-cell MLR using pDCs 
from RA patients and healthy controls 
pDCs (+/- TLR9 ligand CPG B maturation) from healthy controls (n=6, HC) and RA 
patients (n=5) underwent a MLR with naive allogenic CD4+ T cells. A: MLR cytokine 
production (interferon-γ, IL-13 and IL-10) was quantified from the culture supernatant 
and compared between cohorts. Mean values with SEM are depicted. B: Fold changes in 
cytokine production was examined between the cohorts. Box and whisker plots depicted 
which display median, quartile and range. Mann-Whitney U tests 
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4.4 Discussion 
In this chapter I examined pDCs in the peripheral blood of early DMARD/glucocorticoid 
naive RA patients.  PDCs were significantly reduced in early RA compared with healthy 
controls, but despite their type 1 interferon-producing potential their frequency/phenotype 
did not associate with the IGS. However CCR7 expression was increased in seropositive 
early RA patients; it inversely associated with pDC frequency but positively associated 
with anti-CCP titres. In a longitudinal early RA cohort there was a significant fall in pDC 
expression of activation markers, apart from CCR7 and pDC frequency remained static. 
Finally compared with healthy controls, pDCs from established RA had reduced ICOSL 
but increased PDL1 upregulation in response to maturing stimuli. However in a MLR 
there was no difference in their effect on allogenic naive CD4+ T cells.  
This was the first time that pDCs have been examined in early RA. Comparisons were 
made between healthy controls, established RA patients as well as ACPA+ arthralgia 
patients. These latter cohort were chosen for comparison as a “pre-RA” state, to explore 
whether any findings in early RA pre-dated the onset of inflammatory arthritis in a 
susceptible cohort (25). SLE was chosen as a positive disease model as pDCs are known 
to be important in SLE pathogenesis (314, 315). I observed a reduced frequency of 
peripheral blood pDCs, in early RA patients and SLE patients when compared with 
healthy controls. There was a similar identified for ACPA+ arthralgia and established RA 
patients which did not meet significance, although this may have been due to a question 
of power (figure 4.2). PDCs are known to be reduced in established RA, particularly in 
those with active disease (54, 87, 316, 317), so it is interesting to see a similar finding in 
early RA, potentially suggesting an involvement of pDCs in early RA pathogenesis. One 
suggestion for reduced pDCs in established RA is increased TNF-α levels inhibiting the 
differentiation of pDC progenitors (318). However I did not see any association between 
circulating TNF-α levels and pDC frequency in early RA. Others conversely report 
increased generation of pre-pDC in bone marrow of rheumatoid arthritis compared with 
OA patients (319). These data may therefore suggest normal pDC development but 
abnormal migration patterns. When dividing the early RA cohort by serostatus there was 
reduced pDC frequency in seropositive patients compared with seronegative patients and 
this was associated with increased CCR7 expression in the seropositive cohort (figures 
4.4-4.5). In keeping with this I detected an inverse association between CCR7 expression 
and pDC frequency (figures 4.5-4.6). CCR7 is a chemokine receptor expressed on pDCs 
upon activation and it causes pDC migration towards its ligand CCL19/CCL21. This 
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CCR7-CCL19/CCL21 interaction is the main determinant of pDC migration and 
CCL19/CCL21 is normally found in lymph nodes or within the lymphatic system (320, 
321). A number of groups have shown that pDCs are not normally found in the synovial 
compartment but migrate there from the peripheral circulation in inflammatory settings, 
such as RA, where they are relatively increased in number (85-88, 322). In keeping with 
this observation, CCL19/CCL21 is also significantly increased in the synovial fluid of 
RA patients compared with non-inflammatory OA controls (323) and established RA 
patients have increased pDC CCR7 expression when compared with healthy controls 
(317).  I subsequently hypothesise that, in early RA, the pDC population is developing 
normally but migrating to the RA synovial compartment, at least in part by way of CCR7-
CCL19/21 interactions. Supporting this theory was my subsequent observation that pDC 
CCR7 expression over the course of a year remained stable which was in keeping with a 
static frequency in the peripheral blood (figures 4.8-4.9).  
The effect of serostatus on pDC frequency was corroborated by the significant positive 
association between anti-CCP titres and pDC CCR7 expression (figure 4.7). B cells 
produce anti-CCP antibodies and as more is understood about pDC biology their 
interactions with B cells are particularly intriguing; pDCs can influence B cell function 
by either cell-cell contact, such as via CD70-CD27 interactions (324, 325) or by the 
production of inflammatory cytokines, such as interferon-α or IL-6, which causes the 
generation of immunoglobulin secreting plasma cells (142). In RA pDCs have been 
shown to cluster with B-cells within the inflamed synovium and there is a positive 
association between the number of pDCs in the joint and circulating anti-CCP antibodies. 
Indeed RA patients who are seropositive had higher numbers of pDCs in their synovial 
fluid than those that are seronegative (88). There is evidence of raised type 1 interferon 
signalling in the RA joint (85, 89) and exposure to interferon-α can further promote the 
activation and proliferation of autoreactive B cells by stimulating BAFF/BLyS release 
(299). Indeed sustained interferon-α production from pDCs was sufficient to induce RA 
patients’ B cells to produce autoantibodies in vivo (316). B cells, via a cross-talk 
mechanism, can also promote further production of type 1 interferons by pDCs and 
thereby cement pathological signalling pathways (326). Thus pDCs migrating to the joint 
space under the influence of CCR7 could modulate B cell function and autoantibody 
production. As to why this effect may occur intra-articularly comes from the increasing 
appreciation that in RA the synovial tissue can act as a secondary lymphoid organ. For 
example, ectopic lymphoid tissue forms germinal centres within the synovium in 
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approximately 25% of RA patients. Although there is debate as to their ultimate function, 
their number is increased in anti-CCP+ patients and they have been proposed as a site of 
autoantibody generation (105, 327). Pertinently cellular interactions from other cells 
within the synovial compartment can impact on the longevity of autoreactive B cell anti-
CCP responses generated in these centres (328). I therefore hypothesise a model where 
in early RA pDCs express high levels CCR7 resulting in migration towards 
CCL19/CCL21 present in the inflamed RA synovial compartment. Once in the joint the 
pDCs cluster with B cells within ectopic germinal centres and, through both cell-cell 
contact and the production of inflammatory cytokines, promote the development of anti-
CCP antibodies.  
I did not examine additional chemotaxis/migration pathways (only CCR7) however 
CCL10 is more highly expressed in RA synovial fluid compared with crystal 
arthropathies, and pDCs have been shown to migrate to CCL10 (89, 321, 329). It is 
therefore possible that other signalling mechanisms are implicated in pDC migration in 
early RA but given my findings, these may be more important in seronegative disease. 
CCR7 is normally increased upon pDC activation by TLR ligation and this process would 
classically also cause release of type 1 interferons (320). Furthermore pDCs exposed to 
type 1 interferons in vitro have increased migratory potential towards CCL19 (330).  
Therefore, with an increased IGS one could expect increased trafficking of pDCs out of 
the peripheral circulation. It was therefore counter intuitive that there was no association 
between the IGS and pDC frequency or phenotype (figure 4.3). Some suggest that pDCs 
are mainly interferon-α-producing in their immature state, and upon maturation develop 
antigen-presenting capacity and reduced interferon-α production (43). This would in part 
explain the lack of association between pDCs and the IGS however another explanation 
for these anomalies could be the site of exposure to the type 1 interferons. The serum of 
my early RA patients had undetectable interferon-α levels (Chapter 3) and this is similar 
to what has been demonstrated in established RA (187). The exposure to type 1 
interferons could instead be occurring in lymphoid tissue during peripheral blood 
circulation. Thus the IGS would not accurately represent the contemporaneous pDC 
exposure to, or production of, type 1 interferons and would, in part, explain the disconnect 
between the IGS and pDC number or phenotype.  
Following exposure to activating stimuli DCs undergo a process of “maturation”, 
exemplified by the up regulation of MHC, costimulatory molecules (CD80/86) and 
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activation markers (CD40). DCs present either self or foreign antigen, in a MHC complex 
to T cells. How these cells respond to that antigen depends on what additional signals are 
provided by the DC; if it is immature the T cell is skewed towards anergy and preservation 
of tolerance, however if the DC is mature the T cells are skewed towards a cytotoxic 
response against that presented peptide/protein. Thus presentation of self-antigen in the 
context of an inappropriately matured DC could lead to the breach of tolerance towards 
self and the development of autoimmunity (30, 81, 331). The main purpose of pDCs is 
frequently reported to relate to type 1 interferon production which ultimately has 
pleiotropic effects on other immune cells (43). However pDCs also have antigen 
presentation abilities and are involved in the homeostasis of effector and regulatory CD4+ 
T cells (332). Given the DC’s role in the balance between autoimmunity and tolerance I 
was interested in pDC phenotype in early RA and ACPA+ arthralgia. These early disease 
states are theoretically closer to that breach of tolerance and thus more likely to identify 
any abnormal DC function. I found that pDC baseline (pre-treatment) expression of HLA-
DR (MHC class II), CD86 and CD40 was not increased in early RA compared with 
healthy controls, however there was a significant and sustained reduction in all of these 
surface markers’ expression over 12 months following the initiation of disease modifying 
therapies (figure 4.9). This observation is in line with published data where established 
RA patients (on immunomodulatory therapy) had reduced pDC CD80 and CD83 
expression compared with healthy controls (317) and pDC maturation markers were 
reduced following infliximab treatment (333). This is intriguing as this early 
comparatively activated phenotype may have generated inappropriate responses towards 
self-antigen or have contributed to early disease activity (331). Indeed intra-articular 
transfer of activated pDC and mDCs were able to propagate an inflammatory arthritis 
phenotype in mice (270) and pDCs from RA synovial fluid activated T cells and triggered 
the production of inflammatory cytokines (85).  
Despite this, the relative role of pDCs in RA initiating or propagating an inflammatory 
phenotype remains unclear. Indeed some evidence suggests pDCs may actually promote 
tolerance; depletion of pDCs in a RA model resulted in breach of tolerance with 
development of autoantibodies (90) and RA patients with low disease activity had pDCs 
which were able to skew naive T cells towards a regulatory T cell phenotype (54). This 
suggests a beneficial role of pDCs in modulating RA activity and the tolerising potential 
of pDCs is being increasingly appreciated. For example they have recently been shown 
to be important in controlling autoreactivity to RNA-binding nuclear antigens by the 
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production of antigen-specific Tregs (334) and the cancer field comprehensively 
demonstrates that pDC expression of ICOSL primes CD4+ T-cells to differentiate into IL-
10-producing Tregs (56-59). ICOSL can be upregulated following TLR simulation (335) 
and this effect was reproduced in my data (figure 4.10).  However pDCs from established 
RA patients did not upregulate ICOSL to the same degree as healthy controls (figure 
4.10). Reduced expression/upregulation of ICOSL in pDCs has been reported in other 
human diseases. For example in asthma pDCs from patients with persistent disease had a 
significantly lower expression of ICOSL compared with cured patients (336) and in SLE 
pDCs had lower ICOSL mRNA expression in active SLE and an increased expression in 
inactive disease (261). Although some evidence on Treg frequency is contradictory this 
defect is in keeping with some in vivo observations where RA patients have fewer 
functional Tregs (75, 96-99). However this was the first time, to my knowledge, that a 
defect in ICOSL has been reported in RA. What is intriguing though is that while ICOSL 
upregulation in established RA was greatly reduced, programmed cell death 1 ligand 
(PDL1) expression was dramatically increased (figure 4.10). PDL1 is also known to 
promote a tolerogenic phenotype by regulating lymphocyte activation and promoting 
Treg development and function (337, 338). The net function of pDCs, in view of these 
differentially expressed markers, is therefore still unclear. 
Given these gaps in the understanding of pDCs in RA I wished to further examine their 
functional capacity to skew T cell development by performing mixed leukocyte reactions 
(MLRs) with RA pDCs and allogenic naive T cells. By examining the MLR T cell 
phenotype and cytokine production I was able to examine the effects of the differential 
PDL1/ICOSL expression. Interferon-γ and IL-13 were chosen as typical Th1 and Th2 
cytokines respectively and IL-10 due to its association with Tregs.  As expected there was 
a trend towards increased T cell proliferation in the matured DCs and this was significant 
for the RA cohort (figure 4.11). Examining the phenotype of these cells CD25 and FOXP3 
expression was quantified. Although both CD25 and FOXP3 can go up on cell activation, 
they have also been reported to be part of a tolerogenic or regulatory (Treg) phenotype, 
although notably this is normally CD25hi expression, not only CD25+ which I report here 
(75). Nonetheless there was no real change in the expression of CD4+CD25+FOXP3+ T 
cells in the RA pDC MLR when compared with healthy controls (figure 4.11). 
Concerning cytokine production, there was a trend in both healthy controls and RA 
patients to increased IL-13 production in the mature pDC MLRs, but this was non-
significant and there were no similar changes noted for interferon-γ or IL-10. In fact 
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cytokine production was pretty comparable across all groups. Following pDC maturation 
there was a slight (non-significant) trend towards reduced fold-change induction of all 
cytokines in the RA cohort (figure 4.12), although given the similar absolute cytokine 
values this is unlikely to be relevant. Thus despite the differences in ICOSL there was no 
real difference in functional capabilities. One explanation for these findings is, given the 
importance of Tregs and tolerance to self, there may be a potential functional redundancy 
in pathways involved in their generation. For example IDO is also important in pDC 
derived Treg generation (47) although some argue the effects were partially dependent on 
PDL1 expression (339). Nonetheless mature pDCs from RA patients promoted 
differentiation of naive T cells into IL-10-secreting Tregs via IDO activity (54). Thus 
IDO/PDL1 may be compensating for any defect in ICOSL. Notably this assay used 
healthy donor T-cells which would remove any intrinsic abnormalities in the functional 
immunoregulatory abilities of RA derived Tregs; such as their relative resistance to IDO 
activation (96, 99). Thus whether the comparable effect noted between healthy and RA 
pDCs would effect would occur in vivo is unclear. It is conceivable that my observed 
reduced ICOSL upregulation in RA pDCs may therefore have pathogenic importance 
when occurring with concurrent RA T cell defects, i.e. IDO resistance.  
A consideration when interpreting this data is that these functional studies were done with 
established RA patients and in this work I demonstrate a fall in activation and co-
stimulatory marker expression over a year (figure 4.9) These markers are important in the 
interaction with T cells and therefore the phenotype induced by pDCs early on in disease 
may be different to that seen here and examined elsewhere (54). Another consideration is 
that the ages of the healthy controls and established RA patients were not matched. PDCs 
from older people have reduced TLR-7 and TLR-9-induced interferon-α production and 
have poorer T cell stimulatory capacities (340-342). Additionally a transcriptional 
analysis of PBMCs suggested ICOSL-ICOS activity was affected in older women (343) 
although this was not seen in old mice (344). These differences in ICOSL upregulation 
between the cohorts could therefore potentially be an artefact of immunosenescence. 
Furthermore I used established RA patients who were on disease modifying therapies thus 
any differences could have theoretically been medication derived. Further caveats include 
the fact that peripheral blood circulating dendritic cells and their phenotype may not be 
representative of what is happening in the inflamed RA synovial compartment. It is 
known that dendritic cells from at different anatomical sites have different phenotypes, 
derivative origins, cycling kinetics and are exposed to varying antigen loads (345). Indeed 
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when comparing the phenotype of dendritic cells between RA synovium and lymph 
nodes, there were differences in DC maturation and chemokine production (104). 
Therefore care should be taken when extrapolating these findings to synovial pathology. 
Finally I presented the percentage of pDCs in the lymphocyte population and older 
patients become lymphopenic as part of immunosenescence (346, 347). So while their 
absolute number of DCs may fall, their relative proportion amongst lymphocytes could 
remain stable.  I could have therefore missed any potential absolute changes in DC 
numbers over the year, as well as falsely interpreted the data.  
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4.5 Conclusions 
To my knowledge this is the first time that pDCs have been examined in early drug-naive 
RA. I show a decrease in pDCs in the peripheral circulation and hypothesise that they are 
migrating to the inflamed joint via increased CCR7 expression and subsequent intra-
articular CCL19/21 interactions. Once in the joint they have the potential to potentiate the 
function of anti-CCP producing B cells - thus explaining the observed associations with 
serostatus. Anti-CCP antibodies themselves can cause bony erosions due to osteoclast 
activation (348), so understanding mechanisms potentiating their production is of 
therapeutic relevance. 
Established RA pDCs do not appear to cause an activated T cell phenotype, but this could 
be due to therapy-induced modifications. Indeed I show the maturation phenotype of 
pDCs significantly falls 12 months after starting DMARD therapy. While conventional 
or myeloid DCs have been proposed to play a pathological role in early RA, potentially 
in the breach of tolerance (349-351), is not clear from my data if pDCs are also 
contributing to this phenomena.  
There is emerging evidence that the early and aggressive treatment of RA has greater 
long-term beneficial outcomes (11, 352, 353), and therefore having a greater 
understanding of the pathological processes that are prevalent in early disease has future 
therapeutic merit. Additional work is however needed to elucidate these the potential 
contribution of pDCs to these pathological pathways. 
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4.6 Future work 
The number of RA patients in my cohort could be increased. This would consolidate the 
findings regarding differences between seropositive and seronegative patients in relation 
to CCR7 expression as well as the effect of CCR7 expression on the percentage of 
circulating pDCs. I also would examine other markers involved in pDC migration and 
thus examine if CCR7 was exclusively responsible in early RA. I have only looked at DC 
percentage but number would also be beneficial. To accurately compare between groups 
however I would need to know the lymphocyte count from the healthy controls, which 
would be challenging.   
Unfortunately due to patient sample limitations and time pressures we were not able to 
perform the MLRs on pDCs from early RA patients. The pDC-T cell MLRs would 
therefore ideally be repeated using peripheral blood and synovial pDCs from early RA 
patients and suitably age matched healthy controls. When analysing MLR T cells staining 
for CD25, CD39, CD152 (CTLA-4) as well as FoxP3 would allow me to more confidently 
state if the phenotype was tolerogenic or activated.  
To address the recurrent caveat/issue about blood versus synovium I could examine pDCs 
within the synovial compartment and examine for correlations with peripheral blood 
parameters of interest, for example pDC CCR7 and autoantibody titres. The observation 
linking pDCs and anti-CCP status is intriguing and MLRs could be performed with pDCs 
and B cells from the synovial compartment of early RA patients. Cell numbers are likely 
to be challenging so immunohistochemistry on synovial biopsies could also be performed. 
In particular I would examine surface markers linked to activation status and those known 
to be important in the interaction of pDCs and B cells, such as CD70 (324). 
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5.1 Introduction 
Gene expression profiling or transcriptomics is at the forefront of many advances in 
understanding the pathophysiology of multiple conditions. Applying these techniques to 
RA has been crucial in helping to delineate disease-associated pathways (354). However 
the pathological processes in early RA are distinct from established disease. This has been 
shown at both a clinical and a transcriptomics level where different signalling pathways 
are activated in early RA compared with established RA (5-8). Steroids and treatments 
used to treat RA have profound effects on the transcriptome and thus potentially mask the 
contribution of certain cellular pathways in treated disease (23, 355). To overcome these 
confounding effects the transcriptome of certain cell subsets, such as CD4+ T cells (9), 
have been examined in early drug naïve RA. However the transcriptome of peripheral 
blood pDCs has not been analysed in early drug naïve RA. Indeed pDCs have only 
recently had their transcriptome examined in the context of autoimmunity, namely 
primary Sjogrens syndrome (pSS) (236), and have never been examined in established 
RA.  
The role of pDCs in RA has been contradictory with ongoing debate if their net function 
is actually inflammatory or tolerogenic (54, 85, 89, 90). I therefore decided to focus on 
pDCs for in-depth transcriptional analysis comparing early RA patients with healthy 
controls. All immune cell types have the potential to produce type 1 interferons but given 
their prolific production of type 1 interferons pDCs have been the logical cell subset 
presumed to promote the generation of the IGS detected in autoimmunity (43). Indeed in 
SLE there have been therapies developed that target pDCs and their production of type 1 
interferons (157). However it is not clear in RA if pDCs are the main source of type 1 
interferons and generate the IGS. I therefore wished to compare type 1 interferon 
production across the 6 major peripheral blood cell subsets in the context of the IGS. 
Type 1 interferons have pleiotropic effects on multiple immune cell subsets (145, 155, 
260) and my findings in Chapter 3 demonstrated associations between the IGS and RF. 
Additionally in ACPA+ arthralgia a RA prediction model based on B cell phenotype was 
improved upon including the IGS (356). I decided therefore to examine the transcriptional 
profile of B cells IGS+ and IGS- patients thereby exploring any correlations between the 
IGS and B cell gene expression profiles.  
This work would further dissect the role of pDCs in RA as well as the role of the IGS on 
B cell function. 
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5.2 Aims 
The aims of this chapter are to address the following questions: 
1. Is there a difference in the transcription profile of circulating pDCs between 
early RA and healthy controls? 
2. Does the interferon gene signature associate with the transcription profile of 
pDC and B cells? 
3. Which immune cell subset is responsible for producing type 1 interferons in 
both early RA patients and the healthy controls? 
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5.3 Results 
5.3.1 Demographics  
Patient and healthy control demographics for use in the subsequent transcriptomics 
analysis are shown in table 5.1. In brief, there were 8 early RA patients recruited, all 
double seropositive for RF and anti-CCP antibodies, 4 of whom had a positive IGS and 
the other 4 had a negative IGS. An additional 4 healthy controls were also recruited. There 
was no significant difference between the age or sex of any of the groups. Furthermore 
there was no significant difference in the IGS+ or IGS- cohorts with regard to DAS-28, 
ESR, CRP, anti-CCP or RF titres.  As expected however there was a significant difference 
between the IGS score between the groups.  
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Table 5.1 Demographics table of cohort used for cell sorted NanoString analysis 
Flow cytometry cell sorting was performed on 8 early RA patients (eRA) and 4 heathy 
controls (HC). The early RA patients were further split into 4 IGS+ and 4 IGS- patients. 
The respective demographics for each are shown.* One-way ANOVA was used to 
compare age, male: female ratio and median IGS score between the IGS+, IGS- and 
healthy control groups.  ± Mann-Whitney U tests were used to compare clinical and 
disease activity parameters between the IGS+ and IGS- early RA cohorts.  
 
 Early RA 
 
 
HC 
Difference 
between IGA+, 
IGS- eRA & 
HC cohorts  
P value* 
Difference 
between 
IGA+ & IGS- 
eRA cohorts  
P value± 
 IGS +  IGS - All 
Number in 
cohort 
4 4 8 4 - - 
Age (years) 
Median 
[range] 
56 
[49-64] 
54.5 
[53-60] 
55 
[49-64] 
53 
[48-62] 
0.905 0.771 
Male: Female 
ratio 
3:1 3:1 3:1 1:1 0.750 0.847 
Median IGS 
Score 
0.001156 0.000203 0.00071 0.000198 0.0003 0.028 
RF titre 
(IU/ml) 
[Median and 
range] 
263.5 
[122-650] 
384 
[20-501] 
339.5 
[20-650] 
- - 1 
Anti-CCP 
titre (U) 
Median 
[range] 
684.5 
[457-7156] 
999 
 [14-13745] 
684.5 
[14-13745] 
- - 0.886 
DAS-28 
Median 
[range] 
3.4 
[2.63-4.28] 
4.38 
[1.63-6.18] 
3.71 
[1.63-6.18] 
- - 0.689 
CRP mg/L 
Median 
[range] 
6 
[4-11] 
7.5 
[4-56] 
7 
[4-56] 
- - 0.661 
ESR mm/hr 
Median 
[range] 
17 
[2-33] 
26 
[7-56] 
22.5 
[2-56] 
- - 0.384 
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5.3.2 Technical validation  
To address the aims of this chapter I flow cytometry cell sorted 6 immune cell subsets 
(pDCs, mDCs, B cells, CD8+ T cells, CD4+ T cells and CD14+ monocytes). To validate 
that the cells sorted fitted the conventional morphology of those subsets, cytospins were 
performed for each sorted subset (figure 5.1). 
A principal components analysis was performed on the gene expression data from the 6 
immune cell subsets (figure 5.2). As expected there was clear separate clustering of each 
of the immune cell subsets separated by cell type. The CD8+ and CD4+ T cell populations 
clustered tightly as expected. The mDCs in turn were closer to the monocytes, which were 
also of myeloid lineage. Interestingly however the pDCs were more closely affiliated with 
B cells than the mDCs.  
Notably however there was no obvious difference between the healthy control and early 
RA groups for each of the subsets. 
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Figure 5.1 Cytospin images of flow cytometry sorted immune cell subsets.  
Cytospins to validate morphology and appearance were performed on the 6 cell sorted 
subsets which included pDCs (CD19-, CD20-, CD3-, CD14-, HLA-DR+, CD1c-, CD11c-, 
CD123+), mDCs  (CD19-, CD20-, CD3-, CD14-, HLA-DR+, CD1c+, CD11c+), B cells 
(CD19+, CD20+, CD14-, CD3-), CD8+ T cells (CD19-, CD20-, CD14-, CD3+, CD4-, CD8+, 
CD56-), CD4+ T cells (CD19-, CD20-, CD14-, CD3+, CD4+, CD8-, CD56-) and CD14+ 
monocytes (CD3-, CD14+). Cytospins were stained with May-Grunwald and Giemsa to 
visualise the cell nucleus.  
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Figure 5.2 Principal components analysis (PCA) of immune cell subset gene 
expression  
Immune cell subsets have clear, distinct gene expression profiles. Six separate immune 
cell subsets (pDCs, mDCs, B cells, CD4+ T cells, CD8+ T cells and CD14+ monocytes) 
were isolated from the peripheral blood of healthy controls and RA patients using flow 
cytometry sorting. RNA was extracted and run on a custom NanoString system. A 
principal components analysis was run using R Core team (2016).  CD4 = CD4+ T cell; 
CD8 = CD8+ T cell; CD14 = CD14+ monocytes; pDC = plasmacytoid dendritic cell; mDC 
= myeloid dendritic cell; HC = healthy controls; RA = early rheumatoid arthritis patients.  
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5.3.3 Differential gene expression in pDCs by disease and IGS status 
A comparison of pDC gene expression between the RA patients and healthy controls was 
performed. Differences were termed significant when the false discovery rate (FDR) 
adjusted p-value was <0.05 and the fold change was >1.5. I first compared expression 
between all RA patients and healthy controls. There were 12 differentially expressed 
genes; in the early RA cohort 3 of these genes were upregulated and the remaining 
downregulated. The top upregulated genes included PRDM1 and IRF4 (figure 5.3) 
Ingenuity® Pathway Analysis (IPA®) uses the differentially expressed gene lists to 
identify trends in expression that could indicate differential activation or involvement of 
known biological networks or pathways. These associations are based on the current 
published literature in the IPA® database. A p value and an activation Z score (or Z score) 
is generated; the Z score infers activation state, i.e. either an increase (positive score) or 
decrease (negative score) in associated biological functions. Scores > ±2 are deemed a 
strong association. For some biological networks there is insufficient published evidence 
to identify if gene involvement would denote activation or inhibition; for these scenarios 
no Z score is given.  
IPA® was performed on the significantly differentially expressed pDCs genes observed 
when comparing early RA patients and healthy controls. This strongly (Z score ≥ 2) 
suggested early RA patients had increased pDC proliferation. It also suggested early RA 
pDCs had reduced apoptosis although this effect was less pronounced. Early RA pDCs 
also had differential gene expression linked to rheumatoid arthritis, inflammation of the 
joint and systemic autoimmune disease, although it was not clear if these pathways were 
activated or inhibited (no Z score) (figure 5.4). 
When comparing IGS+ and IGS- early RA patients, pDCs had only 2 genes that were 
significantly differentially expressed, one was significantly upregulated (IFI44L), an IRG 
and the other downregulated (S100A8) (figure 5.5.A). However when looking at IGS+ 
early RA versus healthy controls, there were 25 significantly differentially expressed 
genes; 5 of these were upregulated and the remaining 20 down regulated. The top 
differentially expressed gene was IFI44L and other top genes included those seen earlier; 
PRDM1 and IRF4 (figure 5.5.B).  
An IPA® was performed on the significantly differentially expressed pDCs genes 
observed when comparing IGS+ early RA and healthy controls. This strongly (Z score ≥ 
± 2) suggested IGS+ patients had increased pDC proliferation and reduced lymphocyte 
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migration. It also suggested IGS+ pDCs had reduced adhesion and an increase in 
pathways concerning inflammation of an organ or anatomical region. These latter 
associations however were not as strong (figure 5.6) 
In light of potential upstream triggers for type 1 interferons a specific examination of the 
gene list was performed for any abnormally expressed pDC genes relating to nucleic acid 
sensing pathways, such as TLR7, TLR9, MDA-5, RIG1, MAVS, cGAS, STING etc.  
The only significantly differentially expressed gene was TMEM173 which encodes 
STING, a cytosolic DNA senor. However counterintuitively expression was reduced in 
the IGS+ early RA cohorts when compared with healthy controls.  
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Figure 5.3 Statistically differentially expressed genes in pDCs between early RA 
patients and healthy controls.  
PDCs were flow cytometry sorted from early RA patients (n=8) and age- and sex-matched 
healthy controls (n=4). PDC RNA was isolated and the transcriptome analysed using 
NanoString nCounter technology. Genes achieved differential expression significance 
when adjusted p-value <0.05 (FDR corrected) and fold change >1.5. Volcano plots show 
the Log2Fold change against the –Log10 Adjusted p value where genes plotted in red are 
termed significant. 2 are additional red dots shown as positively upregulated, these are 
spiked controls and an artefact of the technology.  
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Figure 5.4 IPA® analysis for differentially expressed genes in pDCs between early 
RA patients and healthy controls 
IPA® analysis was performed on pDC differentially expressed genes in early RA patients 
(n=8) and healthy controls (n=4). Red denotes genes upregulated in early RA and blue 
downregulated. Pathways identified in the early RA cohort include: increased 
proliferation (p=1 x 10-9, Z-score 2.17), reduced apoptosis (p=1.02 x 10-7, Z-score -0.97), 
rheumatoid arthritis (p=2.49 x 10-6), inflammation of the joint (p=4.24 x 10-8) and 
systemic autoimmune disease (p=9.18 x 10-8) in RA. For the latter 3 pathways no Z score 
was available.  
 The colour of the shape in the centre of the network describes, based on the Z score, 
the predicted state of the associated biological network; orange, activated; blue, 
inactive; white, not known. The shape itself denotes the strength of that association; 
complete circle, high Z score; cross, low Z score. The colour of the gene denotes its 
relative expression; red, upregulated; blue, downregulated. The colour of the line from 
the gene to the centre denotes what is the predicted effect a gene has on a downstream 
pathway; orange, activation; blue, inhibition; yellow, variable or inconsistent findings; 
grey, not known. Finally the line’s terminal shape indicates the ultimate effects of that 
downstream pathway on the central biological function, i.e. arrow, activation; flat line, 
inhibition. 
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Figure 5.5 Statistically differentially expressed genes in pDCs by IGS and disease 
PDCs were flow cytometry sorted from early RA patients (IGS+ n=4, IGS- n=4) and age- 
and sex-matched healthy controls (n=4). PDC RNA was isolated and the transcriptome 
analysed using NanoString nCounter technology. Genes achieved differential expression 
significance when adjusted p-value <0.05 (false discovery rate corrected) and fold change 
>1.5. Volcano plots show the Log2Fold change against the –Log10 Adjusted p value where 
genes plotted in red are termed significant. A Comparison between IGS+ and IGS- early 
RA pDCs B comparison between IGS+ early RA and healthy control pDCs. Note 4 
additional genes are demonstrated in the volcano plot as being differentially expressed, 
these are control spikes and an artefact of the technology. 
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Figure 5.6 IPA® analysis for differentially expressed genes in pDCs between IGS+ 
early RA patients and healthy controls  
IPA® analysis was performed on pDC differentially expressed genes in IGS+ early RA 
patients (n=4) and healthy controls (n=4). Red denotes genes upregulated in IGS+ early 
RA and blue downregulated. Pathways identified in the early RA cohort include: 
increased proliferation (p=6.32 x 10-10, Z-score 2.17), reduced lymphocyte migration 
(p=1.10 x 10-8, Z-score -2.03), and adhesion (p=2.06 x 10-7, Z score -1.97). Pathways 
concerning inflammation of an organ (p=3.07 x 10-15, Z-score 1.05) or anatomical region 
(p=7.38 x 10-17, Z-score 1.57) were also activated. 
 
 Interpretation and explanation of this figure format is described in Figure 5.4 
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5.3.4 B cell differential gene expression by IGS  
In light of the effect of type 1 interferons on B cells (145) and the reported link between 
the IGS and RF titres (Chapter 3), comparisons were made between IGS+ and IGS- early 
RA patient B cells. There were 14 statistically significant differentially expressed genes 
(figure 5.7); 13 of these genes were upregulated in the IGS+ cohort and only 1 was 
downregulated (PECAM-1). Surprisingly none of these upregulated genes were clearly 
defined as IRGs. However they did associate with a more activated phenotype, e.g. CD80, 
which was the most differentially expressed in early RA with a fold change of 3.8. Other 
markers relating to specific B cell phenotypes were also identified, e.g. CD27. The highest 
significance (p=0.00008), and indeed one of the largest fold changes (3.226), was seen in 
TNFRSF13B which encodes the B cell receptor TACI. These examples all relate to 
proteins expressed on the cell surface, but differentially expressed genes also encoded 
transcription factors, such as XBP1.  
IPA® was performed on these gene lists. Analysis showed that in IGS+ early RA there 
was a strong suggestion of increased B cell proliferation and evidence of pathways related 
to viral infection. There was also evidence of increased B-cell activation and reduced B 
cell number, although the association for these latter pathways was not as robust.  There 
was once more involvement of pathways linked to RA pathology which included systemic 
autoimmunity and joint inflammation, although for these there was no Z score so the net 
involvement to biological function was unknown (figure 5.8).   
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Figure 5.7 Statistically differentially expressed genes in early RA B cells by IGS  
B cells were flow cytometry sorted from early RA patients (IGS+ n=4, IGS- n=4). 
Cellular RNA was isolated and the transcriptome analysed using NanoString nCounter 
technology. Genes achieved differential expression significance when adjusted p-value 
<0.05 (false discovery rate corrected) and fold change >1.5. Volcano plots show the 
Log2Fold change against the –Log10 Adjusted p value where genes plotted in red are 
termed significant.  
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Figure 5.8 IPA® analysis for differentially expressed genes in B cells between IGS+ 
and IGS- early RA patients  
IPA® analysis was performed on B cell differentially expressed genes in IGS+ early RA 
patients (n=4) and IGS- early RA patients (n=4). Red denotes genes upregulated in early 
RA and blue downregulated. Pathways identified in the IGS+ cohort include: B cell 
proliferation (p=1.43 x 10-6, Z-score 2.29), B-cell activation (p=2.93 x 10-6, Z-score 1.57), 
viral infection pathways (p=1.76 x 10-4, Z-score 2.39), Reduced B cell number (p=3.22 x 
10-7, Z-score 1.08) and systemic autoimmunity (p=7.89 x 10-9) and joint inflammation 
(p=3.29 x 10-9). There was no Z score available for the latter 2 pathways.  
 Interpretation and explanation of this figure format is described in Figure 5.4 
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5.3.5 Cellular origin of interferon-α in early RA 
To question what cell subset was responsible for promoting the IGS the source of type 1 
interferons was examined across the immune cell subsets in IGS+ early RA patients. 
Immune cell subsets included pDCs, mDCs, B cells, CD4+ T cells, CD8+ T cells and 
CD14+ monocytes. Of note these comparisons were not multiple test corrected however 
there was large variability between the donors which would have compromised 
significance; this was likely due to our small sample size.  
There was no significant difference in IFNA2 or IFNA1/13 expression between any of the 
immune cell subsets in IGS+ early RA (figure 5.9).  
To examine if the IGS was instead caused by uniform increase in immune cell expression 
of type 1 interferons I compared IFNA2 or IFNA1/13 expression between healthy 
controls, IGS+ and IGS- early RA patients for each immune cell subset (figure 5.10). 
CD4+ T cells from IGS- patients had significantly increased IFNA1/13 expression 
compared to CD4+ T cells from IGS+ patients and healthy controls. However no other 
significant differences between healthy controls, IGS+ and IGS- cohorts in the remaining 
immune cell subsets for either IFNA2 or IFNA1/13 expression. Thus there was no global 
increase in IFNA1 or IFNA1/13 in immune cell subsets from IGS+ patients.  
I further examined IFNA2 and IFNA1/13 expression in the context of the IGS (continuous 
score) using linear regression for all the early RA patients. For both IFNA subtypes and 
for each cell subset there was no significant association between the IGS and cellular 
expression of type 1 interferons (data not shown). 
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Figure 5.9 Immune cell IFNA2 and IFNA1/13 expression in IGS+ early RA patients   
A IFNA2 and B IFNA1/13 mRNA expression as determined by NanoString nCounter 
technologies was compared across flow cytometry cell sorted immune cell subsets in 
IGS+ early RA patients (n=4).  Data are presented as box and whisker plots, in which the 
horizontal line represent the median value, the box represents upper and lower quartiles 
and the error bars represent range. Kruskal-Wallis test. 
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Figure 5.10 Immune cell IFNA2 and IFNA1/13 expression by disease cohort and 
IGS+ status 
A IFNA2 and B IFNA1/13 mRNA expression, as determined by NanoString nCounter 
technologies, was compared across flow cytometry cell sorted immune cell subsets in 
healthy controls (HC, n=4), IGS+ early RA patients (IGS+ eRA, n=4) and IGS- early RA 
patients (IGS- eRA, n=4). Data are presented as box and whisker plots, in which the 
horizontal line represent the median value, the box represents upper and lower quartiles 
and the error bars represent range. Kruskal-Wallis tests. *p<0.05 
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5.4 Discussion 
In this chapter I examined the transcriptome of pDCs in early RA and compared them 
with healthy controls. There were marked differences in gene expression between early 
RA patients and healthy controls, as well as between IGS+ and IGS- early RA patients. 
PDCs in early RA appeared to have pathways related to increased proliferation but 
reduced apoptosis in early RA. However there was no indication if pDCs in early RA had 
a more activated or tolerogenic transcript. Unexpectedly pDCs did not appear to be the 
main interferon-α producing subset in IGS+ early RA. Compared with IGS- early RA, B 
cells from IGS+ patients demonstrated increased expression of genes related to B cell 
activation, proliferation and plasma cell generation. This further confirms the relevance 
of B cell and IGS interactions in RA.  
This is the first time the transcriptome of pDCs from patients with RA has been examined. 
IPA® pathway analysis demonstrated increased proliferation and reduced apoptosis in 
early RA pDCs (figure 5.4). This is counter intuitive with respect to the known reduced 
pDC number in the peripheral circulation of RA patients (54, 87, 316) (and as shown in 
Chapter 4). However there is a suggestion that the pDCs migrate to the synovial 
compartment in RA and numbers are increased in the inflamed joint (85-88). Therefore 
increased pDCs proliferation in the peripheral circulation could be relevant in synovial 
disease. Conversely when examining IGS+ early RA patients versus healthy controls 
there was increased proliferation but pathways relating to cell migration and adhesion 
were reduced. These latter features are contrary to what was shown in Chapter 4 where 
there was no effect of the IGS on pDC frequency or phenotype.  
However one of the main caveats interpreting this IPA® data is the low patient sample 
size and the subsequent relatively small gene list generated. This is particularly relevant 
in the context of RA being a highly heterogeneous disease where large numbers are often 
required to overcome patient variability. In addition, much of the literature in the IPA® 
database used to generate these associations relates to other cell subsets, the functions of 
which may not be reproduced in pDCs. For example, one of the highest upregulated genes 
between early RA (all) or IGS+ early RA patients and healthy controls was PRDM1, 
which encodes B lymphocyte-induced maturation protein-1 (Blimp-1). Blimp-1 has been 
most extensively investigated in B cells where it promotes proliferation and 
differentiation of autoantibody secreting plasma cells (357). However the effect of Blimp-
1 expression in DCs is less clear. It may promote DC survival as Blimp-1 knockout mice 
have reduced mDC and pDC numbers (358). Another mouse study demonstrated Blimp-
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1 negatively regulating mDCs during homeostatic development and promoting DC 
maturation (359). However, Blimp-1 may have an anti-inflammatory role; Blimp-1 
knockout in mDCs caused adult female mice to spontaneously develop a lupus-like 
phenotype (360) and in human monocyte derived DCs Blimp-1 inversely correlated with 
HLA-DR expression (361). As demonstrated these are mainly murine mDC studies, and 
little work has been done looking at the role of Blimp-1 in human pDCs. Thus the effect 
of increased Blimp-1 expression in early RA pDCs remains unknown and IPA® 
conclusions involving its expression are weakened. As highlighted by this example, the 
paucity of literature relating to pDC-specific function of the differentially expressed 
genes identified makes interpretation of the global function of pDCs in early RA 
challenging. Nonetheless IFI44L was most differentially expressed gene in pDCs from 
IGS+ early RA patients when compared with both healthy controls and IGS- patients 
(figure 5.5). The function of IFI44L is unknown, however it is an IRG and makes up part 
of an anti-viral response (362). Although it was not similarly increased in the IGS+ B 
cells (figure 5.7), its increased expression in pDCs supports increased type 1 interferon 
exposure the IGS+ cohort. IRF4 was also increased in the same pattern as PRDM1. IRF4 
is an interferon regulatory factor which modifies interferon production following viral 
exposure (363). However its expression in pDCs has recently been shown to skew T cells 
towards a Th2 response (364).  In early RA there is evidence of an increased Th2 response 
with increased IL-13 in synovial fluid which falls with time (95). It is possible that early 
RA pDCs may be involved in this process. Examining the effect of the IGS on pDCs from 
early RA patients there were only 2 differentially expressed genes; increased IFI44L as 
discussed above, and significantly reduced S100A8. The protein product of S100A8 forms 
a heterodimer with S100A9 and this complex has many pro-inflammatory properties, 
such as TLR4 ligation. Increased circulating levels of S100A8/A9 have been detected in 
autoimmunity (365-367) and its secretion by pDCs is increased in SLE upon immune 
complex stimulation (366). The reduced S100A8 expression therefore conversely 
suggests a less inflammatory phenotype in the IGS+ cohort.  Overall, when analysing 
these data, it ultimately remains unclear what is the overall effect of the IGS on pDC 
function as well as whether the net role of pDCs in early RA is pro- or anti-inflammatory. 
The only conclusion that can be drawn is their role in RA is likely to be complex and 
potentially alters during the different stages of disease. 
Pathogen-derived nucleic acids are the main trigger for the production of type 1 
interferons (260). A recent study showed increased expression of RNA sensors TLR7, 
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RIG1 and MDA-5 in pDCs from pSS IGS+ patients and the authors suggested increased 
detection and exposure to either host- or pathogen-derived RNA as a potential promotor 
of the IGS (236). However there was no evidence of RNA sensing pathways being 
involved in the IGS+ early RA cohorts. Autoantibodies to self-RNA, such as anti-
ribonucleoprotein (anti-RNP) which include anti-Ro/SSA and anti-La/SSB are 
commonly found in pSS (368). Their related immune complexes can directly bind to 
FcγIIa expressed on pDCs, resulting in internalization and interaction with intracellular 
RNA sensing pathways causing interferon-α production (369). These RNP autoantibodies 
are not as widespread in RA, indeed antibodies against nuclear antigens are relatively rare 
in RA. This might explain the differences in pDC expression of RNA sensing pathways 
between IGS+ patients from pSS and early RA. When examining DNA sensing pathways 
between the cohorts I unexpectedly detected reduced STING expression, a cytosolic DNA 
sensor, in both the IGS+ cohort and the early RA cohort. Ligation of STING causes an 
increase in its expression as well as interferon-α release and this pathway is known to be 
functional in human pDCs (370). Type 1 interferons further promote increase in STING 
expression, thereby promoting a positive feedback mechanism (120). This suggests that 
pDC sensing of cytosolic DNA is not promoting the IGS in early RA and is in fact not 
following the normal physiological response to type 1 interferon exposure.  
However pDC pathways involved in the triggering of type 1 interferons could be 
irrelevant as it is unknown what cell type is primarily responsible for generating the IGS 
in early RA. Due to the known function of pDCs and their potential to produce vast 
quantities of type 1 interferons (43) it was expected that their IFNA2 and IFNA1/13 
transcripts would be increased in IGS+ RA and associate with the IGS. However this was 
not the case and my data did not show which cellular subset was ultimately responsible 
for the IGS (figures 5.9-5.10).  In SLE there is a suggestion that pDCs become “fatigued” 
and actually produce less interferon following repeated stimulation (279). Furthermore 
herpes virus induced interferon-α production is decreased in SLE PBMCs and SLE 
patients exhibit a reduced number of BDCA-2 expressing pDCs; this is the pDC subset 
generally thought to be primary interferon producing (371). All cells have the ability to 
produce type 1 interferons and it is presumed that with time other cell subsets take over 
as primary producers of type 1interferons in SLE. Potentially similar processes may have 
occurred in early RA although none of the other immune cell subsets examined had an 
association between expression of IFNA2 and IFNA1/13 transcripts and the IGS (figure 
5.10). Another potential explanation for these observations is the anatomical origin of the 
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cells examined. There is no detectable interferon-α in the serum of RA patients (187) 
(which I have also shown – see Chapter 3) and activated pDCs migrate to lymph nodes 
and areas of local inflammation such as the synovial lining in RA (320). PDCs also 
require a critical density to initiate a spontaneous type I interferon response which can 
have an autocrine effect on promoting further interferon-α production (372); this is more 
likely to occur in lymphoid tissue/synovium. Therefore in RA those pDCs, and indeed 
any other cell, involved in type 1 interferon production may not be in the peripheral 
circulation but rather clustered in either lymphoid or inflammatory tissue. They would 
therefore not have been identified in this peripheral blood analysis. One final 
consideration is the complexity of type 1 interferons themselves. There are 12 different 
functional interferon-α products (159) as well as ligand-specific differences in induced 
expression; TLR9 agonists elicited expression of all type I interferon subtypes by pDCs 
but TLR7 agonists did not (308). I only examined 2 members of the interferon-α family 
(IFNA2 and IFNA1/13). It may be that other pDC derived IFNA subsets are implicated in 
generating the IGS or triggered from pathological stimuli in RA.  
The effect of the IGS on the B cell transcriptome in early RA was also examined. IPA® 
databases examining the differential gene expression profile in B cells were more robustly 
supported by B cell relevant literature. Identified pathways included increased 
proliferation and activation in the IGS+ early RA cohort (figure 5.8). This is consistent 
with what is known about the effect of type 1 interferons on B cell function (145). 
However type 1 interferons can also promote B cell differentiation into antibody-
producing plasma cells; low concentrations of interferon-α cause B cell differentiation 
into plasmablasts, whereas higher concentrations cause plasma cell maturation (373). 
Furthermore IFNAR-/- knockout mouse models of SLE (with resultant loss of interferon-
α signalling) do not develop autoantibodies (374). In keeping with this I saw increased 
XBP1, a crucial transcription factor in the development of plasma cells, in the IGS+ B 
cells (375, 376). There was also a higher expression of CD27 in the IGS+ cohort. CD27 
belongs to the tumor necrosis factor receptor family and is involved in the late-stage 
differentiation of B cells into plasma cells, and plasma cells have markedly increased 
CD27 expression (CD27++). In addition increased expression of CD27 on memory B cells 
suggests ongoing differentiation into plasma cells with the acquired ability to secrete high 
levels of immunoglobulin (377). CD80 was also increased in the IGS+ cohort. Increased 
surface expression of CD80 is associated with B cell activation but also been implicated 
in plasma cell generation (378). This has further pathogenic relevance as RA B cells have 
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increased CD80 expression and often also co-express receptor activator of nuclear factor 
kappa-B ligand 9 (RANK-L). This has implications for bone reabsorption and erosion 
development (379). TNFSRF13B encodes the B cell transmembrane activator and CAML 
interactor (TACI) and its expression was also increased in the IGS+ cohort. TACI is 
expressed on the cell surface and is a receptor for APRIL and BAFF/BLyS. It is highly 
expressed on marginal zone and CD27+ memory B cells and upregulated following TLR9 
or BCR ligation (184, 380). Its function has been contradictory and enigmatic when 
comparing across mouse and human studies but nonetheless activation of TACI results in 
B-cell differentiation into plasmablasts, isotype switch and antibody production which 
includes T cell-independent antibody production (298, 380, 381). TACI also promotes 
sustained Blimp-1 expression on B cells, which limits the clonal expansion of B-cells and 
facilitates the maintenance and/or generation of long-lived antibody secreting cells (382); 
a phenotype potentially involved in autoantibody production (383). Increased TACI also 
has further relevance to RA as increased BAFF/BLyS-TACI signalling may cause the 
escape of autoreactive B cells and promote breach of tolerance (73). Indeed in very early 
RA patients there was increased TACI mRNA expression in the PBMCs when compared 
with healthy controls (384) and TACI polymorphisms in immunodeficiency syndromes 
predispose to autoimmune disease and lymphoid hyperplasia (385) (all figure 5.7). 
Although not directly related to plasma cell generation, the significant downregulation of 
PECAM1 (CD31) in the IGS+ early cohort (figure 5.7) may also promote autoantibody 
generation. PECAM-1 is a member of the immunoglobulin superfamily and is expressed 
on the surface of all of hematopoietic cells, including B cells (386). B cell PECAM-1-/- 
knockout mice have an activated and hyper responsive B-cell phenotype and develop 
autoantibodies. These mice also have increased numbers of B1 cells, which are the subset 
in mice associated with IgM production, and have increased serum IgM but normal levels 
of other immunoglobulin isotypes (387). This downregulation of PECAM-1 is likely to 
have implications in vivo as rheumatoid factor (RF) is an IgM autoantibody. Together 
these findings all suggest that B cells in the IGS+ cohort are primed towards plasma cell 
differentiation and potentially the production of IgM subclass of antibody.  
These demonstrated in vivo effects of IGS on B cells gene expression in early RA further 
corroborates findings relating to the effect of the IGS in longstanding disease. There has 
been a large body of evidence in established RA demonstrating that a positive IGS 
negatively influences the clinical response to rituximab, an anti-CD20 B cell depleting 
therapy (23, 186, 200-202). Furthermore early reconstitution of CD27+ B cells (388), as 
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well as high numbers of CD27++ plasmablasts pre–treatment (389) is a negative predictor 
of remission following rituximab. I showed increased CD27 expression in the IGS+ group 
(figure 5.7) and promotion of this B cell phenotype may be one of the mechanisms 
whereby the IGS negatively influences rituximab response.  
Finally the connection between the IGS and an abnormally activated or proliferative 
phenotype is interesting in the context of the increased risk of B cell malignancies in RA 
patients (390-394). CD58 was increased in the IGS+ B cells and B cell expression of this 
marker is normally only seen in malignant plasma cells, such multiple myeloma, where 
is it widely expressed (395). There was also upregulation of CD99, IL10RA and IGBT1 
(CD29) in the IGS+ cohort which are also overexpressed in B cell malignancies, such as 
diffuse large B cell lymphoma (DLBCL) (396-398). Finally TCF7 was also increased in 
the IGS+ cohort and this mediates Wnt signaling by associating with β-catenin in the 
nucleus. In mice Wnt signaling promotes proliferation of bone marrow pro-B cells (399) 
and many tumors, including chronic lymphocytic leukemia, DLBCL and multiple 
myeloma display increased Wnt/β-catenin signaling (400-404). Cumulatively this 
suggests that normal pathways regulating plasma cell differentiation may be deranged in 
IGS+ early RA allowing for inappropriate expansion of a potentially pathological subset.  
A caveat of transcriptomics is that mRNA levels do not always equate to protein levels. 
There is therefore not always a definitive link between the level of gene expression and 
the relative impact on biological functions. Nevertheless, the application of this technique 
is primarily hypothesis generating rather than hypothesis testing and is useful to identify 
trends for further investigation. I used NanoString to analyse the transcriptome in the cell 
subsets. This uses a dual probe hybridization to directly enumerate specific RNA 
molecules with no RNA amplification thus minimising variability and error. Reactions 
are also performed with excess transcript-specific probes to avoid hybridization and 
measurements are made on a digital instead of analog scale to reduce fluorescence scale 
biases (256). NanoString data is highly robust to different normalisation methods 
providing reassurance that computational processing biases are not skewing my findings 
(405) and results have been shown to be comparable to other more established methods, 
such as microarray (406). Nonetheless there are some considerations; I ran each cell 
subset on an individual chip meaning that, despite data normalisation, batch effect 
differences could occur. This would compromise any comparisons made between cell 
subsets and this caveat must be fully considered. 
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5.5 Conclusions 
The transcriptome of peripheral blood pDCs was examined in early RA and compared 
with healthy controls. This is the first time the transcriptome of pDCs has been examined 
in RA but the net inflammatory vs tolerogenic function remains unclear. Unexpectedly 
there was no clear evidence that pDCs were the primary interferon-α subset in the 
peripheral blood. It may be that the other interferon-α subtypes are more important for 
RA, the subtypes I measured have relatively less relevance, or that the interferon-α 
producing pDCs have migrated out of the peripheral blood (320). Nonetheless given the 
distinct nature of early RA compared with established RA there may be a separate 
function of pDCs in early disease compared with established disease. As treatment 
increasingly is targeted towards early RA (11-20) the relevance of these findings is 
increased.  
B cells were compared between IGS+ and IGS- early RA patients and IGS+ patients 
demonstrated increased gene expression related to pathways involving proliferation, 
activation, plasma cell differentiation and autoantibody production. I also detected 
upregulation of genes previously identified in B cell malignancies. This suggests that B 
cells may be pathologically relevant in IGS+ early RA and thus are a potential cellular 
target of any type 1 interferon targeting therapies.  My findings also support the 
recognised observation in established RA where a positive IGS negatively impacts on 
outcomes related to B cell depletion (186, 200) and propose mechanistic pathways that 
may be potentially involved.  
This work is preliminary and performed on a very small number of individuals. 
Nevertheless it findings raises some intriguing questions about the role of the IGS in early 
RA and suggests that B cells are pathologically affected. Consolidation of this work may 
therefore propose novel therapeutics options and applications of interferon targeting 
therapies in early RA.  
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5.6 Future work 
This was a small pilot study and clearly further work and increased sample numbers is 
required to improve the power and validate these preliminary findings. 
One of goals of this work was to identify what cell subset was most responsible for the 
production of type 1 interferons in IGS+ early RA patients. There was no clear answer 
but this may have been due to the fact I only measured two subtypes of interferon-α due 
to a limitation of space on the NanoString technologies customised panel. Ideally this 
work would be repeated with an additional customised panel to quantify all interferon-α 
subtype transcript expression in the above cell subsets but also additional immune cells 
if possible, such as NK cells or neutrophils. 
There was clear upregulation of some known IRGs in the IGS+ pDC population (e.g. 
IFI44L). However this was not clearly seen in the B cells. I would therefore like to analyse 
in depth if the differentially expressed genes in the B cells were mainly IRGs. 
Furthermore I would like to identify which cell subset had the highest increased 
expression of IRGs which may suggest increased sensitivity or increased proximity to 
interferon-α production. This could potentially involve the use of modelling techniques 
or online platforms/databases that allow in depth analysis of interferon related genes, such 
as the Interferome V2.0 (http://interferome.its.monash.edu.au/interferome/) (407). 
Nonetheless the B cell transcriptome of IGS+ early RA patients compared with IGS- 
patients was distinctly different. A crucial first step would be to validate the expression 
of these genes using qRT-PCR. I would also need to increase patient numbers, especially 
including patients that were seronegative. If these genes were increased using qRT-PCR 
a next step would be to study the protein level either using flow cytometry or western 
blot.  
I used NanoString in this series of experiments mainly due to the low numbers of dendritic 
cells available and thus low RNA yield, and as a way of avoiding subsequent 
amplification bias normally required when using other transcriptomic technology. 
However if I were to focus primarily on B cells there would be adequate material for next 
generation sequencing technology, such as RNA sequencing. This would widen the 
number of genes examined and provide a more comprehensive transcriptional 
comparison.  
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B cells cultured with interferon-α could be examined specifically for changes in those 
genes identified on the NanoString as well as examine B cell functional characteristics 
and surface marker expression. This would validate if the gene expression data translated 
into B cell phenotype and if interferon-α alone was responsible. If the proteins/genes 
related to B cell malignancies were confirmed to be upregulated an additional step would 
be to recruit patients with a new diagnosis of a RA related B cell malignancy and measure 
their IGS and B cell phenotype.  
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6.1 Introduction  
There is increasing evidence that prior to the development of autoimmunity there is a 
series of events, both genetic and environmental, that prime and direct the immune system 
towards self-reactivity. One proposed mechanism for the development of autoimmune 
disease is the presence and activation of retrotransposons.  This so called “junk” virus-
derived DNA (retroelements) makes up to 40% of the human genome and, rather than 
being inert as previously thought, some repeat insertions have retained ability to replicate 
within a cell (213, 230). There are distinct types of retroelements: 1) Those that are 
autonomous and are able to encode all the proteins necessary for replication include 
endogenous retroviruses (ERVs) (often detected as long terminal repeats, LTRs) and long 
interspersed elements (LINEs); 2) Those that are non-autonomous include short 
interspersed elements (SINEs), of which Alu is the most common.  These require the 
presence of active LINEs for their mobility and hijack the LINEs replication machinery 
during replication (121).  These separate classes of retroelement are depicted in figure 6.1  
 
Figure 6.1 Types of retroelements in a mammalian genome 
Autonomous retroelements include endogenous retroviruses (ERV) - detected as long 
terminal repeats (LTRs) - as well as long interspersed nuclear element 1 (LINE-1). These 
both encode all proteins necessary for their replication and retrotransposition. Non-
autonomous retroelements, such as short interspersed nuclear element 1 (SINE), the most 
common of which is Alu, are much smaller and hijack LINE-1 machinery to facilitate 
their mobility. Gag, group-specific antigen; Prt, protease; Pol polymerase; Env, envelope; 
UTR untranslated region.  Figure adapted from Volkman et al., 2014 (121).  
 
Retroelements are viral nucleic acids and during their replication process they are exposed 
to intracellular nucleic acid sensors which triggers downstream anti-viral pathways. 
Activation of these pathways frequently culminates in type 1 interferon production and 
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contributes to generalised immune activation. This would subsequently promote more 
effective presentation of antigen, potentially of self-components, and thus promote 
autoimmunity (121, 230). This clearly has relevance to diseases where there is a marked 
IGS, primarily SLE but also RA. Indeed LINE-1 elements are increased in the synovium 
of RA patients (237, 239). Furthermore human ERVs are increased in RA synovium and 
evidence of their transcriptional activity, as well as viral protein products, are detected in 
the peripheral circulation of RA patients (217, 238).  
Given this background I was interested in the role of retroelements in generating the IGS. 
I hypothesised that increased activity in RA would be driving the IGS. Retroelement 
activity is determined by transcript expression and can be detected by standard mRNA 
detection methodology, such as qRT-PCR. I wished to look at whole blood but also pDC 
specific retroelement activity. This was due to the pDC potential of prolific type 1 
interferon production (43) as well as a recent study linking the IGS in pSS to increased 
pDC expression of cytosolic RNA/DNA sensing pathways, and thus potential 
retroelement activity (236).   
Retroelements, however, may contribute to the development of autoimmunity 
independently of interferon-α induction. Some ERVs retain their ability to produce viral 
protein and molecular mimicry may occur where foreign retrovirus derived proteins share 
sequence homology with peptides on self-reactive cells, and therefore cross-activate these 
cells (216, 217). ERV proteins may also present as antigens and this could be a 
mechanism for the development of antibodies in autoimmunity. Interestingly both 
serological and molecular assays showed significant increases in the endogenous 
retrovirus HERV-K (HML-2) gag activity in RA patients compared to disease controls 
and these gag and env proteins shared the same peptide sequences with rheumatoid factor 
epitopes on IgG1Fc (242, 243). Antibody responses can also develop to cell components 
associated with retroelement nucleic acid and their virus like proteins; anti-Ro60 binds a 
RNA motif derived from Alu retroelements (232). This association could direct immune 
responses against these self-derived elements resulting in the production of 
autoantibodies. 
In light of these associations between retroelements and B cell function I wished to 
specifically examine any associations between whole blood retroelement activity and 
autoantibodies in my early RA cohort. Additionally I wished to focus on the relative 
expression of retroelements in B cells between early RA patients and healthy controls.  
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6.2 Aims 
In this chapter I wished to address the following questions: 
1) Are whole blood LINE-1 elements increased in early RA patients compared with 
healthy controls? 
2) Do whole blood LINE-1 elements associate with the IGS or any other circulating 
cytokines? 
3) Do whole blood LINE-1 elements associate with autoantibodies? 
4) Does pDC and B cell retroelement activity vary between early RA patients and 
healthy controls?  
5) Do pDC retroelements associate with actively transcribed genes?  
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6.3 Results 
6.3.1 Whole blood LINE-1 analysis: c-DNA and qRT-PCR optimisation 
cDNA was initially generated using the standard protocol described for IGS analysis. 
Whole blood LINE-1 activity was measured by transcription of the LINE-1 5 prime 
untranslated region (L1-5’UTR) and the LINE-1 open reading frame 2 (L1-ORF2). 
However, during qRT-PCR it became clear that, although the water control amplified L1 
5’UTR at >35CT, the –RT control (i.e. no superscript II) amplified at a similar level to the 
test samples (figure 6.3.A). As the retroelement sequences present in cDNA and genomic 
DNA (gDNA) are identical the primers used in qRT-PCR can amplify both cDNA and 
gDNA. The amplification in the –RT control suggested that there was gDNA 
contamination. Furthermore there was no successful amplification of L1-ORF2 (figure 
6.3.B).  
I therefore optimised a new method of cDNA generation (“super-clean” method) which 
had additional DNAse steps within the protocol to remove any gDNA. In addition, I used 
gene specific primers to amplify up only the desired mRNA (L1-5’UTR, L1-ORF2 and 
housekeeper gene TBP). To test the efficiency of the gDNA removal by the additional 
DNase step a PCR was performed which used primers spanning an exon-intron-exon 
region in the HPBI gene. If pure cDNA is present only one short band will be formed 
(152bp) as the intron regions are not present in cDNA, whereas if there is gDNA 
contamination an additional large band (570bp) will be seen due to the added presence of 
intron regions. This is demonstrated in the following schematic (figure 6.2) 
 
Figure 6.2 Schematic of different PCR product size generated from either genomic 
DNA or c-DNA when using intro-exon spanning HBPI primers  
PCR primers spanning the intron-exon regions of the HBPI gene will generate different 
sized product depending on if genomic DNA (gDNA) or c-DNA is used; gDNA will 
retain an intron section and have a larger band size (570bp) compared with intron-less c-
DNA (152bp). 
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A gel electrophoresis was subsequently performed to validate the purity of my c-DNA 
(figure 6.4). I could see for the c-DNA samples generated using the “super-clean” method 
there was only one band detected at 152bp (indicating c-DNA generated from intron-free 
mRNA), whereas for our positive gDNA control there was an additional band seen at 
570bp indicating presence of intronic gDNA.  
As there was no amplification of L1-ORF2 using a TaqMan assay I tested a SYBR green 
assay, which does not rely on probes in addition to primers to amplify the message. I 
found using this method there was successful amplification of both L1-5’UTR and L1-
ORF2 (figure 6.5). Furthermore, in for both transcripts, the –RT control amplified at the 
level of the water control confirming the success of the gDNA elimination step. 
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Figure 6.3 Genomic DNA contamination is observed in c-DNA generated from whole 
blood RNA 
RNA was extracted from whole blood using the Tempus RNA system. C-DNA generated 
using SuperScript II reverse transcriptase following the manufacture’s protocol. A 
TaqMan assay was used to quantify LINE-1 5’UTR (A) and ORF2 (B). A representative 
of the amplification plots is shown for each assay. 
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Figure 6.4 An optimised “superclean” cDNA generation method eliminates gDNA 
contamination 
RNA was extracted from whole blood using the Tempus RNA system. cDNA was 
generated using the “superclean” optimised method and a PCR performed using primers 
which spanned an intron and exon region the HBPI gene. cDNA with contaminating 
genomic DNA (gDNA) will produce 2 bands (570bp and 152bp), while uncontaminated 
cDNA will have just one product (152bp).  I show here representative findings using 
patient samples (EA2929, EA2944, EA3024 and EA2954) as well as a positive DNA 
control.  
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Figure 6.5 Both LINE-1 5’UTR and ORF2 successfully amplify using a SYBR green 
assay  
RNA was extracted from whole blood using the Tempus RNA system. C-DNA generated 
using the “superclean” optimised method. A SYBR green assay was used to quantify 
LINE-1 5’UTR (A) and ORF2 (B). A representative of the successful amplification plots 
is shown for each assay  
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6.3.2 Whole blood LINE-1 analysis: Associations with age or gender 
 
Early RA patients and healthy controls had their peripheral whole blood L1-5’UTR and 
L1-ORF2 expression quantified using the optimised SYBR Green assay.  
The demographics of each group are shown in table 6.1. There was a significant 
difference between the groups regarding age where the early RA cohort were older, but 
there was no difference between the groups regarding gender.  
Correlations were examined between age and the LINE-1 elements for the whole cohort. 
There was no significant association between age and L1-5’UTR or L1-ORF2 expression 
(figure 6.6.A). However due to the age differences between the cohorts the association 
with age was looked at separately for each cohort; again there was no association with 
age detected for either cohort (figure 6.6.B-C).   
I next examined the effect gender may have on LINE-1 expression. Again for the whole 
cohort, there was no effect of gender on L1-5’UTR or L1-ORF2 expression (figure 6.7.A). 
In early RA patients alone there were no significant differences in expression of either 
L1-5’UTR or L1-ORF2 (figure 6.7.B). However, healthy controls demonstrated a 
significant increase in L1-ORF2 expression in females compared to males, although there 
was no significant difference in L1-5’UTR expression (figure 6.7.C).  
In light of these findings when comparing whole blood LINE-1 activity between the 
cohorts age and sex corrections were performed, whereas within a cohort it was not.  
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Table 6.1 Demographic data for early RA and healthy control cohorts 
Early RA patients (n=56) and healthy controls (n=23) had their peripheral whole blood 
LINE-1 retrotransposon activity measured (as described in figure 6.5). The demographics 
for the two cohorts are shown here. Differences between groups were calculated using a 
Mann Whitney U test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Early RA 
 
Healthy control 
Difference between 
groups (p value) 
Number 56 23 - 
Age (years) 
Median [range] 
58  
[30-87] 
39 
[23-62] 
<0.0001 
Male: Female ratio 1:1.8 1:1 0.325 
% seropositive 
(either anti-CCP+ or 
RF+) 
 
77% 
 
- 
 
 
- 
DAS-28 
Median [range] 
4.3  
[1.3-7.6] 
 
- 
 
- 
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Figure 6.6 Age and whole blood LINE-1 expression  
Whole blood LINE-1 expression was analysed (as described in figure 6.5) in early RA 
patients (n=56) and healthy controls (p=23). Associations with age were examined. A: 
Plots depict linear regression between age and L1-5’UTR and L1-ORF2 expression in 
pooled early RA and healthy controls. B: Plots depict linear regression between age and 
L1-5’UTR and L1-ORF2 expression in early RA patients. C: Plots depict linear 
regression between age and L1-5’UTR and L1-ORF2 expression in healthy controls.  
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Figure 6.7 Gender and whole blood LINE-1 expression 
Whole blood LINE-1 expression was analysed (as described in figure 6.5) in early RA 
(n=56) and healthy controls (n=23). Associations with gender were examined. A: Pooled 
early RA and healthy control LINE-1 activity divided by gender. B: Early RA patient 
LINE-1 activity divided by gender C: Healthy control LINE-1 activity divided by gender. 
Horizontal lines depict median values. Mann-Whitney U tests. *p<0.05 
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6.3.3 Whole blood LINE-1 analysis: LINE-1 activity, the IGS and clinical phenotype 
LINE-1 activity was compared between the early RA and healthy control cohorts 
(corrected for age and gender). No significant difference between the cohorts for either 
L1-5’UTR or L1-ORF2 expression was detected (figure 6.8). 
Published literature suggests a possible link between autoantibody production and 
retroviral activity. I therefore sought to see if such a link existed in my RA cohort. The 
early RA cohort was split into seropositive (either anti-CCP+ or RF+) or seronegative 
(double anti-CCP- and RF-) but there was no difference in either L1-5’UTR or L1-ORF2 
expression between these sub-groups (figure 6.9.A). I next looked at patients that were 
either RF+ or RF- and again there was no significant difference between the groups for 
either L1-5’UTR or L1-ORF2 expression (figure 6.9.B). This was the same when splitting 
the cohort into anti-CCP+ or anti-CCP- (figure 6.9.C). However when I examined 
absolute anti-CCP titres there was a significant positive association between both L1-
5’UTR and L1-ORF2 expression and anti-CCP titres (figure 6.10.A). This effect however 
was not seen with RF titres (figure 6.10.B). Smoking can cause both an increase in anti-
CCP titres and retroelement activity (408, 409), so smoking history was examined as a 
potential confounding variable. However there was no significant difference in whole 
blood LINE-1 activity between those who had never smoked and those that were actively 
smoking. Furthermore there was also no difference in anti-CCP titres between these 
cohorts either (data not shown).  
In view of the ability of retroelements to trigger interferon-α production the early RA 
cohort was next divided by IGS. I detected significantly increased L1-5’UTR activity in 
the IGS-cohort compared to the IGS+ cohort (figure 5.11.A) and although a similar trend 
was seen in L1-ORF2 expression, it was not significant (figure 5.11.B). I next examined 
the IGS (as a continuous variable) and correlated this with the whole blood LINE-1 
elements but found no significant correlation between the two (data not shown).  
High levels of inflammatory cytokines, including IL-6, can inhibit ERV activity (242). I 
therefore examined circulating cytokines levels and LINE-1 activity in the early RA 
cohort. There was no association between retroelement activity and cytokines (interferon-
γ, IL-6, IL-12 p70, TNF-α, IL-1β, IL-2, IL-13, IL-4 and IL-10) (data not shown). There 
was also no significant association between LINE-1 activity and CRP or ESR (data not 
shown). 
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Figure 6.8 Disease cohorts and whole blood LINE-1 expression  
Whole blood LINE-1 expression was analysed (as described in figure 6.5) early RA 
patients (n=56) and healthy controls (HC, n=23). A. L1-5’UTR expression between 
cohorts B. L1-ORF2 expression between cohorts. Horizontal lines depict median values. 
Univariate generalised linear model (age and sex corrected).  
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Figure 6.9 Early RA autoantibody status and whole blood LINE-1 activity  
Whole blood LINE-1 expression was analysed (as described in figure 6.5) in early RA 
patients (n=56) and compared according to antibody status. A L1-5’UTR and L1-ORF2 
activity between seropositive early RA (either RF+ or anti-CCP+, n=43) and seronegative 
early RA (both RF- and anti-CCP-, n=13). B. L1-5’UTR and L1-ORF2 activity in RF+ 
(n=37) and RF- (n=19) patients C. L1-5’UTR and L1-ORF2 activity in anti-CCP+ (n=43) 
and anti-CCP- patients (n=13). Horizontal lines depict median values. All Mann-Whitney 
U tests.  
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Figure 6.10 Autoantibody titres and whole blood LINE-1 activity  
Whole blood LINE-1 expression was analysed (as described in figure 6.5) in early RA 
patients and compared according to circulating antibody titres. A. Plots depict linear 
regression between early RA patient (n=39) anti-CCP titres and whole blood L1-5’UTR 
and L1-ORF2 expression. B. Plots depict linear regression between early RA patient 
(n=34) RF titres and whole blood L1-5’UTR and L1-ORF2 expression. Linear regression 
for all.  
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Figure 6.11 Whole blood LINE-1 expression and the IGS 
Whole blood LINE-1 expression was analysed (as described in figure 6.5) in early RA 
patients who were divided by their IGS status; IGS + (n=21) and IGS- (n=35). A L1-
5’UTR expression between the IGS+ and IGS- cohort. B L1-ORF2 expression between 
the IGS+ and IGS- cohort. Horizontal lines depict median values. Mann-Whitney U tests. 
*p<0.05 
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6.3.4 Early RA retrotransposon transcriptomics: Technical validation  
I wished to examine retrotransposon expression in individual immune cell subsets rather 
than in whole blood. Rather than looking only at LINE-1 elements (L1-5’UTR and L1-
ORF2) as had been done in whole blood, Alu sequences (AluYa5 and AluYb9) as well 
as an ERV (LTR5) were also examined. Early RA patients and healthy controls had 6 
immune cell subsets cell sorted by flow cytometry; pDCS, mDCs, B cells, CD4+ and 
CD8+ T cells and CD14+ monocytes. The sorting method and cohorts used for this for this 
analysis are the same as described in Chapter 5. In summary, 4 age and sex matched 
healthy controls were compared with 8 early RA patients who were further split into IGS+ 
and IGS-. The full demographics for this cohort are shown in Chapter 5, table 5.1.  
The lack of transcription in NanoString nCounter technology means that the sample is not 
heated to a level that could cause genomic DNA to denature and cause contamination; 
thus avoiding gDNA hybridization to oligonucleotide probes and potential background 
noise. However despite this I wished to optimize gDNA removal from the RNA to prevent 
findings being compromised. 
Healthy control CD14+ monocytes and CD8+ T cells were sorted by flow cytometry and 
split into two equal fractions. RNA was isolated either without or with the incorporation 
of a gDNA spin column to remove any residual contaminating gDNA. To validate that 
gDNA removal step was effective a PCR was performed on the RNA product using 
primers for the HBP1 gene, which would only amplify from a gDNA template, not RNA. 
The subsequent products were run on a gel (figure 6.12). Any contaminating gDNA 
would produce a PCR product at 1011bp. As well as sorted immune cell subsets 
with/without use of the gDNA spin column, positive controls of gDNA as well as a 
standard curve of decreasing amounts of gDNA were used. After use of the gDNA spin 
columns there was <0.05ng of contaminating gDNA in the RNA preparation. Therefore, 
use of a gDNA spin column enables sufficient elimination of gDNA for subsequent 
downstream assays.  
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Figure 6.12 Successful gDNA removal from cell subset RNA to less than 0.05ng 
using gDNA spin columns  
CD14+ monocytes and CD8+ T cells from healthy controls were sorted using flow 
cytometry. The RNA was extracted with or without a genomic DNA (gDNA) eliminator 
spin column. A PCR was then performed with primers designed to only amplify gDNA 
(HBPI gene, band size 1011bp). The PCR products underwent agarose gel (1%) 
electrophoresis along with a reducing titration of gDNA (positive control) and water 
(negative control). This gel is pictured. 
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6.3.5 Early RA retrotransposon transcriptomics:  Retroelement activity in early RA  
Retroelement expression was examined in pDCs and B cells from early RA patients and 
healthy controls. These subsets were chosen in view of the type 1 interferon producing 
potential of pDCs and the potential association between retroelement and autoantibodies 
(B cells). In pDCs there was significant reduction in all the classes of retroelement (SINE, 
LINE-1 and ERV) activity in the early RA cohort compared to healthy controls (figure 
6.13). This pattern was not seen in B cells where there was instead comparable expression 
between the two cohorts for all retroelement subsets (figure 6.14). 
These data demonstrate that in RA retroelement expression may differ from healthy 
controls in only certain immune cell subsets. I therefore questioned if the extent of 
retroelement activity was in fact distinct across multiple immune cell subsets in early RA 
and so compared retroelement expression in pDCs, mDCs, B cells, CD4+ T cells, CD8+ T 
cells and CD14+ monocytes from early RA patients. There were marked differences in all 
immune cell subsets when comparing SINE, LINE-1 and ERV activity (figures 6.15-
6.17). For all retroelements there was reduced expression in pDCs, mDCs and CD14+ 
monocytes but increased expression both T cell subsets and B cells. For Alu and LTR5 
retroelements sequences the median expression in B cells tended to be the highest, but 
this was only significantly so when examining LTR5 expression (figure 6.17.B). When 
the RA patients were grouped by IGS status the same pattern was seen with no additional 
differences between IGS- and IGS+ patients (data not shown). A similar pattern was also 
noted when examining healthy controls in isolation (data not shown). 
I next questioned what could be precipitating the difference in retroelement expression 
between immune cell subsets. Although, retroelement activity can induce type 1 
interferons, there is a suggestion that type 1 interferons inhibit retroelement propagation 
(410).  Sensitivity to type 1 interferons can be measured by IFNAR expression (248), 
therefore expression of IFNAR1 and IFNAR2 was compared across the immune cell 
subsets in healthy controls (figure 6.18). Given the significant difference in the IGS 
between healthy controls and RA patients (table 5.1)  healthy controls were chosen to 
minimise any confounding change in expression that may have occurred following 
exposure to type 1 interferons.  I found IFNAR1 expression was significantly higher in 
pDCs and B cells than T cells and borderline significantly higher than CD14+ monocytes. 
IFNAR2 expression was significantly highest in pDCs. Taken together this suggests that 
pDC may have intrinsically increased sensitivity to type 1 interferons. Finally, as pDCs 
in healthy controls demonstrate the highest level of interferon receptor expression (both 
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IFNAR1 and IFNAR2) I sought to compare expression of both receptor subunits between 
RA patients and healthy controls. IFNAR1 expression in pDCs was significantly reduced 
in early RA but this pattern was not repeated with IFNAR2 expression (figure 6.19).  
Finally in view of the earlier association between anti-CCP titres and whole blood LINE-
1 activity associations between B cell retroelement activity and autoantibody titres were 
examined. However, there were no significant associations seen for any of the 
retroelements, including LINE-1 (data not shown). 
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Figure 6.13 Retroelement expression in pDCs from healthy controls and early RA 
patients 
Retroelement expression (SINE: Alu Ya5, Alu9b9; LINE-1: L1-5’UTR, L1-ORF2; ERV: 
LTR5) was examined using NanoString nCounter technology in flow cytometry sorted 
pDCs from early RA patients (eRA, n=8) and healthy controls (HC, n=4).  Data are 
presented as box and whisker plots, in which the horizontal line represent the median 
value, the box represents upper and lower quartiles and the error bars represent range. 
Mann-Whitney U tests. *p<0.05 
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Figure 6.14 Retrotransposon expression in B cells from healthy controls and early 
RA patients 
Retroelement expression (SINE: Alu Ya5, Alu9b9; LINE-1: L1-5’UTR, L1-ORF2; ERV: 
LTR5) was examined using NanoString nCounter technology in flow cytometry sorted B 
cells from early RA patients (eRA, n=8) and healthy controls (HC, n=4). Data are 
presented as box and whisker plots, in which the horizontal line represent the median 
value, the box represents upper and lower quartiles and the error bars represent 
range.Mann-Whitney U tests.   
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Figure 6.15 Alu expression in different immune cell subsets in early RA 
Early RA patients (n=8) had their peripheral blood immune cells (plasmacytoid dendritic 
cells, pDCs; myeloid dendritic cells, mDCs, B cells, CD4+ T cells, CD4; CD8+ T cells, 
CD8; CD14+ monocytes, CD14) flow cytometry cell sorted and cellular RNA was 
analysed using NanoString nCounter technology for SINE activity:  A: AluYa5 and B: 
AluYb9. Data are presented as box and whisker plots, in which the horizontal line 
represent the median value, the box represents upper and lower quartiles and the error 
bars represent range. Kruskal-Wallis tests.  *p<0.05, ** p<0.01, ***p<0.001. 
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Figure 6.16 LINE-1 expression in different immune cell subsets in early RA 
Early RA patients (n=8) had their peripheral blood immune cells (plasmacytoid dendritic 
cells, pDCs; myeloid dendritic cells, mDCs, B cells, CD4+ T cells, CD4; CD8+ T cells, 
CD8; CD14+ monocytes, CD14) flow cytometry cell sorted and cellular RNA was 
analysed using NanoString nCounter technology for LINE-1 activity: A L1-5’UTR and 
B L1-ORF2. Data are presented as box and whisker plots, in which the horizontal line 
represent the median value, the box represents upper and lower quartiles and the error 
bars represent range. Kruskal-Wallis test.  *p<0.05, ** p<0.01, ***p<0.001. 
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Figure 6.17 LTR5 expression in different immune cell subsets in early RA 
Early RA patients (n=8) had their peripheral blood immune cells (plasmacytoid dendritic 
cells, pDCs; myeloid dendritic cells, mDCs, B cells, CD4+ T cells, CD4; CD8+ T cells, 
CD8; CD14+ monocytes, CD14) flow cytometry cell sorted and cellular RNA was 
analysed using NanoString nCounter technology for ERV LTR5 activity:  A: LTR5 5’end 
and B: LTR5 3’end . Data are presented as box and whisker plots, in which the horizontal 
line represent the median value, the box represents upper and lower quartiles and the error 
bars represent range. Kruskal-Wallis test. *p<0.05, ** p<0.01, ***p<0.001. 
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Figure 6.18 IFNAR1 and IFNAR2 expression in immune cell subsets from healthy 
controls 
Healthy controls (n=4) had their peripheral blood immune cells (plasmacytoid dendritic 
cells, pDCs; myeloid dendritic cells, mDCs, B cells, CD4+ T cells, CD4; CD8+ T cells, 
CD8; CD14+ monocytes, CD14) flow cytometry cell sorted and cellular RNA was 
examined using NanoString nCounter technology for A: IFNAR1 and B: IFNAR2 
expression. Data are presented as box and whisker plots, in which the horizontal line 
represent the median value, the box represents upper and lower quartiles and the error 
bars represent range. Kruskal-Wallis test.  *p<0.05 
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Figure 6.19 IFNAR1 and IFNAR2 expression in early RA pDCs 
Healthy controls (n=4) and early RA patients (n=8) had peripheral blood pDCs flow 
cytometry cell sorted and the respective cellular RNA examined, using NanoString 
nCounter technology, for A: IFNAR1 and B: IFNAR2 expression. Data are presented as 
box and whisker plots, in which the horizontal line represent the median value, the box 
represents upper and lower quartiles and the error bars represent range. Mann-Whitney U 
tests. *p<0.05  
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6.3.6 Early RA retrotransposon Transcriptomics: Retroelement expression and 
signalling pathways  
I had concurrently performed an extensive gene expression analysis on the immune cell 
subsets used for retroelement analysis (See Chapter 5). To compare retroelement activity 
and cellular type 1 interferon production I compared concurrent IFNA2 and IFNA1/13 
expression and retroelement activity in all immune cell subsets. There was no significant 
association between IFNA2 and IFNA13 and any of the retroelements for either pDCs or 
the other immune cell subsets examined (data not shown).  
I next compared the expression of all genes (n=593) analysed in the NanoString nCounter 
with each of the retroelements in all the immune cell populations. This analysis was 
corrected for FDR, i.e. multiple test corrected, with significance when the FDR adjusted 
p value was <0.05. Only 2 significant associations were found. In pDCs there was a highly 
significant positive association between MAVS expression and LTR5 expression (figure 
6.20.A). There was also a positive association between ILF3 and L1-5’UTR expression 
in CD4+ T cells. In view of L1-5’UTR and L1-ORF2 activity being connected I sought to 
see what the association was between ILF3 and L1-ORF2. There was a similar pattern 
seen for ILF3 and L1-ORF2 expression, but upon FDR adjustment the p value was far 
from significant (figure 6.20.B).  
There were no significant associations with any of the other pathways linked to nucleic 
acid or retroelement sensing, retrotransposition or degradation (e.g. Trex1, RNaseH2, 
STING, cGAS, RIG-1, MDA5, SAMHD1, TLR3, TLR7-9) in any of the immune cell 
subsets (data not shown). 
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Figure 6.20 Retroelement activity is screened for any associations with other genes: 
associations noted for pDCs and CD4+ T cells 
In the whole cohort (both healthy controls and early RA, n=12) retroelement expression 
in flow sorted peripheral blood subsets was screened for any associations with other genes 
(n=593) examined during the NanoString nCounter analysis A: pDC LTR5 (5’end) 
expression significantly associates with MAVS expression. B: CD4+ T cell ILF3 
expression significantly associates with L1-5’UTR expression but not L1-ORF2. 
Pearson’s Correlation tests. 
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6.4 Discussion 
I examined for the first time retroelement activity in both peripheral whole blood cells 
and isolated peripheral blood immune cell subsets of early RA patients. There was no 
difference in whole blood LINE-1 activity (mRNA transcription) between early RA 
patients and healthy controls. In addition, there was no association between retroelement 
expression and biochemical markers of disease activity. However, whole blood LINE-1 
activity positively associated with anti-CCP titres in RA patients. Interestingly, this trend 
was not reproduced when examining B cell specific retroelement activity. Unexpectedly 
IGS+ RA patients had reduced whole blood LINE-1 activity compared to IGS- RA 
patients. Furthermore, early RA pDCs had consistently reduced retroelement expression 
when compared with healthy controls, although there was no difference between the IGS+ 
and IGS- cohorts. Early RA retroelement expression varied between immune cell subsets 
with increased expression in T cells and B cells and reduced expression in DCs and 
monocytes.  Finally there was a clear positive association between pDC LTR5 and MAVS 
expression as well as between CD4+ T cell L1-5’UTR and ILF3 expression. There were 
however no other associations between retroelement activity and pathways related to their 
sensing or degradation.  
When examining age and gender in the cohort there was no association between whole 
blood LINE-1 activity and these parameters in the RA cohort, however healthy controls 
females had increased LINE-1 expression (figure 6.6-6.7). There are several potential 
explanations; MECP2 is encoded on the X chromosome and its product binds the LINE-
1 promoter (411); the testis-determining factor gene SRY can also modulate LINE-1 
promoter activity (412) and Piwi proteins, expressed in the ovary, can regulate LINE-1 
activity (413). Why this effect was not seen in the early RA cohort is unclear. 
Hypothetically regulatory mechanisms are potentially deranged in early RA allowing for 
relatively higher expression in men, or reduced expression in women. Retroelement 
activity has been shown to increase with age (414), however effect was not seen in either 
of my cohorts. This could have been due to insufficient power. 
There was comparable whole blood LINE-1 activity in both the early RA and healthy 
control cohorts (figure 6.8). Notably most published literature has focused on increased 
retroelement expression in RA synovium and SLE or pSS disease affected tissue (217, 
231, 237, 239, 240, 415). Given the anatomical origin of RA pathology is predominantly 
synovial, it is possible that peripheral blood was the wrong place to identify pathological 
associations. Nevertheless I did detect a positive association between anti-CCP titres and 
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whole blood LINE-1 activity (figure 6.10). Retroelements may be involved in generation 
of autoantibodies from either associating with self-peptides, molecular mimicry or by 
producing a de novo antigen (216, 217, 232, 416). However another possible explanation 
involves the contribution of smoking to both retroelement activity and anti-CCP 
antibodies. Smoking causes hypomethylation of LINE-1 thereby promoting its 
transcription (408) but I did not detect any significant difference in LINE-1 activity based 
on smoking history. Furthermore I did not see any impact of smoking status and anti-CCP 
antibodies. This was unexpected as their generation has been extensively and robustly 
linked to smoking (417). However this latter effect is predominantly in those who carry 
the shared epitope (409, 417) which I did not examine. Furthermore the association with 
anti-CCP antibodies was identified using large RA population studies, whereas my cohort 
size is relatively small. Therefore although LINE-1 hypomethylation is unlikely to depend 
on the underlying genotype, this experiment was unlikely to pick up similar effects with 
LINE-1 due to comparatively lack of power. Moreover the cohort was divided into 
“currently smoking” and “never smoked” so nuances related to duration or heaviness of 
smoking history would have been missed. It is therefore possible that the association 
between anti-CCP titres and LINE-1 elements is still confounded by smoking but a larger 
study is required to examine this more robustly. 
One of my main questions was if retroelements were driving the IGS in early RA. 
However despite the ability of retroelements to trigger type 1 interferons, there was 
reduced whole blood LINE-1 activity (L1-5’UTR) in IGS+ early RA patients (figure 
6.11). This is counterintuitive, but while retroelements trigger type 1 interferon 
production, type 1 interferons themselves can trigger negative feedback mechanisms 
which inhibit further retrotransposon replication (410). This may explain why IGS+ RA 
patients have a low retroelement expression/activity despite having a high type 1 
interferon response. Interestingly, however when examining the individual immune cell 
subsets there was varied modulation of retroelement activity in pDCs and B cells (figures 
6.13-6.14). In early RA pDCs displayed reduced expression of SINEs, LINE-1 and ERVs 
but this was not seen in B cells. One explanation may be the relative sensitivity of each 
cell subset to type 1 interferon exposure. As mentioned type 1 interferon signalling can 
negatively affect LINE-1 propagation (410), and I show that pDCs have the highest 
expression of both IFNAR1 and IFNAR2 (figure 6.18). IFNAR1 and IFNAR2 expression 
have been proposed as a surrogate marker of interferon-α sensitivity (248). Upon ligation 
IFNAR1 is downregulated (418), and I further show reduced pDC IFNAR1 expression in 
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the early RA cohort as compared to healthy controls (figure 6.19) suggesting increased 
type 1 interferon signalling occurs in early RA. Overall and contrary to expectations, these 
data suggest that in early RA retroelements are negatively regulated by interferon-α 
exposure and pDCs are most sensitive to this effect due to their high sensitivity to type 1 
interferons. Since pDCs are also primary producers of type 1 interferons in a viral setting 
(43), having these cells modulated first would make evolutionally and biological sense.  
As to why I do not detect a corresponding fall in IFNAR2 expression may be explained 
by the variability in affinity of different interferon-α proteins for the interferon receptor 
subunits (419).  
Additional differences were observed when comparing retroelement activity across 
immune cell subsets in early RA. Expression was higher in B cells and T cells and lower 
in DCs and monocytes (figures 6.15-figure 6.17). Although sensitivity to type 1 
interferons may contribute to this effect, there is known to be variation in retroelement 
expression in healthy tissues depending on the spectrum of retroelements supported by 
individual cell types (420). One reason for this differential cell expression is methylation. 
This is an important factor controlling retroelement activity where hypomethylation 
causes increased transcription and activity (421, 422). Human peripheral blood subsets 
have different DNA methylation status (423). Furthermore when compared with T cells, 
B cell LINE-1 methylation was increased in both established RA and healthy control 
patients (424). Methylation is an epigenetic modification and these phenomena have been 
of increasing interest with regards to RA disease susceptibility and phenotype (425). 
Indeed chronic exposure to inflammatory cytokines, such as IL-1, can inhibit DNA 
methyltransferase enzymes, which maintain methylation, potentially resulting in 
hypomethylation (426). It is interesting therefore that the cell subsets (T cells and B cells) 
with the most retroelement activity, and potential hypomethylation, are known to be 
highly pathogenic in RA. 
I also saw significantly increased LTR5 (an ERV) expression in B cells when compared 
with all other subsets. In mouse models T cell independent antigen immunisation causes 
upregulation of ERVs in antigen-specific B cells (427). Potentially a similar phenomenon 
may have occurred in early RA causing increased LTR5 in B cells. LTR5 expression 
denotes HERV-K (HML-2) activity (428) and some of the most compelling evidence of 
the involvement of retroelements in RA has been regarding this ERV; a viral load is 
detected in plasma samples from RA patients, with higher levels observed for those with 
active disease (241). However in relation to specific B cell function and autoantibodies 
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there was also upregulation of HERV-K mRNA, anti-HERV-K antibodies and gag 
protein in RA patient PBMCs compared with healthy controls. Furthermore of these viral 
proteins shared the same peptide sequences with rheumatoid factor epitopes on IgG1Fc 
(216, 241, 242). My small cohort size would undoubtedly have limited the subsequent 
power of any downstream associations between B cell retroelement activity and 
autoantibody titres. Nonetheless the B cell specific increase of an ERV known to be 
associated with antibodies in RA is intriguing.  
Retroelements use both RNA and DNA intermediates for retrotransposition, and these 
can both trigger the production of type 1 interferons. The most widely known nucleic acid 
sensors are the TLRs. However, other cytosolic sensors are important, such as RIG-1 and 
MDA-5, which recognise short dsRNA and long dsRNA, respectively. DNA 
intermediates within the cytosol are recognised by STING. In addition, the enzyme cGAS 
binds immunostimulatory DNA and catalyses cyclic GMP-AMP formation, which also 
binds to STING. From work in the HIV field and Aciardi-Goutieres syndrome (AGS), 
additional sensing pathways in the detection and degradation of retrotransposition 
intermediates have been identified and include Trex1, RNaseH2 and SAMHD1 (121). 
These, along with the above cytosolic sensing pathways, were examined here for any 
association with retroelement activity in the immune cell subsets. Trex1 was of particular 
interest as RA synovial fibroblasts have been shown to have a deficiency in Trex1, which 
permits a longer half-life of gene products encoded by active LINE-1 retrotransposons 
(240). However, there was no association with Trex1 nor any difference in its expression 
between the cohorts. Nonetheless there was a highly significant association between 
LTR5 activity and MAVS expression in pDCs (figure 6.20.A). MAVS is a mitochondrial 
transmembrane protein which serves as an adaptor between RIG-1/MDA5 and 
downstream signalling pathways. MAVS activates TBK1 and transcription factors IRF3 
and IRF7 which ultimately leads to the release of type 1 interferons. This strongly 
suggests that ERV LTR5 activity in pDCs results in activation of pathways downstream 
of RIG-1 and/or MDA-5 thereby promoting type 1 interferon production. In SLE patients 
increased MAVS aggregation in PBMCs was associated with type 1 interferons and 
autoantibody production (429). In another study, although MAVS activity was not 
assessed, pDCs from IGS+ pSS patients, when compared with IGS- patients, had 
upregulated RIG-1 and MDA-5 expression. This profile is believed to in part explain the 
increased pathogenic type 1 interferon production detected in these patients (236). As 
mentioned LTR5 or HERV-K mRNA levels are increased in the circulation of established 
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RA patients and have been linked with disease activity (216, 241, 242). Why there was 
an association with MAVS and not RIG-1 or MDA-5 may relate to a cumulative increase 
in MAVS expression due to both these signalling pathways feeding into its expression. 
With increased power additional associations with these sensors could also potentially be 
detected. My data therefore suggests that through the signaling of cytosolic RNA sensors 
MDA-5/RIG-1 and subsequent downstream MAVS activation, pDC HERV-K LTR5 
activity may also be involved in type 1 interferons production. However I actually saw 
lower pDC HERV-K expression (as detected by LTR-5) in my early RA cohort. 
Furthermore there was no differential expression of MDA-5, RIG-1 or MAVS when 
comparing pDCs from IGS+ or IGS- early RA patients (Chapter 5). This may suggest that 
the HERV-K upregulation reported in established RA (216, 242) is a later event driven 
by more established inflammatory processes (426) or an acquired resistance to the 
negative effects of type 1 signalling (410).  
When screening across the whole cohort for any other associations between retroelements 
and any other genes (as examined in the nCounter, NanoString, see Appendix A 2.0 for 
full list of genes), I saw a significant positive association between ILF3 and L1-5’UTR 
in CD4+ T cells (figure 6.20.B). The ILF3 gene can generate 2 distinct proteins depending 
on splicing; interleukin enhancer-binding factor 3 (Ilf3) and nuclear factor 90 (NF90). 
These are both double-stranded RNA-binding proteins (DRBPs) that regulate RNA 
metabolism including RNA recognition, RNA processing, and RNA stability (430). In 
HIV, an exogenous retrovirus, NF90 increased the half-life of the HIV RNA as well as 
promoting HIV infection, gene expression, and virus production (431). Why this is most 
evident in CD4+ T cells is unclear, however this is the cell subset most affected by HIV 
and potentially this cell-specific effect may make CD4+ T cells more susceptible to also 
harbouring endogenous retroviruses. I hypothesise that this protein may be playing a 
similar role in retroelement replication by stabilizing LINE-1 RNA thereby promoting 
the observed association.  
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6.5 Conclusion 
This highly novel work examines retroelement activity in whole blood and in isolated 
peripheral blood immune cell subsets from patients with early RA as well as healthy 
controls. I found that there was no clear difference in whole blood retroelement activity 
between the RA patients and healthy controls, and that, contrary to expectation, it was 
actually reduced in IGS+ RA patients compared to IGS- RA patients. Furthermore pDC 
retroelement activity is reduced in early RA and does not appear to be a trigger for 
interferon-α production. I propose type 1 interferon driven negative feedback mechanisms 
as a potential reason for these counter intuitive observations (410). I also observed 
differences in retroelement expression between immune cell subsets in early RA with 
increased expression in T cells and B cells. Methylation status can vary between 
peripheral subsets (424), and this epigenetic variation can affect retroelement activity 
which may account for my observations. Given the increasing importance of epigenetic 
modifications in RA pathogenesis, this increased retroelement expression in known 
pathogenic cell subsets, is intriguing. 
This is a pilot study and many of my findings are likely to be compromised by the small 
sample number. Nonetheless it hints towards intriguing differences in activity and 
regulation of retroelements across cell subsets which, given their ability to either 
influence or modulate immune function, may be relevant to RA pathology.  
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6.6 Future work  
There was a relatively small sample number when looking at the individual immune cell 
subsets. Ideally I would increase the sample size (in context of a power calculation) as 
well as examine more disease relevant tissue, i.e. synovium. Previous caveats relating to 
the NanoString technology discussed in Chapter 5 remain relevant to this interpretation. 
In particular, despite normalisation procedures, the running of each cell subset on 
individual chips could introduce the possibility of batch effects.   
One of the main factors regulating retroelement expression is methylation status. 
Therefore I would isolate DNA from each of the immune cell subsets and, using 
bisulphate sequencing, determine each subset’s relative methylation. This could then be 
correlated with respective activity of the retroelements. 
I observed reduced retroelement activity in patients with a positive IGS. A potential 
theory for this is a negative feedback mechanism which has been shown for LINE-1 
elements. This has not been examined previously in SINEs (Alus) or ERVs (LTRs). A 
logical step would be to validate this effect by culturing either cancer cell lines expressing 
constitutively high levels of retroelements or primary PBMCs with interferon-α and 
recording any change in retroelement activity. In addition, the ERV HERV-K (LTR5) has 
been most strongly linked with RA with evidence of gag and env protein in the peripheral 
circulation. Examining potential ERV activity at the protein level as well as at the mRNA 
level in early RA would be beneficial. Associations with autoantibodies could then be 
examined more extensively.  
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7.1 General discussion  
RA is a highly heterogeneous disease and, whilst most patients present with a 
symmetrical, inflammatory polyarthritis there is diversity in patterns of onset, 
autoantibody status, as well as responses to therapies. One example of this heterogeneity 
is the interferon gene signature (IGS), which is present only in a subset of RA patients 
(155, 184-186). It is currently unclear what are the full implications of this phenomenon 
but, for example, the IGS can affect response to certain biological therapies (153, 185-
187, 191, 200). Pathological mechanisms in early disease are increasingly being shown 
to be distinct from those in established disease (6-9). I therefore wished to investigate the 
IGS in early RA as well as attempting to delineate the origin and triggers of type 1 
interferon production, with a particular focus on plasmacytoid dendritic cells (pDCs). I 
used a variety of techniques to address these questions and the 4 main strands of interest 
to emerge from this work are discussed below.  
7.1.1 The IGS as a predictor of response to initial treatment 
An IGS has been identified in numerous autoimmune conditions. It is most extensively 
studied in SLE, where it is present in 50-70% of patients and associates with disease 
activity and certain presentations, such as lupus nephritis (156, 157). An IGS is also 
present in 20-30% of established RA patients where current evidence demonstrates no 
correlation with either disease phenotype or activity (153, 185-187, 191). Type 1 
interferons are proposed to be important at disease onset in other autoimmune conditions 
(148, 265, 266, 270) and, indeed, in an ACPA positive population a positive IGS was a 
predictive factor for the development of RA (182, 183). Furthermore some individuals 
receiving interferon-α therapy for viral infections developed a symmetrical inflammatory 
polyarthritis consistent with RA (180). Certain therapies, such as glucocorticoids, can 
modulate the IGS which could confound analyses in established RA (23). I therefore 
examined the prevalence of the IGS, as well as any effects on disease activity or 
therapeutic response, in early drug naive RA.  
I found the IGS was significantly higher in early RA than established RA. Corroborating 
this was a significant fall in the IGS from baseline when examining a longitudinal cohort 
of early RA patients. This fall was sustained at up to 12 months independently of any 
glucocorticoids administration. This supports the observation that patients with a longer 
duration of RA had a lower IGS (191) and, as seen in other autoimmune diseases (148, 
265, 266, 270), emphasises the importance of type1 I interferon signalling early in RA. 
Uniquely in this early drug naïve cohort I also demonstrated an association between the 
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baseline IGS and disease activity (DAS-28) both at baseline as well as 6 months after 
initiation of treatment. Furthermore the baseline IGS had a strong predictive effect on 6 
month clinical outcomes whereby the higher the baseline IGS the poorer the outcome. 
These outcomes included DAS-28, number of additional glucocorticoid injections 
required and EULAR response. Importantly the IGS outperformed current conventional 
clinical markers of disease activity; thus baseline CRP, ESR or indeed DAS-28 did not 
predict these outcomes. An IGS has been shown to predict poorer response to certain 
biological therapies in established RA, most particularly rituximab (23, 186, 200-202), 
however it has never previously been shown to associate with disease activity or predict 
response to DMARDs. 
I was particularly interested to see whether hydroxychloroquine (HCQ) could modulate 
the IGS associations, because patients who developed a RA phenotype following 
exogenous interferon-α administration responded well to HCQ (180). HCQ reduces the 
number of circulating immune complexes in RA (432) and, in SLE, RNA/DNA 
containing immune complexes induce interferon-α production from pDCs (147, 149-151, 
433). Furthermore HCQ modulates endosomal acidification thereby modifying TLR 
ligand induction of type 1 interferons (280). The association between IGS and poor 
outcome was weaker when patients were also taking HCQ but the study was not 
adequately powered to draw definite conclusions. The effect of the IGS on the apparent 
poor response to glucocorticoids was also interesting. In SLE pDCs become relatively 
resistant to the effect of glucocorticoids due to concurrent TLR7 and TLR9 signalling 
mediated by immune complexes (276). A similar process may occur in early RA although 
this remains to be elucidated. The main findings for this section are summarised in figure 
7.1 
These data proposes that the type 1 interferon axis is more important than hitherto 
appreciated in RA pathophysiology. This in turn suggests therapeutic potential in 
modulating type 1 interferon production and signalling in early RA treatment. Prompt 
treatment of early RA leads to better long term outcomes (11, 352, 353), thus modulating 
the type 1 interferon axis in early RA could be a valid therapeutic goal. Type 1 interferon 
targeting therapies are being developed for SLE, the most successful of which is the 
IFNAR1 blocker, anifrolumab, which intriguingly also improved inflammatory joint pain 
symptoms (161, 162). Furthermore JAK1/3 inhibitors, recently licenced for the treatment 
of RA in some jurisdictions, inhibit type 1 interferon signalling (309) and, as mentioned 
previously, HCQ could also modulate the IGS. There is therefore a range of available 
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approaches for the modulation of an IGS in early RA. Their application could allow for 
better management of patients in the crucial early stages of disease and provide not only 
a biomarker for response to treatment, but also a more personalised approach to 
management.   
 
Figure 7.1 Summary of findings relating to the IGS prevalence in early RA as well 
as its predictive effect on disease severity and response to initial therapies 
The interferon gene signature (IGS) in early RA falls with the initiation of treatment, 
however the baseline IGS predicts clinical outcome measures at up to 6 months.  
 
7.1.2 The IGS and autoantibodies 
Extensive evidence confirms the permissive effects of type 1 interferons on B cell 
activation, class switch and antibody production (139-142, 145, 296). I therefore sought 
associations between a raised IGS and autoantibodies in early RA. I observed a clear 
association between the IGS and RF titres, but not anti-CCP titres. However my data 
could not clearly determine if the IGS was a primary event or a secondary phenomenon, 
for example, RF containing immune complexes interacting with pDCs (147, 149-151, 
433). Nonetheless B cells from RA patients stimulated with interferon-α in vitro produce 
IgM RF (290) and RF developed de novo in 34% of individuals given interferon-α 
therapy, whereas anti-CCP antibodies were much rarer (180). RF is predominantly a non-
switched IgM antibody against self-IgG and some have proposed that, contrary to anti-
CCP generation, RF is generated following TLR signaling in a T cell independent manner 
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(291). Like pDCs, B cells express TLR 7 and 9 (292) so it is conceivable that triggers for 
pDC interferon-α production could also trigger RF generation in parallel. Additionally B 
cells from IGS+ early RA patients had increased TACI gene expression. TACI is a B cell 
surface receptor which is important in T cell independent B cell activation and causes 
increased TLR7 expression upon ligation (434, 435). I also demonstrated a positive 
association between circulating BAFF/BLyS and RF but not anti-CCP titres. BAFF/BLyS 
binds to TACI (as well as to other receptors) and, in doing so, promotes B cell activation, 
immunoglobulin production and survival of autoreactive B cells (297, 298, 380, 381). I 
hypothesise that, in the IGS+ cohort, increased TACI results in increased sensitivity to 
BAFF/BLyS as well as promoting T cell independent B cell activation. This could 
culminate in RF production, thus providing a mechanistic link for my observations 
associating the IGS with RF titres. The differential association between the IGS, and RF 
and anti-CCP autoantibodies development was corroborated when examining the B cell 
transcriptome of IGS+/- early RA patients. PECAM-1 was reduced in the IGS+ cohort 
and mouse knockouts of this gene had activated and highly proliferative IgM producing 
B cells (386, 387). This is the same immunoglobulin class as RF (when detected by 
conventional assays) whereas anti-CCP antibodies are mainly IgG. Other differentially 
expressed genes in the IGS+ cohort included XBP-1, CD27 and CD80, suggesting both 
an activated B cell phenotype as well as increased plasma cell differentiation (375-378). 
Plasma cells are the subset of B cells which produce antibodies.  
All this evidence suggests that in early RA a positive IGS is associated with the generation 
of a B cell phenotype that is abnormally active and skewed towards plasma cell 
development, IgM production and potentially T cell independent activation. This may 
culminate in a pathogenic B cell phenotype, with potential implications for disease 
progression, as well as increased RF titres. Conversely in established RA there was no 
association between autoantibody status (either RF or anti-CCP) and the IGS (294). 
However I showed that the IGS falls with treatment, as does the proportion of IgM anti-
CCP (4) which may potentially confound previously published work examining 
associations between the IGS and autoantibodies (294). This further emphasises the 
benefit of examining drug naive early RA. 
This interaction in early RA between the IGS and B cells is supported by the prediction 
model in ACPA+ arthralgia where the use of B cell phenotype to predict development of 
RA was improved after including the IGS (356). My findings also support the established 
clinical observation that IGS+ RA patients have a poorer response to rituximab, a CD20 
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depleting therapy (23, 186, 200-202). Poor responders also have early expansion of 
CD27+ B cells (388), as well as high numbers of CD27++ plasmablasts pre–treatment 
(389). My findings of high CD27 expression in the IGS+ cohort and a highly proliferative 
phenotype skewed towards development of plasmablasts, provides mechanisms whereby 
a positive IGS could materially influence response to rituximab. This also suggests that 
the response to rituximab might be optimised by targeted co-administration of type 1 
interferon blocking therapies. As these are already in phase 3 trial for SLE (162), this is 
an intriguing possibility in the development of a personalised approach to the use of 
biologics in the treatment of RA. 
The IGS+ cohort also had increased expression of genes normally associated with B cell 
malignancy, particularly multiple myeloma and diffuse large B cell lymphoma (DLBCL). 
In RA there is a 5 times increased risk of developing non-Hodgkin’s lymphoma (NHL), 
and these are predominantly of a DLBCL phenotype (390, 391). This risk is highest 
amongst RF positive patients (436). This would correlate with my findings of a raised 
IGS, and thus potentially malignant phenotype, in RF positive patients. Although not as 
established there is also a suggested link between RA and an increased risk of developing 
multiple myeloma, a plasma cell malignancy (392-394). Notably numerous genes 
associated with plasma cell development were increased in the IGS+ cohort, as were 
genes more specifically associated with multiple myeloma. Conversely however 
interferon-α has been used as a therapy for some forms of relapsed non-Hodgkin’s 
lymphoma (437). Nonetheless chronic exposure to type 1 interferons in an at risk 
population, i.e. RA, may promote different B cell phenotypes when compared with an 
acute short exposure. Although this is very preliminary it is nonetheless intriguing. If 
exposure to type 1 interferons promotes this pathological phenotype in RA, there may be 
scope to prevent these rare complications with interferon-α targeting therapies.  
These findings are summarised in figure 7.2. 
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Figure 7.2 Summary schematic regarding the IGS and B cells in early RA 
Type 1 interferons cause increase in B cell gene expression which is normally associated 
with B cell activation and differentiation into plasma cells or plasmablasts. There is also 
a suggestion of increased IgM production, which may promote further interferon-α 
production by immune complexes associating with pDCs. Furthermore genes related to 
malignancy are also upregulated, particularly those relating to diffuse large B cell 
lymphoma (DLBCL).  
 
The “malignant” weighting of the B cell gene expression data in the IGS+ cohort is also 
interesting with respect to retroelement expression. In early RA there was most 
retroelement expression in B cells and T cells but LTR5 (HERV-K) expression was 
greatest in B cells. Retroelements have long been connected with malignancy (226) and 
there is evidence of increased ERV activity, such as HERV-K (which has also been 
associated with RA), in lymphoma and DLBCL (438, 439). Indeed there was a single 
case report of a patient with HIV and refractory DLBCL who had clinical improvement 
(along with immune reconstitution) upon treatment with anti-retroviral therapy which 
would have concurrently reduced ERV replication (440).  The relevance of this 
observation to early RA is unclear, although there was an increase in gene expression 
pathways related to viral infection, and by proxy potential ERV activity, in IGS+ patients. 
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A potential scenario envisages retroelement activation being promoted by a concurrent 
and persistent infection (242), which also causes upregulation of type 1 interferons. This 
increased retroelement activity ultimately results in a malignant cell phenotype and, in a 
susceptible genetic background, potentially the development of lymphoma. Whilst this is 
highly speculative there is currently minimal understanding of the role of retroelements 
in RA and, as a potential risk factor for autoimmune-associated malignancy, they may 
warrant further investigation.  
My data suggests that the IGS pathologically affects B cell gene expression and, 
potentiall, function in early RA. They raise many intriguing avenues for future research, 
including the application of interferon-α blocking therapies to a subset of RA patients in 
order to optimise current therapeutic strategies.  
7.1.3 pDCs in early RA 
PDCs are the primary interferon-α producing cell (43) however their role in established 
RA is contradictory (87, 90). I therefore attempted to dissect any potential pathological 
contribution in early drug naïve RA. The frequency of circulating pDCs was significantly 
reduced in early RA compared with healthy controls and comparable to the reduced level 
seen in established RA (54, 87, 316). Additionally pDC frequency was significantly 
reduced in seropositive early RA patients where it inversely associated with the 
concurrently increased CCR7 expression. CCR7 expression is increased upon pDC 
activation and normally facilitates lymph node migration (320, 321) but its ligand, 
CCL19/21, is increased in RA synovial tissue and fluid (323). PDCs are increased in the 
RA synovial compartment (85-88, 322) and I hypothesise they migrate there via CCR7-
CCL19/21 interactions. The link with serostatus is supported by my observation that 
CCR7 expression positively associated with anti-CCP titres as well as published work 
linking synovial pDC number with anti-CCP titres (88). PDCs cluster with B cells in the 
RA synovium (88) and the potential for activation of B cells, including autoreactive B 
cells, by pDCs is increasingly appreciated; this can be via either cell-cell interactions or 
inflammatory cytokines, such as interferon-α (142, 324, 325, 373). Some suggest ectopic 
germinal centres within the synovium are partly responsible for the production of anti-
CCP antibodies (105) and I hypothesise that this process could be potentiated by pDC-B 
cell interactions. One could envisage a potential scenario whereby pDCs are activated by 
anti-CCP autoantibody immune complexes, causing CCR7 upregulation (147, 149-151, 
433); pDCs then migrate to the synovial compartment (via CCR7-CCL19/21) and activate 
autoreactive B cells within ectopic germinal centres. This promotes further anti-CCP 
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autoantibody generation thereby initiating a vicious cycle. This hypothesis is pictured in 
figure 7.3.  
This process could theoretically be further potentiated by the effects of B cells on pDC 
function. It has been shown that the interferon-α production of pDCs is increased by 
proximity to B cells by both cell-cell contact as well as release of B cell derived soluble 
factors (326). Since interferon-α can further affect B cell function (139-142, 145, 296) a 
positive feedback mechanism may also occur. Thus the effect of simultaneous pDC and 
B cell presence in the synovial compartment, may have hitherto unappreciated effects on 
rheumatoid pathogenesis.  
 
Figure 7.3 Schematic of hypothesis linking pDC number and CCR7 expression with 
anti-CCP autoantibody titres 
Seropositive RA pDCs have increased CCR7 expression causing increased migration to 
CCL19/21 expressed in the RA joint. Once in the joint pDCs cluster with B cells within 
ectopic germinal centres and following cell-cell interactions and inflammatory cytokines 
production promote anti-CCP antibody production. These autoantibodies return to the 
peripheral circulation where they form immune complexes which activate pDCs causing 
further enhanced CCR7 expression, thereby promoting a positive, and potentially 
pathogenic, feedback mechanism.  
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I demonstrated that although pDC had no baseline difference in maturation status between 
healthy controls and early RA patients, activation markers fell with time and the initiation 
of therapy. This is in keeping with published evidence where pDCs have a less activated 
phenotype in established RA than healthy controls (317) and may suggest that pDCs have 
a relatively more activated, or pathogenic phenotype, in early disease. Conversely, when 
examining early RA drug naïve and healthy control pDC transcriptomes there was no 
clear upregulation of genes associated with a matured or pathogenic state in the early RA 
cohort. However notably these interpretations were limited by the relative paucity of 
human pDC literature. Contrary to expectation pDCs were not the main interferon-α 
producing subset in IGS+ early RA patients: all immune cell subsets had comparable 
interferon-α production in IGS- and IGS+ early RA patients. Consistent with this there 
was no detectable interferon-α in the circulation of early RA patients, similar to 
established RA (153, 185-187, 191), suggesting that interferon-α producing pDCs may 
have migrated to the lymph nodes or other inflamed tissues. Indeed there is a suggestion 
of increased type 1 interferon signalling within the RA synovial compartment (85, 89). 
This highlights the importance of microenvironment when examining pDCs; examining 
peripheral blood pDCs is unlikely to truly define their role in synovial pathology.  
In conclusion the role of pDCs in RA is likely to be both time- and site-specific. 
Nonetheless my findings, and the work of others, hint of an interplay between B cells, 
autoantibodies and pDCs. However whether the net role of pDCs is pro-inflammatory or 
immunomodulatory remains to be further clarified.  
7.1.4 Retrotransposons and early RA 
Recently retroelement activity has been linked to autoimmunity. There are increased 
LINE-1 transcripts in RA synovium, lupus nephritis tissue and in the salivary glands of 
pSS patients (231, 237, 238, 240). ERV protein products are also increased in RA and 
associate with disease activity (242). Retroelements undergoing retrotransposition are 
essentially viral nucleic acids. They activate the immune system by triggering widely 
expressed cytosolic RNA/DNA sensing pathways resulting in type 1 interferon 
production (121). In RA there is likely to be an event which triggers the development of 
RA on a susceptible genetic and environmental background. As mentioned (Section 
7.1.1), type 1 interferons may be relevant in the breach of tolerance (148, 182, 183, 265, 
266, 270) and it is therefore possible that retroelement activity could be an initial trigger 
for the development of autoimmunity in RA (242, 245, 441). I therefore examined 
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retroelement activity in early RA peripheral blood, including individual immune cell 
subsets.  
There was no difference in whole blood retroelement activity between early RA patients 
and healthy controls but unexpectedly there was reduced retroelement expression in IGS+ 
early RA patients. One explanation is that while retroelements can trigger type 1 
interferons, negative feedback mechanisms exist whereby type 1 interferon signalling 
itself limits retroelement activity (410). I showed that pDCs had the highest 
IFNAR1/IFNAR2 expression which would make them most sensitive to the negative 
feedback effects of type 1 interferon exposure. Indeed all retroelement activity (ERV, 
SINE and LINE) was reduced in early RA pDCs.  
Anatomically RA pathology is predominantly articular and increased retroelement 
activity has been mostly shown in synovial tissue. I examined peripheral blood and so 
could have missed key differences between the cohorts by not examining the synovium. 
In addition my data may point to differences in modulatory feedback mechanisms 
between SLE and RA, despite the presence of an IGS in both diseases. 
This was the first time multiple classes of retroelements were compared across immune 
cell subsets in the peripheral blood of early drug naïve RA patients. There was relatively 
increased expression in T cells and B cells and lower expression in DC subsets and 
monocytes. One potential explanation for this is differential methylation between the cell 
subsets. Methylation is an epigenetic modification and retroelement hypomethylation 
increases their transcriptional activity (421, 422).  Epigenetic modifications are of 
increasing interest in RA (99, 426, 442), thus the potentially differentially methylated 
state of cell subsets known to be pathogenic in RA is intriguing and downstream effects 
may have relevance to disease.  
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7.2 Strengths and weaknesses 
The strengths and weaknesses relating to the specific scientific approaches are 
summarised in table 7.1. However there are additional global considerations when 
considering the experimental design employed. This type of work comes under the 
umbrella of translational research, which aims to define human disease and unmet clinical 
need. This involves rigorous characterisation of patients and disease mechanisms, thereby 
defining potential therapeutic targets, such as the IGS. It frequently, as I have done, uses 
human samples to dissect pathological processes. However the early phases of this work 
are frequently performed in vitro, or using tissue which may not be relevant, such as in 
my case examining the peripheral blood instead of synovial tissue. Furthermore RA is 
highly heterogeneous and genetic risk factors are polygenic and can be subject to 
environmental interference. This variability is challenging requiring sufficiently sized 
cohorts to both discover and validate observations, which is not always possible.  Finally, 
even if associations are identified they cannot robustly link cause and effect. Instead some 
argue that reductionist mouse models of disease, particularly with “humanised” 
characteristics, provide more tractable models to examine knockout particular pathways 
in vivo. There are considerations, however, that limit the value of mouse models for my 
investigations. For example, although there is interferon-α homology between mouse and 
man (443) there is no direct equivalent of a human pDC in mice (444). Furthermore, mice 
have increased basal retroelement activity when compared with humans (215) and 
although PRRs, such as TLRs are present in both mice and humans, the distribution, 
number, ligand specificity and in some cases function varies across species (445, 446). 
Finally an interesting aspect of this work was the link between RF and the IGS. Although 
some RA mouse models result in spontaneous disease with autoantibodies, the subtle 
relationships between RF, anti-CCP and the IGS may be lost. Similar caveats in other 
studies have been overcome by designing specific transgenic mouse models or using 
humanised mice. However in view of the above considerations the merit of these findings 
at this preliminary stage would be debated. Ultimately, human and murine experiments 
can inform one another, but generally human experimentation is required to provide the 
most relevant insights into human disease. 
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Strengths Weaknesses 
 Drug naïve early RA patients 
 Novel population for IGS examination 
 5 IRGs used to calculate IGS 
 Disease controls included (SLE positive 
control) as well as healthy controls 
(negative control) 
 Longitudinal and cross sectional 
analysis of early RA patients 
 pDCs examined in early RA – unique  
 Intrinsic and extrinsic triggers of 
interferon-α analysed 
 Multiple retroelement classes examined 
simultaneously and across different 
immune cell subsets 
 NanoString technology allowed 
examination of rare subsets while 
avoiding any amplification bias  
 Rigorous QC controls in transcriptome 
technology 
 Whole blood, not synovia examined 
 No validation of predictive model  
 Insufficient power to identify role of 
DMARDs on IGS prognostic effect 
 Low patient number in transcriptome 
work – potential for disproportionate 
skewing of data 
 Transcriptome only examined  in 
seropositive patients 
 No validation by qRT-PCR of 
transcriptome findings 
 Comparison between cell subsets – 
potential batch effects 
 Only 2 IFNA subtypes examined 
 No MLR performed on early RA pDCs 
 
Table 7.1 Outline of specific experimental design strengths and weaknesses  
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7.3 Future work  
The findings discussed here are intriguing and suggest multiple avenues for further 
investigation. One of the first directions would be to increase participant numbers; this 
would help validate the IGS signal as a predictor of response. If confirmed I would 
attempt to modulate the adverse effects in IGS+ early RA patients by the prompt initiation 
of type 1 interferon modulating therapies, such as JAK1 inhibitors, potentially HCQ or 
ideally more specifically IFNAR1 blockers.  To provide robust data this would need to 
be in a prospective clinical trial design which, when using the above oral therapies, would 
need to be double blinded and placebo controlled. Outcome measures would include the 
clinical parameters reported here, longitudinal IGS and, given the link between the IGS 
and TJC/SJC, ultrasonography would be a beneficial adjunct. HCQ is already a first line 
treatment in early RA and use of biological therapies in early disease is being increasingly 
trialled, making this an ethically sound proposal. One could envisage development of a 
chip based assay which could rapidly detect a raised IGS prompting additional IGS 
modifying therapies at RA diagnosis and thus optimisation of rapid disease control.  
A highly interesting aspect of my findings relates B cell gene expression and the IGS. 
Correlations with B cell protein expression would need to be performed in conjunction 
with gene expression data and validation of associations with autoantibodies would again 
be achieved by increasing cohort size. Next generation sequencing on a larger cohort of 
B cells from early RA and ACPA+ arthralgia patients would provide more extensive 
pathway analysis, as well as exploring further the potential link between the IGS and 
malignancy in RA patients. This latter aim would also involve quantifying the whole 
blood IGS in RA patients with new onset B cell malignancies as well as examining the B 
cell transcriptome and retroelement activity (including methylation) in relevant tissue. 
Finally I would like to examine the IGS and serum immunoglobulins (IgM and IgG) to 
assess for specific or global B cell activation in both my current cohort and in any 
potentially larger future cohort. 
Finally anti-CCP antibodies have been implicated in osteoclast activation and bone 
erosions (348), therefore if contribution of pDCs to their generation was validated, the 
pDC may provide a new therapeutic target. Examination of the appropriate tissue, i.e. 
blood vs synovium, is a caveat that has existed for both my retroelement and pDC work. 
What occurs within the synovial compartment is likely to be distinct from the peripheral 
blood and I would like to repeat these analyses using matched peripheral blood and 
synovium and, where possible, lymph node biopsies as well. Given the link with smoking 
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and retroelement hypomethylation (408, 414), as well as the smoke exposure in lungs 
being reported site for breach of tolerance in RA (447), an intriguing option would be to 
also examine retroelement activity in RA lung and oral mucosal tissue.  
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7.4 Final conclusions 
In conclusion the IGS is increased in early RA and falls with time from diagnosis, and I 
propose a potential role for type 1 interferons in the initiation of disease. Furthermore in 
early RA the baseline IGS predicts the response to initial therapies at 6 months better than 
any conventional markers of disease activity and inflammation. Given the emerging 
importance of early and prompt disease control, and the fact that interferon-α targeting 
therapies are in development for the treatment of SLE, I suggest that inhibiting interferon-
α signalling in a subset of early (IGS+) RA patients may deliver a useful therapeutic 
adjunct. The effect of the IGS is most marked on B cells where genes associated with 
activated phenotype and plasma cell differentiation are upregulated. The potential 
downstream effects of this are also demonstrated in vivo as the IGS positively associates 
with RF titres in early RA. The source of type 1 interferons was examined, but contrary 
to expectations pDCs in early RA were not the primary interferon-α producer in the 
peripheral blood. Despite this their numbers were significantly reduced in early RA and 
displayed an activated phenotype which fell with time and treatment. As a potential 
trigger of type 1 interferons I analysed retroelement activity in whole blood and peripheral 
immune cell subsets but there was no clear evidence that they were responsible for 
triggering type 1 interferon production. However there was differential activity between 
immune cell subsets which suggests epigenetic modifications are present, which may also 
impact cellular function. 
Overall I offer an intriguing insight into the IGS in early RA and suggest that, rather than 
being an incidental finding, it has implications for disease pathogenesis and prognosis as 
well as generation of autoantibodies. I believe understanding these mechanisms further 
will allow optimisation of early RA treatment by the administration of concurrent 
interferon-α modulating therapies.  
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ACR/EULAR (2010) Classification Criteria for Rheumatoid Arthritis 
Requirements: patients who have at least 1 swollen joint, and not better explained by 
another disease to be applied.  A score ≥ 6 points is required for classification as definite 
RA. 
Symptom Duration (as reported by patient)                                                Points 
 < 6 weeks                                                                                                    0 
 > 6 weeks                                                                                                    1 
Joint Distribution                                                                                           Points 
 1 large joint                                                                                                 0 
 2-10 large joints                                                                                          1 
 1-3 small joints (with or without involvement of large joints)                   2 
 4-10 small joints (with or without involvement of large joints)                 3 
 > 10 joints (at least 1 small joint)                                                                5 
Serology                                                                                                         Points 
 RF- and CCP-                                                                                             0 
 Low RF+ or CCP+                                                                                      2 
 High RF+ or CCP+                                                                                     3 
Acute Phase Reactants                                                                                Points 
 Normal ESR or CRP                                                                                  0 
 Abnormal ESR or CRP                                                                              1 
 
Appendix A 1.0: ACR/EULAR Classification Criteria for Rheumatoid Arthritis.  
This criteria was used to define which one of the patients attending the Early Arthritis 
Clinic had a clear diagnosis of RA. RF: rheumatoid factor.  CCP: anti-citrullinated citric 
peptide.  ESR: erythrocyte sedimentation rate.  CRP: C-reactive protein.  Low: < 3 x 
upper limit of normal (ULN).  High: > 3 x ULN 
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Appendix A 2.0: 
ABCB1 C6 CD164 CD96 CXCL11 
ABL1 C7 CD19 CD97 CXCL12 
ADA C8A CD1A CD99 CXCL13 
AHR C8B CD1D CDH5 CXCL2 
AICDA C8G CD2 CDKN1A CYBB 
AIRE C9 CD209 CEACAM1 DEFB1 
APP CAMP CD22 CEACAM6 DEFB103A 
ARG1 CARD9 CD24 CEACAM8 DEFB103B 
ARG2 CASP1 CD244 CEBPB DEFB4A 
ARHGDIB CASP10 CD247 CFB DPP4 
ATG10 CASP2 CD27 CFD DUSP4 
ATG12 CASP3 CD274 CFH EBI3 
ATG16L1 CASP8 CD276 CFI EDNRB 
ATG5 CCBP2 CD28 CFP EGR1 
ATG7 CCL11 CD34 CHUK EGR2 
ATM CCL13 CD36 CIITA ENTPD1 
B2M CCL15 CD3D CISH EOMES 
B3GAT1 CCL16 CD3E CLEC4A ETS1 
BATF CCL18 CD3EAP CLEC4E FADD 
BATF3 CCL19 CD4 CLEC5A FAS 
BAX CCL2 CD40 CLEC6A FCAR 
BCAP31 CCL20 CD40LG CLEC7A FCER1A 
BCL10 CCL22 CD44 CLU FCER1G 
BCL2 CCL23 CD46 CMKLR1 FCGR1A/B 
BCL2L11 CCL24 CD48 CR1 FCGR2A 
BCL3 CCL26 CD5 CR2 FCGR2A/C 
BCL6 CCL3 CD53 CRADD FCGR2B 
BID CCL4 CD55 CSF1 FCGR3A/B 
BLNK CCL5 CD58 CSF1R FCGRT 
BST1 CCL7 CD59 CSF2 FKBP5 
BST2 CCL8 CD6 CSF2RB FN1 
BTK CCND3 CD7 CSF3R FOXP3 
BTLA CCR1 CD70 CTLA4_all 
(common probe) 
FYN 
C14orf166 CCR10 CD74 CTLA4-TM 
(membrane-
bound form) 
GATA3 
C1QA CCR2 CD79A sCTLA4 (soluble 
form) 
GBP1 
C1QB CCR5 CD79B CTNNB1 GBP5 
C1QBP CCR6 CD80 CTSC GFI1 
C1R CCR7 CD81 CTSG GNLY 
C1S CCR8 CD82 CTSS GP1BB 
C2 CCRL1 CD83 CUL9 GPI 
C3 CCRL2 CD86 CX3CL1 GPR183 
C4A/B CD14 CD8A CX3CR1 GZMA 
C4BPA CD160 CD8B CXCL1 GZMB 
C5 CD163 CD9 CXCL10 GZMK 
Appendix A 2.0 Continued: 
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HAMP IKZF3 IL4 KIR3DL3 MAP4K4 
HAVCR2 IL10 IL4R KIT MAPK1 
HFE IL10RA IL5 KLRAP1 MAPK11 
HLA-A IL11RA IL6 KLRB1 MAPK14 
HLA-B IL12A IL6R KLRC1 MAPKAPK2 
HLA-C IL12B IL6ST KLRC2 MARCO 
HLA-DMA IL12RB1 IL7 KLRC3 MASP1 
HLA-DMB IL13 IL7R KLRC4 MASP2 
HLA-DOB IL13RA1 IL8 KLRD1 MBL2 
HLA-DPA1 IL15 IL9 KLRF1 MBP 
HLA-DPB1 IL16 ILF3 KLRF2 MCL1 
HLA-DQA1 IL17A IRAK1 KLRG1 MIF 
HLA-DQB1 IL17B IRAK2 KLRG2 MME 
HLA-DRA IL17F IRAK3 KLRK1 MR1 
HLA-DRB1 IL18 IRAK4 LAG3 MRC1 
HLA-DRB3 IL18R1 IRF1 LAIR1 MS4A1 
HRAS IL18RAP IRF3 LAMP3 MSR1 
ICAM1 IL19 IRF4 LCK MUC1 
ICAM2 IL1A IRF5 LCP2 MX1 
ICAM3 IL1B IRF7 LEF1 MYD88 
ICAM4 IL1R1 IRF8 LGALS3 NCAM1 
ICAM5 IL1R2 IRGM LIF NCF4 
ICOS IL1RAP ITGA2B LILRA1 NCR1 
ICOSLG IL1RL1 ITGA4 LILRA2 NFATC1 
IDO1 IL1RL2 ITGA5 LILRA3 NFATC2 
IFI16 IL1RN ITGA6 LILRA4 NFATC3 
IFI35 IL2 ITGAE LILRA5 NFIL3 
IFIH1 IL20 ITGAL LILRA6 NFKB1 
IFIT2 IL21 ITGAM LILRB1 NFKB2 
IFITM1 IL21R ITGAX LILRB2 NFKBIA 
IFNA1/13 IL22 ITGB1 LILRB3 NFKBIZ 
IFNA2 IL22RA2 ITGB2 LILRB4 NLRP3 
IFNAR1 IL23A ITLN1 LILRB5 NOD1 
IFNAR2 IL23R ITLN2 LITAF NOD2 
IFNB1 IL26 JAK1 LTA NOS2 
IFNG IL27 JAK2 LTB4R NOTCH1 
IFNGR1 IL28A JAK3 LTB4R2 NOTCH2 
IGF2R IL28A/B KCNJ2 LTBR NT5E 
IKBKAP IL29 KIR_Activating_ 
Subgroup_1 
LTF PAX5 
IKBKB IL2RA KIR_Activating_ 
Subgroup_2 
LY96 PDCD1 
IKBKE IL2RB KIR_Inhibiting_ 
Subgroup_1 
MAF PDCD1LG2 
IKBKG IL2RG KIR_Inhibiting_ 
Subgroup_2 
MALT1 PDCD2 
IKZF1 IL3 KIR3DL1 MAP4K1 PDGFB 
IKZF2 IL32 KIR3DL2 MAP4K2 PDGFRB 
 
Appendix A 2.0 Continued: 
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PECAM1 SELL  TLR3 ZEB1 
PIGR SELPLG  TLR4  
PLA2G2A SERPING1  TLR5  
PLA2G2E SH2D1A  TLR7  
PLAU SIGIRR  TLR8  
PLAUR SKI  TLR9  
PML SLAMF1  TMEM173  
POU2F2 SLAMF6  TNF  
PPARG SLAMF7  TNFAIP3  
PPBP SLC2A1  TNFAIP6  
PRDM1 SMAD3  TNFRSF10C  
PRF1 SMAD5  TNFRSF11A  
PRKCD SOCS1  TNFRSF13B  
PSMB10 SOCS3  TNFRSF13C  
PSMB5 SPP1  TNFRSF14  
PSMB7 SRC  TNFRSF17  
PSMB8 STAT1  TNFRSF1B  
PSMB9 STAT2  TNFRSF4  
PSMC2 STAT3  TNFRSF8  
PSMD7 STAT4  TNFRSF9  
PTAFR STAT5A  TNFSF10  
PTGER4 STAT5B  TNFSF11  
PTGS2 STAT6  TNFSF12  
PTK2 SYK  TNFSF13B  
PTPN2 TAGAP  TNFSF15  
PTPN22 TAL1  TNFSF4  
PTPN6 TAP1  TNFSF8  
PTPRC_all 
(common 
probe) 
TAP2  TOLLIP  
CD45R0 TAPBP  TP53  
CD45RA TBK1  TRAF1  
CD45RB TBX21  TRAF2  
PYCARD TCF4  TRAF3  
RAF1 TCF7  TRAF4  
RAG1 TFRC  TRAF5  
RAG2 TGFB1  TRAF6  
RARRES3 TGFBI  TYK2  
RELA TGFBR1  UBE2L3  
RELB TGFBR2  VCAM1  
RORC THY1  VTN  
RUNX1 TICAM1  XBP1  
S100A8 TIGIT  XCL1  
S100A9 TIRAP  XCR1  
S1PR1 TLR1  ZAP70  
SELE TLR2  ZBTB16  
Appendix A 2.0: Full list of genes included on NanoString nCounter Human 
Immunology V2 Panel. 
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Customised 
probe 
Sequence 
 
AluYa5 GGAAGAAGGGGGCCGGGCGCGGTGGCTCACGCCTGTAATCCCA
GCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAG
ATCGAGACCATCCCGGCTAAAACGGTGAAACCCCGTCTCTACT
AAAAATACAAAAAATTAGCCGGGCGTAGTGGCGGGCGCCTGTA
GTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATGGCGTGAAC
CCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCCCGCCACTGCA
CTCCAGCCTGGGCGACAGAGCGAGACTCCGTC 
AluYb9 GTAGGCAATGGGCCGGGCGCGGTGGCTCACGCCTGTAATCCCA
GCACTTTGGGAGGCCGAGGCGGGTGGATCATGAGGTCAGGAG
ATCGAGACCATCCTGGCTAACAAGGTGAAACCCCGTCTCTACT
AAAAATACAAAAAATTAGCCGGGCGCGGTGGCGGGCGCCTGT
AGTCCCAGCTACTGGGGAGGCTGAGGCAGGAGAATGGCGTGA
ACCCGGGAAGCGGAGCTTGCAGTGAGCCGAGATTGCGCCACTG
CAGTCCGCAGTCCGG CCTGGGCGACAGAGCGAGACTCCGTC 
LTR5        
5’ end 
AAGGGGGAAATGTGGGGAAAAGCAAGAGAGATCAGATTGTTA
CTGTGTCTGTGTAGAAAGAAGTAGACATAGGAGACTCCATTTT
GTTATGTACTAAGAAAAATTCTTCTGCCTTGAGATTCTGTTAAT
CTATGACCTTACCCCCAACCCCGTGCTCTCTGAAACATGTGCTG
TGTCCACTCAGAGTTGAATGGATTAAGGGCGGTGCAGGATGTG
CTTTGTTAAACAGATGCTTGAAGGCAGCATGCTCCTTAAGAGTC
ATCACCACTCCCTAATCTCAAGTACCCAGGGACACAAAAA 
LTR5  
3’end 
GGTGGGACCTGCGGGCAGCAATACTGCTTTGTAAAGCACTGAG
ATGTTTATGTGTATGCATATCTAAAAGCACAGCACTTAATCCTT
TACATTGTCTATGATGCAAAGACCTTTGTTCACATGTTTGTCTG
CTGACCCTCTCCCCACAATTGTCTTGTGACCCTGACACATCCCC
CTCTTCGAGAAACACCCACAGATGATCAATAAATACTAAGGGA
ACTCAGAGGCTGGCGGGATCCTCCATATGCTGAACGCTGGTTC
CCCGGGTCCCCTTCTTTCTTTCTCTATACTTTGTCTCTGTGTCTTT
TTCTTTTCCAAATCTCTCGTCCCACCTTACGAGAAACACCCACA
GGTGTG 
L1 5’UTR GGGGGAGGAGCCAAGATGGCCGAATAGGAACAGCTCCGGTCT
ACAGCTCCCAGCGTGAGCGACGCAGAAGACGGTGATTTCTGCA
TTTCCATCTGAGGTACCGGGTTCATCTCACTAGGGAGTGCCAGA
CAGTGGGCGCAGGCCAGTGTGTGTGCGCACCGTGCGCGAGCCG
AAGCAGGGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGT
CAGGGAGTTCCCTTTCCGAGTCAAAGAAAGGGGTGACGGACGC
ACCTGGAAAATC 
L1 ORF2 GTAGGGACATGGATGAAATTGGAAACCATCATTCTCAGTAAAC
TATCGCAAGAACAAAAAACCAAACACCGCATATTCTCACTCAT
AGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGG
GAATATCACACTCTGGGGACTGTGGTGGGGTCGGGGGAGGGGG
GAGGGATAGCATTGGGAGATATACCTAATGCTAGATGACACAT
TAGTGGGTGCAGCGCACCAGCATGGCACATGTATACATATGTA
ACTAACCTGCACAATGTGCACATGTACCCTAAAACTTAGAGTA
TAA 
 
Appendix A 3.0: Sequences of customised probes used in NanoString panel plus 
nCounter to identify retroelement activity.  
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